CA2124375C - Compounds containing a fused bicyclic ring and processes therefor - Google Patents

Compounds containing a fused bicyclic ring and processes therefor Download PDF

Info

Publication number
CA2124375C
CA2124375C CA002124375A CA2124375A CA2124375C CA 2124375 C CA2124375 C CA 2124375C CA 002124375 A CA002124375 A CA 002124375A CA 2124375 A CA2124375 A CA 2124375A CA 2124375 C CA2124375 C CA 2124375C
Authority
CA
Canada
Prior art keywords
acid
formula
mmol
product
ethyl acetate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA002124375A
Other languages
French (fr)
Other versions
CA2124375A1 (en
Inventor
Jeffrey A. Robl
Jollie D. Godfrey, Jr.
David R. Kronenthal
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of CA2124375A1 publication Critical patent/CA2124375A1/en
Application granted granted Critical
Publication of CA2124375C publication Critical patent/CA2124375C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C227/00Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C227/30Preparation of optical isomers
    • C07C227/32Preparation of optical isomers by stereospecific synthesis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C315/00Preparation of sulfones; Preparation of sulfoxides
    • C07C315/02Preparation of sulfones; Preparation of sulfoxides by formation of sulfone or sulfoxide groups by oxidation of sulfides, or by formation of sulfone groups by oxidation of sulfoxides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C319/00Preparation of thiols, sulfides, hydropolysulfides or polysulfides
    • C07C319/14Preparation of thiols, sulfides, hydropolysulfides or polysulfides of sulfides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C319/00Preparation of thiols, sulfides, hydropolysulfides or polysulfides
    • C07C319/14Preparation of thiols, sulfides, hydropolysulfides or polysulfides of sulfides
    • C07C319/20Preparation of thiols, sulfides, hydropolysulfides or polysulfides of sulfides by reactions not involving the formation of sulfide groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C327/00Thiocarboxylic acids
    • C07C327/20Esters of monothiocarboxylic acids
    • C07C327/32Esters of monothiocarboxylic acids having sulfur atoms of esterified thiocarboxyl groups bound to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
    • C07C327/34Esters of monothiocarboxylic acids having sulfur atoms of esterified thiocarboxyl groups bound to carbon atoms of hydrocarbon radicals substituted by carboxyl groups with amino groups bound to the same hydrocarbon radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06139Dipeptides with the first amino acid being heterocyclic
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07Optical isomers
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Abstract

Compounds of the formula (See formula I) wherein X is O or S-(O)t; n is one or two; m is zero or one; Y is CH2, O, or S-(O)t provided that Y is O
or S-(O)t only when m is one; and A is (See formula II or III) are dual inhibitors of NEP and ACE. Compounds wherein A is (See formula IV or V) are selective ACE inhibitors. Also disclosed are methods of preparation and intermediates.

Description

~x ~~ -, ' °?
E" t .',. '3 a S

HA629a Compounds Containing A Fused Bicyclic Rind And Processes Therefor This invention is directed to novel compounds 5 containing a fused bicyclic ring which are useful as angiotensin converting enzyme inhibitors. Some of these compounds also possess neutral endopeptidase inhibitory activity. This invention is also directed to pharmaceutical compositions containing such 10 selective or dual action inhibitors and the method of using such compositions. This invention :is also directed to the process for preparing such novel compounds, novel intermediates, and processes for preparing such intermediates.
15 The novel fused bicyclic inhibitors of this invention include those compounds of the formula (I) X\~
( CH2 ) n T l N~CHZ ) m A- IvN
I O
g COOR;

and pharmaceutically acceptable salts thereof wherein:
O
ii A is R;-S- (CH, T-'~ ~ ~' , Ri2 R_ i!
I~, r,r ~ t~ i .>
HA629a O
R~OOC- (CHz ) q ~C~ C- ~ R~OOC - CH -or Rlz RZ R
i O
II
R4_ ( - , ORS
5 X is O or S-(O)t;
R1 and R12 are independently selected from hydrogen, alkyl, alkenyl, cycloalkyl, substituted alkyl, substituted alkenyl, aryl, substituted aryl, heteroaryl, cycloalkyl-alkylene-, aryl-alkylene-, 10 substituted aryl-alkylene-, and heteroaryl-alkylene-or R1 and R12 taken together with the carbon to which they are attached complete a cycloalkyl ring or a benzofused cycloalkyl ring;

R2 is hydrogen, RE C , or R11-S- ;
15 R3, R5 and R~ are independently selected from hydrogen, alkyl, substituted alkyl, aryl-(CH2)p-, substituted aryl-(CH2)p-, heteroaryl-(CH2)p- , O
O

- CH - O - C - R~ , and , -CH,~
Rs R_ ~? 9 ~a n. ~ ~ r~ .r '., ~, ~ HA 6 2 9 a R4 is alkyl, cycloalkyl-(CH2)p-, substituted alkyl, aryl-(CH2)p-, substituted aryl-(CH2)p-, or heteroaryl-(CH2)p-;
R6 is alkyl, substituted alkyl, cycloalkyl-5 (CH2)p-, aryl-(CH2)p-, substituted aryl-(CH2)p-, or heteroaryl-(CH2)p-;
Rg is hydrogen, lower alkyl, cycloalkyl, or phenyl;
R9 is hydrogen, lower alkyl, lower alkoxy, or 10 phenyl;
R1p is lower alkyl or aryl-(CH2)p-;
R11 is hydrogen, alkyl, substituted alkyl, cycloalkyl-(CH2)p-, aryl-(CH2)p-, substituted aryl-(CH2)p-, heteroaryl-(CH2)p-, or -S-R11 completes a 15 symmetrical disulfide wherein R11 is X
(CHZ ) n~Y
O
N~CH~ ) m ;
-(CHZ)r~C\ C-m is zero or one;
Y is CH2, S-(O)t or 0 provided that Y is 20 S-(O)t or O only when m is one;
n is one or two;
p is zero or an integer from 1 to 6;
q is zero or an integer from 1 to 3;
r is zero or one; and 25 t is zero, one, or two.
The term 'alkyl" refers to straight or branched chain radicals having up to seven carbon atoms. The term "lower alkyl° refers to straight or branched radicals having up to four carbon atoms and 30 is a preferred subgrouping for the term alkyl.

~.w ~. f~ -,f.
HA629a The term "substituted alkyl" refers to such straight or branched chain radicals of 1 to 7 carbons wherein one or more, preferably one, two, or three, hydrogens have been replaced by a hydroxy, amino, 5 cyano, halo, trifluoromethyl, -NH(lower alkyl), -N(lower alkyl)2, lower alkoxy, lower alkylthio, or carboxy.
The terms "lower alkoxy" and "lower alkylthio"
refer to such lower alkyl groups as defined above 10 attached to an oxygen or sulfur.
The term "cycloalkyl° refers to saturated rings of 3 to 7 carbon atoms with cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl being most preferred.
15 The term "alkenyl" refers to straight or branched chain radicals of 3 to 7 carbon atoms having one or two double bonds. Preferred "alkenyl" groups are straight chain radicals of 3 to 5 carbons having one double bond.
20 The term "substituted alkenyl" refers to such straight or branched radicals of 3 to 7 carbons having one or two double bonds wherein a hydrogen has been replaced by a hydroxy, amino, halo, trifluoromethyl, cyano, -NH(lower alkyl), 25 -N(lower alkyl)2, lower alkoxy, lower alkylthio, or carboxy.
The term °alkylene° refers to straight or branched chain radicals having up to seven carbon atoms, i.e. -CH2-, -(CH2)2-, -(CH2)3-, -(CH2)4-, - CH-- CH--iH- etc.
3 0 CH' CH; , The term "aryl" refers to phenyl, 1-naphthyl, and 2-naphthyl. The term "substituted aryl" refers to phenyl, 1-naphthyl, and 2-naphthyl having a r3, $ :-~ ,~ ~? '7 F:. . ~ ~, ~ ::

HA629a substituent selected from lower alkyl, lower alkoxy, lower alkylthio, halo, hydroxy, trifluoromethyl, amino, -NH(lower alkyl), or -N(lower alkyl)2, and di-and tri-substituted phenyl, 1-naphthyl, or 2-naphthyl 5 wherein said substituents are selected from methyl, methoxy, methylthio, halo, hydroxy, and amino.
The term "heteroaryl" refers to unsaturated rings of 5 or 6 atoms containing one or two 0 and S
atoms and/or one to four N atoms provided that the 10 total number of hetero atoms in the ring is 4 or less. The heteroaryl ring is attached by way of an available carbon or nitrogen atom. Preferred heteroaryl groups include 2-, 3-, or 4-pyridyl, 4-imidazolyl, 4-thiazolyl, <?- and 3-thienyl, and 2- and 15 3-furyl. The term heteroaryl also includes bicyclic rings wherein the five or six membered ring containing O, S, and N atoms as defined above is fused to a benzene or pyridyl ring. Preferred bicyclic rings are 2- and 3-indolyl and 4- and 5-20 quinolinyl. The mono or bicyclic heteroaryl ring can also be additionally substituted at an available carbon atom by a lower alkyl, halo, hydroxy, benzyl, or cyclohexylmethyl. Also, if the mono or bicyclic ring has an available N-atom such N atom can also be 25 substituted by an N-protecting group such as -CH2 -O -CH~ ~ ' -SO~ ~CH, 2,4-dinitrophenyl, lower alkyl, benzyl, or 30 benzhydryl.
The compounds of formula I wherein E~ ~: '~i. ~) ~ ;
HA629a O O
A iS ~-C-S -(CHz)r-C-C - . X is O Or S, RiRI
and Y is CH2, O, or S can be prepared by coupling the acylmercapto containing sidechain of the formula (II) II
R6 C-S~(CH2)r ~; C-OH
Riz Ri with a fused bicyclic ring compound of the formula (III) X
(CHz ) r~
N~CHz ) m Hz III 'N
O COORS

to give the product of the formula (IV) CHZ X
II II
R6-C-S-(CH2)~; -N N CH )m z R1> R~ ;1 O COOR:

wherein R3 is hydrogen, or an acid protecting group such as methyl, ethyl, t-butyl, or benzyl. The above reaction can be performed in an organic solvent such as methylene chloride and in the presence of a 20 coupling reagent such as i-ethyl-3-(3-dimethylamino-propyl)carbodiimide, dicyicohexylcarbodiimide, c~ s r~ .,.
h~ .~
.. :,) -HA629a benzotriazol-1-yloxytris(dimethylamino)phosphonium hexafluorophosphate, or carbonyldiimidazoie.
Alternatively, the acylmercapto carboxylic acid of formula II can be converted to an activated form 5 prior to coupling such as an acid chloride, mixed anhydride, symmetrical anhydride, activated ester, etc.
The product of formula IV can be converted to the mercaptan product of formula I wherein R2 is 10 hydrogen and R3 is hydrogen by methods known in the art. For example, when R6 is methyl and R3 is methyl or ethyl treatment with methanolic sodium hydroxide followed by aqueous acid yields the products wherein R2 and R3 are hydrogen.
15 The products of formula I wherein R2 is hydrogen can be acylated with an acyl halide of the formula (V) II
R6- C -halo wherein halo is F, Cl or Br or acylated with an anhydride of the formula (VI) II
R~-C -0 -C -RE

to give other products of formula I wherein R2 is II
Ro C -30 The products of formula I wherein R2 is -S-R11 and R11 is alkyl, substituted alkyl, cycloalkyl-(CH2)p-, aryl-(CH2)p-, substituted aryl-(CH2)p-, or ~e~?ta ~, _ g _ HA629a heteroaryl-(CH2)p- can be prepared by reacting the products of formula z wherein R2 is hydrogen with a sulfonyl compound of the formula (VII) in an aqueous alcohol solvent to yield the desired products. The compounds of formula VII are known in the literature or can be prepared by known methods, see for example, Smith et al., Biochemistry, 14, p 10 766 - 771 (1975).
The product of formula I wherein R2 is SH can be prepared by reacting the product of formula I
wherein R2 is hydrogen with a compound of formula VII
wherein R11 is triphenylmethyl or trialkylsilyl 15 followed by removal of the triphenylmethyl or trialkylsilyl group under acidic conditions.
The symmetrical disulfide products of formula I can be prepared by direct oxidation of the product of formula I wherein R2 is hydrogen with iodine 20 according to known procedures, see, for example, Ondetti et al. U.S. Patent 4,105,776.
The acylmercapto sidechain compounds of formula II wherein R12 is hydrogen are described in the literature. See, for example, Ondetti. et al.
25 U.S. Patents 4,105,776 and 4,339,600, Haslanger et al. U.S. Patent 4,801,609, Delaney et al. U.S. Patent 4,722,810, etc.
The acylmercapto sidechain compounds of formula II wherein R1 and R12 are both other than 30 hydrogen and r is zero can be prepared by reacting the substituted carboxylic acid of the formula .,.1 (VIII) O
HC-C-OH
R1z/ \
R.
HA629a 5 with bis[[(4-methoxy)phenyl]methyldisulfide in the presence of lithium diisopropylamide to give the compound of the formula (IX) O
H3C0 ~ HZC-S-C-IC-OH
Ra ~ ~Ri Treatment of the compound of formula IX with strong acid such as trifluoromethanesulfonic acid removes the methoxybenzyl protecting group and is followed by acylation with the acyl halide of formula V or 15 anhydride of formula VI to give the compound of formula II wherein R1 and R12 are both other than hydrogen and r is zero.
Alternatively, the substituted carboxylic acid of formula VIII can be reacted with lithium 20 diisopropyl amide and sulfur to give the mercaptan of the formula (X) O
HS ~C' C- OH
R.~ Ri The mercaptan of formula X can then be acylated with the aryl halide of formula V or the anhydride of v' ~. h!

HA629a formula VI to give the compound of formula II wherein R1 and R12 are both other than hydrogen and r is zero.
The acylmercapto sidechain compounds of 5 formula II wherein R1 and R12 are both other than hydrogen and r is one can be prepared by reacting the substituted carboxylic acid of the formula (XI ) O
HO- CHI ~C~ C- OH
Ri? R1 with para-toluenesulfonyl chloride in pyridine to give the lactam of the formula (XII) O
R, O

Treatment of the lactam of formula XII with a cesium thioacid of the formula (XIII) O
Cs-S-C-R6 in the presence of dimethylformamide yields the desired acylmercapto sidechain of formula II wherein R1 and R12 are both other than hydrogen and r is one.
The compounds of formula I wherein A is ..

O
R~OOC - ( CH2 ) ,~ ~C\ C -HA629a x is O or S, and Y is CH2, 0, or S can be prepared by coupling the acid of the formula 5 (XIV) O
R?OOC - ( CH2 ) q ~C\ C - OH
Ri2 R1 wherein R~ is an acid protecting group with the fused bicyclic ring compound of formula III in the presence 10 of a coupling reagent as defined above to give the product of the formula (XV) X
(CH2 ) n~Y

N~CH2 ) ~' R~OOC-(CH2)Q/ \ C-~ I .
'H O COORS
R12 R..

Alternatively, the acid of formula XIV can be converted to an activated form such as an acid chloride prior to the coupling reaction.
The acids of formula XIV are described by 20 Warshawsky et al. in European Patent Application 534,396 and 534,492.
The compounds of formula I wherein A is :a , i . -x. c;

R~OOC - CH -HA629a X is 0 or S, and Y is CH2, O, or S can be prepared by reacting a keto acid or ester of the formula 5 (XVI) II II

with a fused bicyclic ring compound of formula III
under reducing conditions to give the product of the formula 10 (XVII) X
(CH2)n~
RIO-C-~ H- ~ N, sCH2 ) m R1 H 0 ~,COOR~
The keto acids and esters of formula XVI are 15 described in the literature. See, for example, Ruyle U.S. Patent 4,584,294 and Parsons et al. U.5. Patent 4,873,235.
Alternatively, the fused bicyclic ring compound formula III can be reacted with a triflate 20 of the formula (XVIII) O OSO~CFz R;0-C -CH -R1 to give the product of formula XVII.
25 The compounds of formula I wherein A is :, ,~ ~ >~ ,-'%~ ~ , !~ , >. ~ . " h ~ 1 4e O
II
R4 i , X is O or S, and Y is ORS
CH2, O or S can be prepared by coupling a phosphonochloridate of the formula (XIX) II

HA629a wherein R5 is lower alkyl or benzyl with a fused bicyclic ring compound of formula III to give the product of the formula 10 (XX) X
II (CH2)~~i Rq- ~ - ~ N~CH2 ) m OR5 H ~.1/O
COOR;
Preferably, R3 in the compound of formula III is lower alkyl or benzyl. The R3 and R5 acid protecting 15 groups can then be removed, for example, by hydrogenation to give the corresponding products of formula I wherein R3 and R5 are hydrogen.
The phosphonochloridates of formula XIX are known in the literature. See, for example, 20 Karanewsky et al. U.S. Patents 4,432,971 and 4,432,972 and Karanewsky U.S. Patent 4,460,579.
The products of formula I wherein either X or Y or both are S-(O)t and t is one or two can be prepared by oxidation of r_he compounds of formulas 25 IV, XV, XVII, or XX with a known oxidizing reagent such as meta chloroperbenzoic acid, peracetic acid, s1 ~ :°p ; s r? ~ -.
~~ ..i ~. ~

HA629a monoperoxyphthalic acid, magnesium salt hexahydrate, etc. By controlling the amount of oxidizing reagent and the time of the reaction, the products are obtained wherein t is one or two.
5 The ester products of formula I wherein R5 or R~ is O
O
O O
- CH - O - C - R9 or I -CH~u Ra Rlc 10 can be prepared by treating the corresponding compounds of formula I wherein R5 or R~ is hydrogen and R3 is an acid protecting group with a compound of the formula (XXI) O
O O
L- CH - O - C - R9 or 15 Re Rio wherein L is a leaving group such as chloro, bromo, or tolylsulfonyloxy followed by removal of the R3 acid protecting group.
The ester products of formula I wherein R3 is O
~I o O

20 Rs or R=o t.: ?
:1 ~~ n ~~ c~

HA629a can be prepared by treating the corresponding compounds of formula I wherein R3 is hydrogen and R2 O
II
is R6 C with a compound of formula XXI.
The fused bicyclic ring compounds of formula 5 III can be prepared according to the following processes which also form part of this invention.
For example, when Y is CHI an N-protected amino acid of the formula (XXII) X - P~
( CHZ ) n can be coupled with the amino acid ester of the formula 15 (XXIII) HC -(- O-alkyl ) 2 (CH:) a ( CHI ) m r HEN- CH - COORS
to give the dipeptide of the formula ~~~ 1'~~~ ;~
I:: ~ . s ., (XXIV) HA629a HC --~ 0-alkyl) z z (iHz)z (-H2)n (~ HZ)m P,-N- CH -II ~ CH - COORS

5 wherein P1 is an amino protecting group such as benzyloxycarbonyl or t-butyloxycarbonyl or a group which together with the N-atom forms a protecting group such as phthalimido,P2 is a hydroxy or mercapto protecting group, and R3 is an easily removable ester 10 protecting group. Preferred P2 protecting groups when X is S are acyl groups such as acetyl or benzoyl, especially acetyl. Preferred P2 protecting groups when X is O are acyl groups, tetrahydropyrans, hindered silyl groups and trityls, especially 15 triphenylmethyl and 1,1-dimethylethyldimethylsilyl.
This coupling reaction is preferably performed in the presence of a coupling reagent such as benzotriazol-1-yloxytris-(dimethylamino)phosphonium hexafluorophosphate, ethyl-3-(3-dimethylamino)propyl 20 carbodiimide, or methanesulfonyloxybenzotriazole.
The P2 protecting group can be selectively removed from the intermediate of formula XXIV such as by treatment with sodium methoxide in methanol when P2 is acetyl or benzoyl or treatment with an acid 25 such as p-toluenesulfonic acid in methanol when P2 is acetyl, benzoyl, trityl, tetrahydropyranyl, or 1,1-dimethylethyldimethylsilyi. The resulting product is then subjected to an acid catalyzed cyclization r E: .i h. '.~~. J

HA629a reaction preferably by treating with a strong acid such as trifluoroacetic acid, para-toluenesulfonic acid or a commercially available polystyrene sulfonate polymer type ion exchange resin such as 5 Amberlyst 15~~ This cyclization reaction can be performed in a non-protic solvent such as methylene chloride or chloroform to give the intermediate of the formula (XXV) X
('H2)?
( CHZ ) n~
P1_N N (CH2)n, O COORS
The compounds of formula XXIV after removal of the P2 protecting group and prior to cycli.zation 15 wherein X is O can be converted to the corresponding compounds wherein X is S. This can be done by various methods. For example, the compound of formula XXIV after removal of the P2 group can be treated with triphenylphosphine, diisopropyl 20 azodicarboxylate and thioacetic acid. The resulting thioacetate is then treated with sodium methoxide in methanol to give the corresponding mercaptan which can then be cyclized as described above.
In another method, the compound of formula 25 XXIV after removal of the P2 group is treated by known methods to give the compound of the formula ,i ~. ~4~ Jv i ~i ( XXV I ) HA629a HC -t O-alkyl ) 2 (IHi)2 (CH?)n (CHZ)m P1-N-CH-li -~ -1CH-COOR;

wherein L is a leaving group such as 5 methanesulfonyloxy, para-toluenesulfonyloxy,iodo, or bromo. For example, treatment of the compound of formula XXIV after removal of the P2 protecting group with methanesulfonyl chloride gives the compound of formula XXVI wherein L is methanesulfonyloxy.
10 The compound of formula XXVI is then treated with cesium thioacetate to give the correspopnding thioacetate. Treatment with sodium methoxide in methanol gives the corresponding mercaptan which can then be cyclized as described above.
15 Alternatively, the compound of formula XXIV
wherein X is O can be converted directly t.o the intermediate of formula XXV by treatment with a strong acid such as trifluoroacetic acid, para-toluenesulfonic acid, or a commercially available 20 polystyrene sulfonate polymer type ion exchange resin such as Amberlyst 15~ in a suitable solvent such as methylene chloride or chloroform.
The N-protecting group is then removed from the compound of formula XXV, for example, by 25 treatment with hydrazine monohydrate when P1 together with N atom forms a phthalimido group or by treatment with iodotrimethylsilane or palladium on carbon and ammonium formate or hydrogen when P1 is ø

:J ,~ ~
f~ i F.e 'a. c~ ~ c ~

HA629a benzyloxycarbonyl or by treatment with hydrochloric acid in dioxane or other strong acid when P1 is t-butoxycarbonyl to give the fused bicyclic ring compound of formula III.
5 In still another method when Y is CH2, the N-protected amino acid of formula XXII can be coupled with the hydroxy amino acid ester of the formula (XXVII) CHZ- OH
I
(IH2)2 (CHZ)m HEN- CH- COORS
10 to give the dipeptide of the formula (XXVIII) CHZ-OH
" Pz (i H2)2 (CHZ)r (CHZ)~r.

wherein P1 and P2 are as defined above. This coupling reaction is preferably performed in the 15 presence of a coupling reagent such as methanesulfonyloxybenzotriazole or ethyl-3-(di-methylamino)propyl carbodiimide.
Hydroxy compound XXVIII is then oxidized to the aldehyde of the formula 20 (XXIX) HC=0 X-P~ (CH, ) ( _ ~ _ .
(CHI)-, (CH~)T

P1- N- CH- Ii - i - CH- COOR;

~~ '~ r ~? '~ 1 HA629a by treating with oxalyl chloride/dimethylsulfoxide followed by a tertiary amine in a non-protic solvent such as methylene chloride. The aldehyde of formula XXIX is then treated as described above to remove the 5 P2 protecting group and then subjected to an acid catalyzed cyclization reaction as described above to give the intermediate of formula XXV.
The starting material of formula XXIII wherein m is one can be prepared by selective protection of 10 the N-atom of L-e-hydroxynorleucine to give (XXX) /CHZ \OH
C/H
CH~

15 wherein P3 is an N-protecting group. For example, P3 and the N-atom can form a phthalimido moiety. The N-protected L-~-hydroxynorleucine of formula XXX is then treated to introduce the R3 acid protecting group such as by treatment with methyl iodide in the 20 presence of base or by treatment with a strong acid in methanol wherein R3 is methyl. This ester is then oxidized to give the aldehyde of the formula C'r .~I y a c~ p F" ~ 1.1 ~.ff.' it..:

(XXXI) H
~C =O

HA629a 5 The aldehyde of formula xXxl is then treated with the orthoformate of the formula (XXXII) HC --E- 0-alkyl ) 3 in the presence of a strong acid catalyst and the corresponding alcohol, i.e. HO-alkyl wherein alkyl is the same as in the orthoformate of formula XXXII, to give 15 (XXXIII) H
/C-E- O-alkyl ) CH~
CH, P;-N -CH -COORS
Removal of N-protecting group P3 such as by treatment 20 with hydrazine hydrate when P3 and the N-atom forms a phthalimido moiety yields the starting material of formula XXIII wherein m is one.

? !a F.A629a The starting material of formula XXIII wherein m is zero can be prepared by protecting the N-atom of y-benzyl glutamate to give (XXXIV) COOCHZ

wherein P3 is an N-protecting group such as t-butyloxycarbonyl or where P3 and the N-atom can 10 form a phthalimido moiety. The N-protected glutamic acid of formula XXXIV is then treated to introduce the R3 acid protecting group, as described above, to give ( XXXV ) COOCHy--( [ ) ) CH ~~
15 P3-N -CH-COOR;

Hydrogenolysis when R3 is lower alkyl removes the benzyl ester group from compound XXXV to give (XXXVI) COOH
CH
P3-N -CH -COOR;

CM A r ~ ~ ~'~
s'.; .q. ~,~ ~ e~ ~ ti HA629a Selective reduction of compound XXxVI such as by treatment with ethanethiol, ethyl-3-(3-dimethlamino)propyl carbodiimide, and dimethyl-aminopyridine followed by triethylsilane, palladium 5 on carbon, and acetonitrile gives the aldehyde of the formula (XXXVII) HC=O
CHI

The aldehyde of formula XXXVII is then treated with the orthoformate of formula XXXII as described above and the N-protecting group P3 is removed as described above to give the starting material of formula XXIII
15 wherein m is zero.
The hydroxy amino acid ester starting material of formula XxVII can be prepared by reacting a solution of diethyl acetamidomalonate with a stirred suspension of sodium hydride followed by reaction 20 with a haloalkylacetate of the formula (XXXVIII) halo-(CHZ)m-(CH~)2 CH2'O-C-CH3 wherein halo is Br, I, or C1 to give the compound of the formula e~ -~ ; v ,e, G's : .~
~, .'_ ',, 'r El (XXXIX) O
II
Hz i - O- C- CH3 (~Hz)z (CHZ)m O
H3C-C-NH- ~-COOCzHS
COOCZHS
HA629a A solution of the diethyl ester of formula XXXIX is treated with sodium hydroxide and heat and 5 then acidified and heated again to give the hydroxy amino acid of the formula (XL) HzC-OH
( ~ H2 ) 2 O ( CHZ ) m 10 The hydroxy amino acid of formula XL is then treated with porcine kidney acylase or other suitable hydrolyzing enzyme to give the resolved h~~droxy amino acid of the formula (XLI) Hz ~ - OH
(~Hz)z (CH,)m 15 HzN-CH- COOH , The hydroxy amino acid of formula XLI is then converted to the ester of formula XXVII by conventional means. For example, the hydroxy amino E'A ~ ; ~ F ~1 .~.. ...
a iv G,.
'~ ~ "' HA629a acid of formula XLI can be treated in methanol with trimethylsilyl chloride to give the hydrochloride salt of the methyl ester of formula XXVII.
The starting materials of formula XXII can be 5 prepared as follows. When X is O, the hydroxy a-amino acid of the formula (XLII) OH
( CHZ ) r, HZN CH- COOH
is reacted to introduce the P1 and P2 protecting 10 groups. For example, treatment of the acid of formula XLII with N-carbethoxyphthalimide in the presence of sodium carbonate followed by treatment with chlorotripheriylmethane and triethylarnine gives the starting material of formula XXII wherein X is O, 15 P1 together with N-atom forms a phthalimido, and P2 is trityl. Alternatively, treatment of the acid of formula XLII with N-(benzyloxycarbonyloxy)succinimide in aqueous sodium carbonate and acetone followed by treatment with t-butyldimethylsilyl chloride or an 20 acylating agent of formula V or VI gives the starting material of formula XXII wherein X is O, P1 is benzyloxycarbonyl, and P2 is t-butyldimethylsilyl or an aryl group such as acetyl.
When X is S and n is one, N,N'-bis[(phenyl-25 methoxy)carbonyl]-L-cystine can be treated with zinc dust and aqueous sulfuric acid to give the mercaptan of the formula ~> ~ ~ ~ n ~ J :~, C. ~ ~ ~ i _.i .

(XLIII) HA629a SH
CHz /~ a 1 ~CH~-O-C NH-CH-COOH
The mercaptan of formula XLIII is then treated to introduce the P2 protecting group. For example, 5 treatment of the mercaptan of formula XLIII with acetic anhydride gives the starting material of formula XXII wherein X is S, n is one, P2 is acetyl, and P1 is benzyloxycarbonyl.
When X is S and n is two, L-methionine can be 10 protected on the N-atom. For example, reaction with benzyl chloroformate or N-(benzyloxycarbonyloxy)-succinimide gives N-[(phenylmethoxy)carbonyl]-L-methionine which is then esterified by treatment with an alcohol, alkyl-OH, in the presence of an acid 15 catalyst such as p-toluenesulfonic acid. Treatment with an oxidizing agent such as N-chlorosuccinimide in aqueous solvent gives the sulfoxide of the formula (XLIV) O
i - CH3 O (:H2)~
U r-CH~-0-C NH-1CH-COOalkyl The sulfoxide of formula XLIV is then treated with an acid anhydride such as acetic anhydride to give the compound of the formula a E,:, ~i .-~ ~7 ~' (XLV) HA629a O
II
i - CHZ- O- C- CH3 O (CH2)2 r CHZ-O-C-NH- CH- COOalkyl .
Treatment with alkali metal hydroxide, followed by 5 the removal of formaldehyde such as by treatment with a reducing agent, for example, sodium borohydride, followed by treatment with an acid anhydride such as acetic anhydride gives the starting material of formula XXII wherein X is S, n is two, P2 is acetyl, 10 and P1 is benzyloxycarbonyl.
The fused bicyclic ring compounds of formula III wherein Y is S or O and m is one can be prepared by coupling the N-protected amino acid of formula XXII with the amino acid ester of the formula 15 (XLVI) HC -t- O-alkyl) 2 H~ I
Y
HZN- CH - COOR:
to give the dipeptide of the formula 'r HA629a (XLVII) HC -(O-alkyl ) 2 HZC
~ - P2 ( ~H2 ) n ~Y
P1-N-CH- i-N-CH-COORS
O H
5 wherein P1 and P2 are as defined previously and R3 is an acid protecting group. This coupling reaction is preferably performed in the presence of a coupling reagent such as benzotriazol-1-yloxytris(dimethylamino)phosphonium hexafluoro-10 phosphate or ethyl-3-(3-dimethylamino)propyl carbodiimide.
The P2 protecting group can be selectively removed from the intermediate of formula XLVII such as by treatment with sodium methoxide in methanol 15 when P2 is an acyl group such as acetyl or. benzoyl and treatment with an acid such as p-toluenesulfonic acid in methanol when P2 is a trityl, tetrahydropyranyl, or a hindered silyl group. The resulting product is then subjected to an acid 20 catalyzed cyclization reaction as described above to give the intermediate of the formula 61s .~ : ) .? ~1 ~ ~.1 ~M .ice ~~ 'Z c.~

(XLVIII) / X
(CHZ)n Y

C

HA629a 5 The intermediate of formula XLVIII wherein X
is S and n is two can also be prepared by treating the compound of formula XLVII wherein X is O and n is two to selectively remove the P2 group and convert the hydroxy to a mercaptan as described above 10 followed by acid catalyzed cyclization.
The N-protecting group is then removed from the compound of formula XLVIII for example, by treatment with hydrazine monohydrate when P1 together with N atom forms a phthalimido group or by treatment 15 with iodotrimethylsilane or palladium on carbon and ammonium formate or hydrogen when P1 is benzyloxycarbonyl to give the fused bicyclic ring compounds of formula III.
The starting material of formula XLVI wherein 20 Y is O can be prepared by reacting the N-phthalimino protected amino acid ester of the formula (XLIX) O OH
'N- CH - COORS
O

.s .. ~, n, rr .,.
~: a HA629a with allyl trichloroacetimidate in the presence of trifluoromethanesulfonic acid to give the compound of the formula (L) CH = CH2 \N- CH - COOR;
O
Treatment of the compound of formula L with ozone in methanol then dimethylsulfide followed by 10 the orthoformate of formula XXXII in the presence of p-toluenesulfonic acid yields the protected compound of the formula (LI) H
/C-f0-alkyl) H
O ,.O
'N- CI H - COORS

Removal of the N-protecting group such as by treatment with hydrazine hydrate yields the starting material of formula XLVI wherein Y is O.

~. ':. i~'1 ~ ~ c HA629a The starting material of formula XLVI wherein Y is S can be prepared by reacting the cysteine ester of the formula (LII) SH
HZN- CH - COORS
with the bromoacetal of the formula 10 (LIII) Br-CHz-CH-f0-alkyl) in the presence of sodium hydride and potassium 15 iodide to give the amino acid ester of the formula (LIV) HC -~- O-alkyl ) 2 HzC
S

20 The compounds of formula I contain three asymmetric centers in the fused bicyclic portion of the structure with additional centers possible in the side chain. While the optically pure form of the fused bicyclic products described above is preferred, 25 all such forms are within the scope of this invention. The above described processes can utilize s'~ -A :, ,~ f~l ~~ :~.. 1,. .$ li~ ~ C!

HA629a racemates, enantiomers, or diastereomers as starting materials. When diastereomeric compounds are prepared, they can be separated by conventional chromatographic or fractional crystallization 5 methods. Preferably, the hydrogen attached to the bridgehead carbon is in the orientation shown below H
(CHZX\ ~Y
N~CHZ ) m O .COOR;
10 The compounds of formula I wherein R3, R5 and/or R~ are hydrogen can be isolated in the form of a pharmaceutically acceptable salt. Suitable salts for this purpose are alkali metal salts such as sodium and potassium, alkaline earth metal salts such 15 as calcium and magnesium, salts derived from amino acids such as arginine, lysine, etc. and salts derived from amines such as alkylamines, e.g.
t-butylamine, t-amylamine, etc., substituted alkylamines, e.g. benzylamine, dialkylamines, 20 substituted dialkylamines, e.g. N-methylglucamine, trialkylamines, substituted trialkylamines, and quaternary ammonium salts. These salts can be obtained by reacting the acid form of the compound with a base supplying the desired ion in a medium in 25 which the salt precipitates or in aqueous medium and then lyophilizing.
Preferred compounds of this invention are those wherein:

(~,.~ . ~ ..~.r '~ f~' HA629a O
A i s RZ S ( CHZ ) r~ ~ C-R1? R1 O
II
R2 is hydrogen, R° C , or R11-S-;
R3 is hydrogen or lower alkyl of 1 to 4 5 carbons;
r is zero or one;
R11 is lower alkyl of 1 to 4 carbons;
R1 is aryl-CH2-, substituted aryl-CH2-, heteroaryl-CH2-, cycloalkyl-CH2- wherein the 10 cycloalkyl is of 3 to 7 carbons, or straight or branched chain alkyl of 1 to 7 carbons and R12 is hydrogen; or R1 and R12 taken together with the carbon to which they are attached complete a cycloalkyl ring of 5 to 7 carbons;
15 R6 is lower alkyl of 1 to 4 carbons or phenyl;
n is one or two;
m is zero or one;
X is O or S; and Y is CH2, 0, or S provided that Y is O or S
20 only when m is one.
Most preferred are the above compounds wherein:
O
II
R2 is hydrogen or H3C C , especially hydrogen;
25 R3 is hydrogen;
r is zero or one; especially one;
R1 is benzyl, cyclopropylmethyl, or straight or branched chain alkyl of 3 to 5 carbons, especially benzyl;

:~~g :~ n~~M~-r r. .r ~~J i ~..

HA629a R12 is hydrogen;
n is one or two;
m is zero or one;
x is 0 or S; and 5 Y is CH2, O, or S provided that Y is O or S
only when m is one.
The single most preferred compound is [4S-[4a(R*),7a.,10a(3]]-octahydro-4-[(2-mercapto-1-oxo-3-phenylpropyl)amino]-5-oxo-7H-pyrido[2,1-b]-10 [1,3]thiazepine-7-carboxylic acid, i.e. the compound of the formula S H

N
HS- CH-C-N
.
CH-. H O COOH

15 The compounds of formula I wherein A is O
RZ-S- ( CHI ~~ ~ C R700C - ( CHz ) q ~C~
Riz Ri or Ri2 Ri are dual inhibitors possessing the ability to inhibit 20 angiotensin converting enzyme and neutral endopeptidase. The compounds of ~ , ~ .,l ...
w .i ~u ~.f, J ) iJ

HA629a O
R~OOC - CH -formula I wherein A is I or Ra-i -are selective inhibitors possessing the ability to inhibit the angiotensin converting enzyme. Thus, the compounds of formula I including their 5 pharmaceutically acceptable salts are useful in the treatment of physiological conditions in which angiotensin converting enzyme inhibitors have been shown to be useful. Such conditions include disease states characterized by abnormalities in blood 10 pressure, intraocular pressure, and renin including cardiovascular diseases particularly hypertension and congestive heart failure, glaucoma, and renal diseases such as renal failure, diabetic nephropathy, and renal impairment following treatment with 15 cyclosporine or other immunosuppressants. Other conditions in which angiotensin converting enzyme inhibitors have been reported to be useful include hepatic cirrhosis, inhibiting the progression of atherosclerosis, preventing or treating hypertensive 20 or diabetic retinopathy, improving myocardial dysfunction during or following a myocardial infarction, and preventing restinosis after angioplasty. The dual inhibitors are also useful in the treatment of physiological conditions in which 25 neutral endopeptidase inhibitors have been shown to be useful. Such conditions also include cardiovascular diseases particularly hypertension, hyperaldosteronemia, renal diseases, glaucoma, as well as the relief of acute or chronic pain. Thus, 30 the compounds of formula I are useful in reducing blood pressure and the dual inhibitors of formula I
are additionally useful for this purpose due to their W '~ rt c s E,. .~ ~,: '~ eri ~ t' HA629a diuresis and natriuresis properties. The dual inhibitors are particularly useful in the treatment of congestive heart failure.
The compounds of formula I inclduing 5 pharmaceutically acceptable salts thereof can be administered for these effects in amounts similar to those employed previously for angiotensin converting enzyme inhibitors. For example, the compounds of formula I can be administered to a mammalian host 10 such as man at from about 0.1 mg. to about. 100 mg.
per kg. of body weight per day, preferably from about 0.5 mg. to about 25 mg. per kg. of body weight per day. The compounds of formula I are preferably administered orally but parenteral routes such as 15 subcutaneous, intramuscular, and intravenous can also be employed as can topical routes of administration.
The daily dose can be administered singly or can be divided into two to four doses administered throughout the day.
20 The inhibitors of formula I can be administered in combination with human ANF 99 - 126.
Such combination would contain the inhibitor of formula I at from about 1 to about 100 mg. per kg. of body weight and the human ANF 99 - 126 at from about 25 0.001 to about 0.1 mg. per kg. of body weight.
The inhibitors of formula I can be administered in combination with other classes of pharmaceutically active compounds. For a}:ample, a diuretic, a calcium channel blocker, a potassium 30 channel activator, a cholesterol reducing agent, a ~i-blocker, etc.
The inhibitors of formula I or a pharmaceutically acceptable salt thereof and other pharmaceutically acceptable ingredients can be i'~ ~ 41 :~ ~1 .. i~.r ~3 ;..~ A

HA629a formulated for the above described pharmacetical uses. Suitable compositions for oral administration include tablets, capsules, and elixirs, and suitable compositions for parenteral administration include 5 sterile solutions and suspensions. Suitable compositions for treating glaucoma also include topical compositions such as solutions, ointments, and solid inserts as described in U.S. Patent 4,442,089. About 10 to 500 mg. of active ingredient 10 is compounded with physiologically acceptable vehicle, carrier, excipient, binder, preservative, stabilizer, flavoring, etc., in a unit dose form as called for by accepted pharmaceutical practice.
The following examples are illustrative of the 15 invention. Temperatures are given in degrees centigrade. Thin layer chromatography (TLC) was performed in silica gel unless otherwise stated.

a ~ r~
t'.: . _: . i c!

HA629a f4S-f4a(R*),7oc.l0a1311-Octahydro-4-f(2-mercapto-1-oxo-3-nhenv ropyl)aminol-5-oxo-7H=pvridof2 1--blfl 31-oxazey~ine-7-carboxylic acid S
a) (S)-2-Phthalimido-4-hydroxvbutanoic acid, triethylamine salt A solution of L-homoserine (3.0 g.,. 25.2 mmol.) and sodium carbonate (2.670 g., 25.2 mmol.) in 10 water (60 ml.) was treated with N-carbethoxy-phthalimide (5.570 g., 25.4 mmol.). After stirring at room temperature for 2 hours, the solution was acidified with 6 N hydrochloric acid and extracted into ethyl acetate. The ethyl acetate extract was 15 washed with brine, dried (sodium sulfate), and filtered into a solution of triethylamine (4.0 ml.) in methylene chloride (40 ml.). The cloudy solution was concentrated and triturated with ethyl acetate and ethyl ether to afford 5.11 g. of the title 20 compound as a white solid; m.p. 142 - 144"C. TLC (5a acetic acid in ethyl acetate) Rf = 0.36;
[a]D = -6.2° (c = 0.8, chloroform).
Anal. calc'd. for ClgH2gN205:
C 61.70; H 7.48; N 7.99 25 Found: C 61.45; H 7.47; N 7.84.
b) lS)-2-Phthalimido-4-(triphenylmethoxy)butanoic acid, triethylamine salt A homogeneous solution of the product from 30 part (a) (1.890 g., 5.4 mmol.) in chloroform (20 ml.) was treated with triethylamine (80 ~tl.) followed by solid chlorotriphenylmethane (1.590 g., 5.70 mmol.).
After stirring at room temperature for 2.5 hours, the solution was partitioned between ethyl acetate and C) ~ Cv t 4~ ~ ~,, 'at c~ ~ :~

HA629a 0.1 N hydrochloric acid (150 ml.). The organic layer was washed with water and brine, then dried (sodium sulfate) and filtered into a solution of triethyl-amine (1.0 ml.) in methylene chloride (30 ml.). The 5 solution was concentrated to an oil, redissolved in a small amount of methylene chloride and ethyl acetate and triturated with ethyl ether until the solution became turbid. The mixture was seeded and let stand at room temperature. The resulting precipitate was 10 collected by filtration, washed with ethyl acetate and ethyl ether, and dried in vacuo to afford 2.538 g. of the title compound as a white solid; m.p. - 165 - 170°C. (decomp.). TLC (loo methanol in chloroform) Rf = 0.23; [a]D = +7.0° (c = 1.2, chloroform).

c) (S)-2-Phthalimido-6-hydro hexanoic acid A solution of (+)-L-~-hydroxynorleucine [prepared according to the procedure of Bodanszky et al., J. Med Chem., 1978, ~, 1030 - 1035] (1.030 g., 20 7.0 mmol.) and sodium carbonate (745 mg., 7.0 mmol.) in water (12 ml.) was treated with N-carbethoxy-phthalimide (1.495 g., 7.0 mmol.) and the mixture was stirred at room temperature for 2 hours. The solution was filtered, cooled to 0° C., and acidified 25 with 6N hydrochloric acid to afford a white precipitate. The solid was collected by filtration and dried fir}, vacuo at 80° C . for one hour to give 1.297 g. of the title compound; m.p. 162 - 163°C.;
[a]D = -35.7° (c = 1.3, methanol) .

d1 lS)-2-Phthalimido-6,6-dimethoxyhexanoic acid.
methyl ester A slurry of the product from part (c) (3.752 g., 13.5 mmol.) and cesium carbonate (2.178 g., 6.7 a 4.r _ h, '.r y) ) ; a HA629a mmol.) in dimethylformamide (44 ml.) was treated with methyl iodide (3.0 ml., 6.84 g., 48.2 mmol.). After stirring at room temperature for 2 hours, the mixture was diluted with ethyl acetate and washed 5 successively with water containing a small amount of sodium bisulfate, water, 50o saturated sodium bicarbonate, and brine, then dried (sodium sulfate), filtered and stripped to give the intermediate ester as a colorless oil (3.825 g.). The oil was 10 homogeneous by TLC (1:1-acetone:hexanes) Rf = 0.37.
A -78°C solution of oxalyl chloride (1.37 ml., 2.00 g., 15.7 mmol.) in dry methylene chloride (58 ml.) was treated dropwise with a solution of dry dimethylsulfoxide (2.24 ml., 2.47 g., 31.6 mmol.) in 15 methylene chloride (2 ml.>. After 10 minutes, a solution of the above alcohol-ester (3.825 g., 13.1 mmol.) in methylene chloride (10 ml.) was added.
After an additional 15 minutes, triethylamine (8.0 ml.) was added and the mixture was stirred at -78°C
20 for 5 minutes, then warmed to 0°C. The mixture was diluted with ethyl acetate/ethyl ether and was subsequently washed with 1 N hydrochloric acid, water, and brine, then dried (sodium sulfate), filtered and stripped to give the crude desired 25 aldehyde. The oil was homogeneous by TLC ( 1:1-acetone:hexanes) Rf = 0.48.
A solution of the above aldehyde in methanol (17 ml.) and methylene chloride (17 ml.) was treated with trimethyl orthoformate (1.7 ml.) followed by p-30 toluenesulfonic acid monohydrate (180 mg.). The mixture was stirred at room temperature for 1.5 hours, then partitioned between ethyl acetate and 500 saturated sodium bicarbonate. The organic layer was washed with water and brine, then dried (sodium a ; ', : ~ s'!
4.. .i. _.: -I C~ ~ I~..

HA629a sulfate), flitered and stripped. The residue was flash chromatographed (Merck silica gel, 1:1-ethyl acetate:hexanes) and the pure product fractions were crystallized from ethyl acetate/hexanes to give the 5 analytically pure title product (3.452 g., first crop and 215 mg., second crop) as white needles; m.p. 69 -70°C. TLC (1:1 - ethyl acetate:hexanes) Rf = 0.35;
[a]D = -27.4° (c = 1.5, chloroform).
Anal. calc'd. for C1~H21NOg:
10 C 60.89; H 6.31; N 4.18 Found C 60.80; H 6.32; N 4.16.
e) fS-(R*,R*)1-2-ff2-Phthalimido-4-(trig]enyl-methoxy)-1-oxobuty~.laminol-6,6-dimethoxy-15 hexanoic acid, methyl ester A slurry of the product from part (d) (2.540 g., 7.57 mmol.) in methanol (18 ml.) was treated with hydrazine monohydrate (378 ~1., 390 mg, 7.80 mmol.). The mixture became homogeneous within 20 10 minutes. After stirring at room temperature for 3 days, the resulting slurry was filtered, stripped, slurried in methylene chloride, filtered and stripped again to afford the crude intermediate amine as a colorless oil. Meanwhile a solution of the 25 triethylamine salt product from part (b) (4.622 g., 7.80 mmol.) in methylene chloride (50 ml.) at 0°C.
was treated with benzotriazol-1-yloxytris-(dimethylamino)phosphonium hexafluorophosphate (3.519 g., 7.95 mmol.). The mixture was stirred for 35 30 minutes, then treated with a solution of the above amine in methylene chloride (15 ml.). After 10 minutes at 0° C and 2 hours at room temperature, the solution was partitioned between ethyl ether and water. The organic layer was washed with 500 :Z ~ ~: Yy 'r f.: ...r.~. ~,~ -i ci. ~ i HA629a saturated sodium bicarbonate and brine, then dried (sodium sulfate), filtered and stripped. The residue was flash chromatographed (Merck silica gel, 6:4-ethyl acetate:hexanes) to give 3.580 g. of pure title 5 compound as a white foam. TLC (6:4 - ethyl acetate:hexanes) Rf = 0.32; [a]D = +26.2° !c = 0.6, chloroform).
f) (S-(R* R*)1-2-f(2-Phthalimido-4-hydroxy-1-10 oxobutyl)aminol-6 6-dimethoxyhexanoic acid methyl ester A solution of the product from part (e) (5.420 g., 8.0 mmol.) in methanol (60 ml.) was treated with p-toluenesulfonic acid monohydrate (520 mg.). After 15 stirring at room temperature for 1.5 hours, the mixture was partitioned between ethyl acetate and dilute sodium bicarbonate. The phases were separated and the aqueous layer was extracted again with ethyl acetate. The pooled organic extracts were washed 20 with brine, dried (sodium sulfate), filtered and stripped. The residue was flash chromatographed (Merck silica gel, 8:2-ethyl acetate:hexanes followed by 5o methanol in ethyl acetate) to afford 2.860 g.
of the title product as a colorless oil. TLC (7:3 -25 ethyl acetate:hexanes) Rf = 0.26; [a]D _- +18.7°
(c = 1.3, chloroform).
g ) f 4S- (4a 7a 10a[3) 1 -Octahydro-4=ghthalimid~ 5-Qx~-7H-gyridof2 1-blfl 3loxazepine-7-carboxylic 30 acid, methyl ester A solution of the product from part (f) (2.10 g., 4.95 mmol.) in methylene chloride (100 ml.) was treated with Amberlyst~ 15 ion exchange resin (240 mg., pre-washed successively with 6 N

na c:: _;. '~ J ~ a HA629a hydrochloric acid, water, tetrahydrofuran, then methylene chloride). After stirring at room temperature for 2.5 hours, the solution was filtered, stripped and flash chromatographed (Merck silica gel, 5 6:4-ethyl acetate:hexanes followed by 100a ethyl acetate) to give 1.40 g. of title product as a white foam.
h) (S)-2-(Acetylthio)benzenepronanoic acid 10 Sodium nitrite (10.3 g., 280 mmol.) was added to a solution of D-phenylalanine (30.0 g., 181 mmol.) and potassium bromide (73.5 g.) in sulfuric acid (2.5 N, 365 ml.) over a period of one hour while maintaining the temperature of the reaction mixture 15 at 0°C. The mixture was stirred for an additional hour at 0° C and then for one hour at room temperature. The reaction solution was extracted with ether, the ether was back extracted with water, and the ether layer was dried over sodium sulfate.
20 Ether was removed ~n vacuo, and distillation of the oily residue afforded 25.7 g. of (R>-2-bromo-3-benzenepropanoic acid; b.p. 141°C. (0.55 mm. of Hg);
[a]D = +14.5° (c = 2.4, chloroform).
A mixture of thioacetic acid (7 ml., 97.9 25 mmol_) and potassium hydroxide (5.48 g., 97.9 mmol.) in acetonitrile (180.5 ml.) was stirred under argon at room temperature for 1 3/4 hours. The mixture was cooled in an ice-bath, and a solution of (R)-2-bromo-3-benzenepropanoic acid (20.4 g., 89 mmol.) in 30 acetonitrile (20 ml.) was added over a ten minute period. The reaction was stirred under argon at room temperature for 5 hours, filtered, and the acetonitrile was removed ,~,n vacuo. The oily residue was redissolved in ethyl acetate and washed with 100 ~': .~ C.. .. s1 ~ :, ~

HA629a potassium bisulfate and water. Removal of the ethyl acetate '~n_ vacuo afforded 19,6 g. of crude product.
The crude product was purified via its dicyclo-hexylamine salt using isopropyl ether as solvent for 5 crystallization. An analytical sample of (S)-2-(acetylthio)benzenepropanoic acid, dicyclohexylamine salt was prepared by recrystallization from ethyl acetate; m.p. 146-147°C.; Ia]D = -39.6°C. (c = 1.39, chloroform).
10 Anal. calc~d. for C11H12o3s ' C12H23N=
0,68.11; H,8.70; N,3.45; 5,7.91 Found: 0,67.93; H,8.71; N,3.37; S,7.94.
The free acid was regenerated by partitioning the dicyclohexylamine salt between 5~ potasssium 15 bisulfate and ethyl acetate to yield (S)-2-(acetylthio)benzenepropanoic acid; [a]D = -70.1°C.
(c = 1.91, chloroform).
Anal. calc~d. for C11H12o3s~
0,58.91; H,5.39; S,14.30 20 Found: 0,58.73; H,5.41; 5,14.53.
i) f4S-f4alR*).7a.10a(ill-Octahydro-4-ff2-(acetylthio)-1-oxo-3-nhenvlgrogyllaminol-5-oxo-7H-y~yridof2.1-b1f1.31oxazepine-7-25 carbQxvlic acid, methyl .ester The product from part (g) (620 mg., 1.66 mmol.) in methanol (10m1.) was treated with hydrazine monohydrate (85 ~1., 88 mg., 1.75 mmol.) and the solution was stirred at room temperature for 44 30 hours. The mixture was filtered and the solid was washed with methanol. The filtrate was stripped, triturated with methylene chloride, filtered again and stripped to give the crude amine as a cloudy oil (about 400 mg.).

t1, ~ : a ~ c~r ""'f ~
h ~ ~, ' x e) ~ ~.~

HA629a A cold (0°C) solution of (S)-2-(acetylthio)-benzenepropanoic acid (410 mg., 1.83 mmol.) and triethylamine (250 ~.1., 182 mg., 1.80 mmol.) in methylene chloride (10 ml.) was treated with the 5 above amine (as a solution in 8 ml. methylene chloride) followed by benzotriazol-1-yloxytris-(dimethylamino)phosphonium hexafluorophosphate (808 mg, 1.83 mmol.). The clear, nearly colorless solution was stirred at 0°C for 40 minutes and then 10 at room temperature for 2 hours. The mixture was partitioned between ethyl acetateiethyl ether and water. The organic layer was washed successively with 50~ saturated sodium bicarbonate and brine, then dried (sodium sulfate), filtered and stripped. The 15 residue was flash chromatographed (Merck silica gel, 60-70~ ethyl acetate in hexanes) to give 602 mg., of pure title product as a white foam; TLC (E~:4-ethyl acetate:hexanes) Rf = 0.27.
20 i ) f 4S- f 4a (R* ) 7a 10a~31 1 -Octah~rdro-4- f (2-mercapto-1-oxo-3-phenylprogyl)aminol-5-oxo-7H-gyridof2 1-blf1 3loxazepine-7-carboxylic acid A 0°C. solution of the product from part (i) (590 mg., 1.32 mmol.) in methanol (10 ml., 25 de-oxygenated via argon bubbling) was treated with 1N sodium hydroxide (7 ml., de-oxygenated via argon bubbling). After stirring for 15 minutes, the solution was warmed to room temperature and stirring under argon was continued for an additional 4.5 30 hours. The mixture was acidified with 5o potassium bisulfate, diluted with water and extracted with ethyl acetate. The ethyl acetate extract was washed with water and brine, then dried (sodium sulfate), filtered and concentrated to approximately 3 ml. The i ! ~ :y ~ 1"
.. ~~.:; c~.~ ~ x HA629a residue was slurried in ethyl acetate and a little hexane and the resulting solid was collected by filtration and dried in vacuo to give 413 mg. of the title product; m.p. 180.5°C. (decomp.). TLC (2%
5 acetic acid in ethyl acetate) Rf = 0.39;
[a]D = -37.6° (c = 0.36, methanol).
HPLC: YMC S3 ODS column (6.0 x 150 mm); eluted with 40o A: 90o water-10o methanol-0.2o phosphoric acid and 60o B: 10o water-90o methanol-0.2o 10 phosphoric acid; flow rate 1.5 ml/min detecting at 220 nm; tR = 6.73 min (95.70).
Anal. calc~d. for C2pH2gN204S ~ 0.12 ethyl acetate:
C, 58.05; H, 6.24; N, 6.95; S, 7.9E~
Found C, 58.23; H, 6.34; N, 6.83; S, 7.81..

13R-[3a(S*),6a,9aj311-Hexahvdro-3-f(2-mercapto-1-oxo-.~-oheny>~~rowl)aminol-4-oxo-2H 6H-pyridof2 1-blfl 31-thiazine-6-carboxylic acid Phenvlmethoxvlcarbonvll-L-cvstein A solution of N,N~-bis[(phenylmethoxy)-carbonyl]-L-cystine (4.658 g., 9.16 mmol.) in methanol (35 ml.) was treated with 2 N sulfuric acid 25 (23 ml.) followed by portionwise treatment with zinc dust (2.442 g., 37.3 mmol.). The mixture was heated at 70°C. for 1.5 hours, filtered while still warm, and concentrated on the rotovap. The residual solution was extracted with ethyl ether and the 30 ethereal extract was washed with water and brine, then dried (sodium sulfate), filtered and stripped.
The residue (oil) was dissolved in carbon tetrachloride, cooled to 0°C., and seeded to slowly afford a precipitate. The solid was collected by ?f ~A~ ~'~J~~:~

HA629a filtration and washed with cold carbon tetrachloride to give 2.648 g. of product. The mother liquor was stripped, flash chromatographed (Merck silica gel, ethyl acetate followed by 4o acetic acid in ethyl 5 acetate) to give additional product after crystallization (246 mg.). The total yield of product was 2.894 g. TLC (5~ acetic acid in ethyl acetate) Rf = 0.58.
10 ~) S-ACet~l-N-f(Phenylmethoxy)carbon~ll-L-cysteine A homogeneous solution of the product from part (a) (2.70 g., 10.6 mmol.) in water (s0 ml., de-oxygenated via argon bubbling) containing potassium bicarbonate (2.140 g., 21.4 mmol.) was 15 treated with acetic anhydride (8.0 ml., 8.66 g, 84.8 mmol.). After 10 minutes at room temperature, the mixture was acidified with 10o hydrochloric acid and extracted with ethyl ether. The ethyl ether extract was washed twice with water and brine, then dried 20 (sodium sulfate), filtered and stripped to give an oil. The residue was azeotroped three times with toluene and twice with ethyl ether/hexane, after which time the oil crystallized. The residue was triturated with ethyl ether/hexane and the solid was 25 collected by filtration to give 2.19 g., of pure title product. TLC (5o acetic acid in ethyl acetate) Rf = 0.56.
c) (S)-2-ffN-T(Phen~lmethoxy)carbonyl-S-acetyl-L-30 y snyilaminol-6 6-dimethoxvhexanoic acid ~ethvl- ester A slurry of (S)-2-phthalimido-6,6-dimethoxy-hexanoic acid, methyl ester [prepared as described in Example 1(d), 1.158 g., 3.45 mmol.) in methanol Gt ,e :'.~ n i..F y.' ,..
~'~ .l ~::, '; :~ i ;.~ HA62 9 a _ q8 _ (12 ml.) was treated with hydrazine monohydrate (176 X11., 182 mg., 3.63 mmol.). The mixture became homogeneous within 10 minutes. After stirring at room temperature for 67 hours, the resulting slurry 5 was filtered, stripped, slurried in methylene chloride, filtered and stripped again to afford the crude intermediate amine as a colorless oil.
Meanwhile a partial slurry of the product from part (b) (1.185 g., 3.98 mmol.) in methylene chloride (14 10 ml.) was treated with triethylamine (555 ill., 403 mg., 3.98 mmol.). The now homogeneous solution was cooled to 0°C, treated with the above amine as a solution in methylene chloride (7 mL), then treated with benzotriazol-1-yloxytris(dimethylamino)-15 phosphonium hexafluorophosphate (1.762 g., 3.98 mmol.). The mixture was stirred at 0°C. for 2.5 hours, then at room temperature for 45 minutes. The solvent was removed and the residue was partitioned between ethyl acetate and water. The organic layer 20 was washed with 50o saturated sodium bicarbonate and brine, then dried (sodium sulfate), filtered and stripped. The residue was flash chromatographed (Merck silica gel, 65:35-ethyl acetate:hexanes) to give 1.15 g., of the pure title product as a white 25 foam. TLC (75:25 - ethyl acetate:hexanes) Rf = 0.42.
Analysis Calc~d. for C22H3-~N208S:
C, 54.53; H, 6.66; N, 5.78; S, 6.62;
Found C, 54.79; H, 6.72; N, 5.77; S, 6.95.
30 d) f3R- (3a 6a.9a~3) 1 -Hexahydro-3- f f (phenylmethoxv) -carhr~nvllaminol-4-oxo-2H.6H-pyridal2.l-bl(1.31-thiazine-6-carboxylic acid, methyl ester A de-oxygenated (argon bubbling) solution of the product from part (c) (1.040 g., 2.15 mmol.) in 1-~ ~w. ~.i ''t ~ ~ ~5 HA629a methanol (12 ml.) at 0°C. was treated with sodium methoxide (25o by weight in methanol, 490 X11., 463 mg., 2.14 mmol.). After 20 minutes, the mixture was quenched with saturated ammonium chloride, diluted 5 with water, and extracted with ethyl acetate. The ethyl acetate extract was washed with water and brine, then dried (sodium sulfate), filtered and stripped. The residue was redissolved in methylene chloride (200 ml.) and stirred at room temperature 10 with Amberlyst~ 15 ion exchange resin (820 mg., pre-washed successively with 6 N hydrochloric acid, water, tetrahydrofuran, then methylene chloride).
After 3 hours, the solution was filtered, stripped and flash chromatographed (Merck silica gel, 65:35 15 ethyl acetate:hexanes) to give 757 mg. of the title product as a colorless oil. TLC (75:25 - ethyl acetate:hexanes) Rf = 0.58.
e) (3R-(3a,6a,9a(3)1-Hexahvdro-3-amino-4-oxo-2H,6H-20 pyridof2.1-bl(1,31thiazine-6-carboxylic acid, methyl ester A solution of the product from part (d) (752 mg., 1.99 mmol.) in dry methylene chloride (15 ml.) was treated at room temperature with iodo-25 trimethylsilane (620 X11., 872 mg., 4.36 mmol.).
After stirring for 3 hours, the mixture was quenched with water, treated with a small amount l00 hydrochloric acid, and extracted with ethyl ether.
The layers were separated and the ethereal layer was 30 back-extracted with water. The pooled aqueous layers were made basic (pH 13) with loo sodium hydroxide and extracted twice with methylene chloride. The pooled methylene chloride extracts were dried (sodium sulfate), filtered and stripped to give 290 mg. of .'b C
a . ' c f: .~ , HA629a crude title product as a colorless oil. TLC (10%
methanol in methylene chloride) Rf = 0.38.
f~ f 3R- f 3a (S* ) , 6a, 9a(31 1 -Hexahydro-3- f f 2- (acetyl-5 thio)-1-oxo-3~henvlprogyllaminol-4-oxo-2H.6H-Ryridof2,1-blfl,3lthiazine-6-carboxylic acid.
methyl ester A cold !0° C.) solution of (S)-2-(acetylthio)benzenepropanoic acid (294 mg., 1.31 10 mmol.) and triethylamine (180 ~L, 131 mg., 1.29 mmol.) in methylene chloride (8 ml.) was treated with the product from part (e) (287 mg., 1.17 nunol.) as a solution in 6 ml. methylene chloride. Benzotriazol-1-yloxytrisldimethylamino)phosphonium hexafluoro-15 phosphate (575 mg., 1.30 mmol.) was then added. The clear, nearly colorless solution was stirred at 0°C
for 1 hour and then at room temperature for 1 hour.
The solvent was removed by rotary evaporation and the residue was partitioned between ethyl acetate and 50 20 potassium bisulfate. The organic layer was washed successively with water, 50o saturated sodium bicarbonate and brine, then dried (sodium sulfate), filtered and stripped. The residue was flash chromatographed (Merck silica gel, l:l-ethyl 25 acetate:hexanes) to give 412 mg. of the pure title product as a white foam. TLC (1:1-ethyl acetate:hexanes) Rf = 0.27; [a]D = -107.0°C. (c =
0.6, chloroform).
30 a) f 3R- f 3alS* ) , 6a, 9a,f31 1 -Hexahydro-3- f (2-merca 1-oxo-3-ghenylprogyl)aminol-9-oxo-2H.6H-gyrido-f2.1-b1f1,31thiazine-6-carboxylic acid A 0°C solution of the product from part (f) (406 mg, 0.90 mmol) in methanol (5 ml., de-oxygenated s1 ,n :'~ N '~ ~) ".
E r -~ e.r' 8 ~i HA629a via argon bubbling) was treated with 1 N sodium hydroxide (5 ml., deoxygenated via argon bubbling).
After stirring for one hour, the solution was warmed to room temperature and stirring under argon was 5 continued for an additional 1.25 hours. The mixture was acidified with 5o potassium bisulfate, diluted with water and extracted with ethyl acetate. The ethyl acetate extract was washed with water and brine, then dried (sodium sulfate), filtered and 10 stripped. The residue was flash chromatographed twice (Merck silica gel, 2~ acetic acid in ethyl acetate). Product fractions were checked by HPLC.
The desired fractions were pooled, stripped, and azeotroped twice with eth~~1 acetate. The residue was 15 taken up in a small amount of ethyl acetate and triturated with hexanes. The solvent was stripped and the residue was slurried in hexanes, stripped and dried ~ yaeuo to give 98.3 mg. of the title product as a hard white foam. TLC(2% acetic acid in ethyl 20 acetate) Rf = 0.46; [a]D _ -57.0°
(c = 0.4, chloroform).
HPLC: YMC S3 ODS column (6.0 x 150 mm); eluted with 40o A: 90$water-10o methanol-0.2% phosphoric acid and 60o B: loo water-90o methanol-0.2% phosphoric acid;
25 flow rate 1.5 mL/min detecting at 220 nm; tR = 8.33 min. t95.0a) .
Anal. calc'd. for C1gH22N204S2 ~ 0.2 ethyl acetate:
C, 54.79; H, 5.77; N, 6.80; S, 15.56.
Found C, 54.59; H, 6.04; N, 6.59; S, 15.16.

,L4S-f4a(R*) 7a 10a1311-Octahydro-4-f(2-mercanto-1-oxo-~-nhenylnrc~gyl)aminol-5-oxo-7H-gyridof2,1-b1f1.31-~hiaze~ine-7-carboxylic acid Gll ~! ~ j E. .~ ~,r 1, '~ ~ . a HA629a a) fS-(R*.R*)1-2-ff2-Phthalimido-4-(acetvlthio)-1-Qxobu~vllaminol-6 6-dimethoxvhexanoic acid meth~rl ester 5 A cold (0°C.) solution of triphenylphosphine (1.143 g., 4.36 mmol.) in tetrahydrofuran (20 ml.) was treated with diisopropyl azidodicarboxylate (860 X11., 883 mg., 4.37 mmol.). Within 5 minutes a white slurry developed. After 30 minutes, a solution of 10 [S-(R*,R*)-2-[(2-phthalimido-4-hydroxy-1-oxobutyl]-amino]-6,6-dimethoxyhexanoic acid, methyl ester [prepared as described in Example 1(f), 928 mg., 2.19 mmol.] in tetrahydrofuran (8 ml.) was added followed by neat thioacetic acid (312 ~1., 332 mg., 4.36 15 mmol.). The mixture was stirred at 0°C. for 1.25 hours, then partitioned between 50o saturated sodium bicarbonate and ethyl acetate. The ethyl acetate extract was washed with brine, dried (sodium sulfate), filtered and stripped. The residue was 20 redissolved in ethyl acetate and treated with a small amount of hexane to precipitate triphenylphosphine oxide. The mixture was filtered and the filtrate was flash chromatographed (Merck silica gel, 65:35-ethyl acetate:hexanes) to give 894 mg. of the title product 25 as a colorless oil. TLC (75:25 - ethyl acetate:hexanes) Rf = 0.43.
b) f4S-(4a,7a.l0a(3)1-Octahydro-4-nhthalimido-5-oxo-7H-Dyridof2,1-b1f1,31thiaz~gine-7-carboxylic 30 acid, methyl ester A de-oxygenated (argon bubbling) solution of the product from part (a) (814 mg., 1.65 mmol.) in methanol (15 ml.) at 0°C. was treated with sodium methoxide (25o by weight in methanol, 1.05 ml., 4.6 CA 02124:375 '~~'.002~~~06-05 ._ 53 F~ev.629a rnmol.). After 5 minutes, the mixture was quenched with saturated ammonium chloride, diluted with water, and extracted with ethyl acetate. The ethyl acetate extract was washed with water and larir~e, then dried (sodium sulfate), filtered and stripped.
The residue was redissolved in methylene chloride (180 m1.) and stirred at room temperature with Amberlyst~-~
15 ion exchange resin (285 mg., pre-washed successively with 6 N hydrochloric acid, water, tetrahydrofur-ara, then S~GT!Of~2GORReCTfOt~tmethylene chloride) . After 46 hours, the solution S~~CacRTIFI~AT~ was filtered, stripped and flash chromatographed GOedRECTfOP'.
-AEiT;~'~.r"
~

y~06R04RTI~I~~~ (Merck silica gel, 1:1-ethyl acetate:hex:anes) to give 314 mg. of the title product as a white foam.

Trituration of the foam with ethyl ethez produced the title product. as a white solid; m.p. ~-14'~i - 148C.

TLC (75:25 - ethyl acetate:hexanes) Rg s 0.56: (a.]D =

-143.2 (c = 0.6, chloroform).

c,Z, ( 4S- (4a (k* Y . 7a.10a(il t -Octahvdro-4- ~ C 2-((ace,Y~~io)- -~0-~3-l~henvloroov7lam~n.ol~, o,~~H-pyridio(2.1-b1 C1,,~~thi.'~zet'~inQ-7-.
carboxylic a.~. methvl_ ~t~r The product from part (b) 0280 mg., 4>.72 mmol. ) in methanol (8 ml _ ) was treated ~~ritr.
hydrazine monohydrate C42 ~,~.., 4:3.3 mg., 0.86 mmol.) and the solution was stir°red at room temperature for 67 hours. The mixture was filr_ered and the solid was washed with methanol. The filtrate was ;stripped, triturated with methylene chloride, filtered again and stripped to give the crude amine as ~s yellow oil labout 205 mg.).
A cold (0° C.> solution of CS)-2-(acetylthio)-benzenepropanoic acid (178 mg., 0.79 mmol.) and triethylamine (111 ~tl., 80 rng., 0.80 mmoi.) in HA629a methylene chloride (3 ml.) was treated with the above amine (as a solution in 7 ml. methylene chloride) followed by benzotriazol-1-yloxytris(dimethyl-amino)phosphonium hexafluorophosphate (353 mg., 0.80 5 mmol.). The solution was stirred at 0°C. for 1 hour and then at room temperature for 2 hours. The solvent was stripped and the residue was partitioned between ethyl acetate and 5o potassium bisulfate.
The organic layer was washed successively with water, 10 50% saturated sodium bicarbonate and brine, then dried (sodium sulfate), filtered and stripped. The residue was flash chromatographed (Merck silica gel, 1:1-ethyl acetate:hexanes) to give 272 mg. of the pure title product as a white foam.

d) f4S-f4a(R*).7a.10ai~11-Octahvdro-4-f(2-mercapto-1-oxo-3 ~henylproByl)aminol-5-oxo-7H-ovridof2.1-bl f1.31thiaze8ine-7-carboxylic acid A room temperature solution of the product 20 from part (c) (227 mg., 0.49 mmol.) in methanol (5 ml., de-oxygenated via argon bubbling) was treated with 1 N sodium hydroxide (8 ml" deoxygenated via argon bubbling). After stirring for 1 hour, the mixture was acidified with loo hydrochloric acid, 25 diluted with water and extracted with ethyl acetate.
The ethyl acetate extract was washed with water and brine, then dried (sodium sulfate), filtered and concentrated. The resulting solid was slurried in ethyl acetate and collected by filtration. The 30 filtrate was flash chromatographed (Merck silica gel, to acetic acid in ethyl acetate) and the desired fractions were pooled, stripped, and triturated with ethyl acetate/ethyl ether to give additional solid.

c1 a :i ~ n ~- . ": ~ ~ '-~ ~ '' HA629a The solids were pooled to give a total of 150 mg. of the title product;
m.p.

217C.
(decomp.).
TLC

(2~ acetic acid in ethyl acetate) Rf =
0.56;

[a]D = -72.6 (c = 0.28, dimethylformamide).

5 HPLC YMC S3 column (6.0 x 150 mm); eluted ODS with 40o A: water-loo methanol-0.2o phosphoric 90o acid and 0o B: 10o water-90% methanol-0.20 phosphoricacid; flow rate 1.5 ml/min detecting at 220 nm; tR = 9.48 min. (97.40).

10 Anal. calc'd. C19H24N2~4S2 0.14 ethyl acetate:
for C, 55.82; H, 6.02; N, 6.66; S, 15.24;

Found C, 55.53; H, 6.01; N, 6.63; S, 14.91.

15 f4S-f4alR*) 7a 9a~i11-Octahvdro-4-f(2-mercapto-1-oxo-~~en prog~rl ) aminol -5-oxoByrrolo f 2 1-blfl 3loxazepine-7-carboxylic acid a) (S)-2-Phthalimido-5-oxo-5-(~ylmethoxv>-20 gentanoic acid To a solution of 'y-benzyl-L-glutamate (17.49 g., 73.70 mmol.) in aqueous (180 ml.) sodium carbonate (7.81 g., 73.70 mmol.) and dioxane (120 ml.) was added N-carbethoxyphthalimide (16.50 g., 25 75.27 mmol., 1.02 eq.). After stirring at room temperature for 4.5 hours, The reaction mixture was acidified with 6N hydrochloric acid (30 m:1.) and extracted into ethyl acetate (2 x 400 ml.). The combined ethyl acetate extracts were washed with 50~
30 brine (200 ml.), and brine (200 ml.), dried over sodium sulfate, filtered, concentrated and dried ~
vacuo to yield a crude oii (41.4 g.). To a solution of the crude residue in ethyl ether (100 ml.) was added dicyclohexylamine (14 ml.). After standing in ~1 ~ :'1 P c~
t~. ~..~ '~ c 1 ~ ~:i HA629a the refrigerator overnight, the ethyl ether was removed by rotary evaporation and the oily residue was crystallized from ethyl acetate/ hexane. The resulting precipitate was collected by filtration, 5 washed with hexane and dried ~ vacuo to yield 21.21 g. of the title product as the dicyclohexyl amine salt. A suspension of this dicyclohexylamine salt in ethyl acetate (200 ml.) was washed with 5e potassium bisulfate (3 x 50 ml.), brine (50 ml.) and 10 dried over magnesium sulfate, filtered and concentrated to yield 13.5 g. of the title product as a white foam. TLC: (3o acetic acid in 9:1 ethyl acetate:heptane! Rf = 0.30.
15 b) lS)-2-Ph halimido-5-oxo-5-~phenylmethox_y)-y~entanoic acid methyl ester To a solution of the product from part (a) (13.22 g., 36.0 mmol.) and cesium carbonate (5.86 g., 18.0 mmol.) in dimethylformamide (100 ml.) was added 20 iodomethane (8.1 ml., 129.6 mmol., 3.6 eq.). The yellow solution was stirred for 2.5 hours, and was then partitioned between ethyl acetate (300 ml.) and water (250 ml.). The ethyl acetate extract was washed with 5~ sodium bicarbonate (200 ml.) and 25 brine, dried over magnesium sulfate, filtered and concentrated to yield 13.H8 g. a yellow o.il. The residue was purified by chromatography on a 5 x 20 cm. silica gel column eluting with 30% ethyl acetate/hexane. The desired fractions were combined 30 and concentrated to yield 10.0 g of the title product. TLC (1:1, ethyl acetate: hexane) Rf = 0.45.

~'p 9 G'9 r~ ~', !' ~ ;a ii.., $ ~.i .s. C~ ~!
_ 57 _ HA629a c1 (S)-2-Phthalimido-4-(carboxlr)butanoic acid, methyl ester To a solution of the product from part (b) (10.0 g., 26.22 mmol.) in ethyl acetate (115 ml.) was 5 added 20o palladium hydroxide on carbon catalyst (1.90 g.) and the resulting suspension was stirred under hydrogen atmosphere (balloon) for 2.5 hours.
The mixture was filtered, washed thoroughly with ethyl acetate, concentrated and dried in vacuo to 10 yield 7.29 g. of crude title product as a white solid; m.p. 137-138°C. TLC (10% methanol/ methylene chloride) Rf = 0.43.
d) (S)-2-Phthalimido-5-oxo-5-(ethylthio)pentanoic 15 acid, methyl ester To a solution of the product from part (c) (7.27 g., 24.95 mmol.) in methylene chloride (125 ml.) at 0° C under argon was added ethanethiol (4.81 ml., 64.92 mmol., 2.6 eq), 4-dimethylaminopyridine 20 (609 mg., 4.99 mmol., 0.2 eq.) and ethyl-3-(3-dimethylamino)propyl carbodiimide, hydrochloride salt (5.27 g., 27.47 mmol_, 1.1 eq.). After stirring at Oo C for 2 hours and at room temperature for 1 hour the reaction was concentrated, diluted with ethyl 25 acetate (400 ml.) and washed with 5o potassium bisulfate (200 ml.), saturated sodium bicarbonate (200 ml.), and brine (200 ml.), dried over sodium sulfate, filtered, concentrated and dried ~ vacuo to yield 8.30 g. of title product as a crude oil.
30 TLC (l: l, ethyl acetate: hexane) Rf = 0.47.

c1 a.:t;~ ~?rjo _ 58 _ HA629a e) (S)-2-Phthalimido-5-oxopentanoic acid, methyl ester A suspension of the product from part (d) (8.30 g., 24.75 mmol.) and 10~ palladium on carbon 5 (1.24 g.) in acetonitrile (150 ml.) under argon was treated dropwise with triethylsilane (7.91 ml., 49.5 mmol., 2 eq.). After stirring at room temperature for 45 minutes, the mixture was filtered.
concentrated and dried irk vacuo. The crude residue 10 was purified by chromatography on a 5 x 25 cm silica gel column eluting with 25o ethyl acetate/ hexane (41.) followed by 35% ethyl acetate/hexane (21.).
The desired fractions were combined to yield 5.60 g.
of title product.
15 TLC (1:1, ethyl acetate: hexane) Rf = 0.32.
f) (S)-2-Phthalimido-5,5-dimethoxvnentanoic acid, met 1 ester A solution of the product from part (e) (5.60 20 g., 20.34 mmol.) in methanol (60 ml.) and methylene chloride (40 ml.) was treated with trimethylortho-formate (3.8 ml., 34.59 mmol., 1.7 eq.) and p-toluenesulfonic acid monohydrate (280 mg.). After stirring at room temperature for 1.5 hours the 25 reaction was quenched with 2 ml. of saturated sodium bicarbonate, concentrated, and partitioned between ethyl acetate (400 ml.) and water (100 ml.). The ethyl acetate extract was washed with saturated sodium bicarbonate (100 ml.), brine (100 ml.), dried 30 over magnesium sulfate, filtered and concentrated to a crude oil. The crude residue was purified by chromatography on a 5 x 20 cm silica gel column eluting with 30o ethyl aceatate/hexane (21.). The k1 : ,5 t ~ i 6,. ': c.~ y '~~
_ 59 -HA629a desired fractions were combined, concentrated and dried in vacuo to yield 6.20 g. of title product.
TLC (1:1, ethyl acetate: hexane) Rf = 0.40.
5 g) (S)-2-Amino-5.5-dimethoxyBentanoic acid, meth's ester A solution of the product from part: (f) (6.16 g., 19.18 mmol.) in methanol (125 ml.) was treated with hydrazine monohydrate (0.98 ml., 20.14 mmol., 10 1.05 eq). After stirring at room temperature for 6 days, the resulting slurry was filtered, concentrated, triturated in methylene chloride, filtered, concentrated and dried in vacuo to afford 3.57 g. of title product as a cloudy oil.
15 TLC (10o methanol in methylene chloride) Rf = 0.41.
h) fS-(R*.R*)1-2-ff2-Phthalimido-4-(trighenyl-methoxv)-1-oxobuty_llaminol-5,5-dimethoxypentanoic acid, methyl ester 20 A solution of (S)-2-phthalimido-4-(triphenylmethoxy)butanoic acid, triethylamine salt [prepared as described in Example 1(b), 11..62 g., 19.60 mmol., 1.05 eq.] in methylene chloride (100 ml.) at Oo C was treated with benzotriazol-1-25 yloxytris(dimethylamino)phosphonium hexafluoro-phosphate reagent (8.67 g., 19.60 mmol., 1.05 eq.).
The mixture was stirred for 45 minutes at 0° C, then treated with a solution of the product from part (g) (3.57 g., 18.67 mmol.) in methylene chloride (50 30 ml.). After 10 minutes at 0° C and 2 hours at room temperature, the solution was partitioned between ethyl acetate (300 ml.) and water (100 ml.). The ethyl acetate layer was washed with 50o saturated sodium bicarbonate (100 ml.) and brine (100 ml.), c~ :~ ;~s r~s r~ .,.
1~
'..x', c.>' HA629a dried over magnesium sulfate, filtered and concentrated. The residue was purified by chromatography on a 5 x 25 cm silica gel column eluting with 1:1 ethyl acetate/hexane affording 8.58 5 g. of title product. TLC (1:1, ethyl acetate: hexane) Rf = 0.20.
i) ~S-(R* R*)1-2-f(2-Phthalimido-4-)~droxy-1-Qxobutyl)aminol-5,5-dimethoxypentanoic acid, methyl 10 ester A solution of the product from part (h) (8.58 g., 12.91 mmol.) in methanol (100 ml.) was treated with p-toluensulfonic acid monohydrate (850 mg.).
After stirring at room temperature for 3.5 hours, the 15 mixture was partitioned between ethyl acetate (200 ml.) and 10o saturated sodium bicarbonate (100 ml.).
The phases were separated and the aqueous layer was extracted again with ethyl acetate (100 ml.). The combined ethyl acetate extracts were washed with 20 brine, dried over magnesium sulfate, filtered and concentrated. The residue was purified by chromatography on a 5 x 20 cm silica gel column eluting with 8:2 ethyl acetate: hexane (11.) followed by to methanol in ethyl acetate (21.). The desired 25 fractions were combined, concentrated and dried in vacuo to yield 4.33 g. of title product.
TLC (8:2 ethyl acetate: hexane) Rf = 0.21.
i) ~4S-(4a,7a,9a(31-Octahydro-4-phthalimido-5-30 oxonyrrolo(2,1-b1f1,31oxazepine-7-carboxylic acid.
methyl ester A solution of the product from part (i) (1.89 g., 4.48 mmol.) in methylene chloride (90 ml.) was treated with Amberlyst~ 15 ion exchange resin (400 ,. ._ HA629a mg., pre-washed successively with 6N hydrochloric acid, water, tetrahydrofuran and methylene chloride).
After stirring at room temperature for 3 hours the solution was filtered, concentrated and flash 5 chromatographed on a 5 x 15 cm silica gel column eluting with 6:4 ethyl acetate: hexane to afford 1.51 g. of title product as a white foam.
TLC t8:2 ethyl acetate: hexane) Rf = 0.32.
10 k) f4S-(4a,7a.9a,f3)1-4-Amino-octahydro-5-oxcZgvrrolof2.l-b1f1.31oxazepine-7-carboxylic acid.
methyl ester The product from part (j) (764 mg., 2.13 mmol.) in methanol (15 ml.) was treated with 15 hydrazine monohydrate (109 ~1., 2.24 mmol., 1.05 eq.) and the solution was stirred at room temperature for 4 days. The mixture was filtered and the solid was washed with methanol. The filtrate was concentrated, triturated with methylene chloride, filtered again 20 and concentrated. The residue was purified by chromatography on a 2 x 15 cm silica gel column eluting with 3% methanol in methylene chloride (31.) followed by 10o methanol in methylene chloride (11.).
The desired fractions were combined and concentrated 25 to afford 451 mg. of title product as an oil.
TLC (10 o methanol in methylene chloride) Rf = 0.18.
1) f4S-(4a(R*).7a.9x(311-OCtahydro-4-ff2-(acetyl-30 rhi~1-1-oxc-3-ohenylpropvllaminol-5-oxogyrrolof2,1-ht f ~ . '~ t oxazepine-7-carbox~~1 is acid, methyl ester A suspension of the dicyclohexylamine salt of (S)-2-acetylthio-3-benzenepropanoic acid (prepared as described in Example 1(h), 870 mg., 2.14 mmol., 1.14 ~-~ ~ , , . ~ ..
r',~ v.~ e) q ,~.

HA629a eq.) in ethyl acetate (70 ml.) was washed with 50 potassium bisulfate (5 x 20 ml.), 50o brine (20 ml.), and brine (20 ml.), dried (anhydrous sodium sulfate), filtered, concentrated and dried ,~n_ vacuo overnight 5 to give (S)-2-(acetylthio)benzenepropanoic acid.
This free acid was dissolved in dry methylene chloride (10 ml.), cooled to 0° C (ice-salt bath) and treated with triethylamine (298 X11, 2.14 mmol.) followed by a solution of the product from part (k) 10 (430 mg., 1.88 mmol.) in methylene chloride (10 ml.) and benzotriazol-1-yloxytris(dimethylamino) phosphonium hexafluorophosphate (947 mg., 2.14 mmol., 1.14 eq.). The resultant solution was stirred at 0° C for 50 minutes then at room temperature for 3 15 hours. The reaction mixture was concentrated, diluted with ethyl acetate (150 ml.), washed with 0.5 N hydrochloric acid (50 ml.), water (50 ml.), saturated sodium bicarbonate (50 ml.), wager (50 ml.) and brine (50 ml.), dried (anhydrous magnesium 20 sulfate), filtered, and evaporated to dryness. The crude product was adsorbed onto Celite~ and chromatographed on a silica gel column (5 x 10 cm), eluting with 60o ethyl acetate/hexane (31.). The desired fractions were combined and concentrated, 25 affording 779 mg. of pure title product. TLC (6:4, ethyl acetate: hexane) Rf = 0.17.
m) f 4S- f 4a (R* ) . 7a. 9a, (31 1 -Octah~rdro-4- f (2-mercapto-1-oxo-3-~henylpropyl)aminol-5-oxogyrrolof2.l-bl 30 f1.31oxaze~ine-7-carboxylic acid A solution of the product from part (1) (754 mg., 1.74 mmol.> in methanol (15 ml.) was purged with argon for 30 minutes, cooled to OoC (ice-salt bath) then treated dropwise with a previously purged .~ n, ,a a~
'a . ~J .~

HA629a (argon, 30 minutes) solution of 1.0 N sodium hydroxide (12 ml.) maintaining the bubbling of argon throughout the addition and length of the reaction.
The reaction mixture was stirred at OoC for 3 hours, 5 acidified at OoC with 5o potassium bisulfate to pH 1 then extracted with ethyl acetate (3 x 100 ml.). The combined organic extracts were washed with 50o brine (100 ml.), brine (100 ml.), dried (anhydrous sodium sulfate), filtered, evaporated to dryness and dried 10 ~n_ vacuo to yield a white foam. The residue was purified by chromatography on a 2.5 x 15 cm silica gel column eluting with ethyl acetate (500 ml.) and 0.3o acetic acid in ethyl acetate (11.). The desired fractions were concentrated, stripped with chloroform 15 and dried in vacuo overnight at 50o C over phosphorus pentoxide to yield the title product as a white foam;
m.p. 88 - 92°C; [a]D = -63.8° (c = 1.0, methanol).
TLC (1% acetic acid in ethyl acetate) Rf = 0.24.
1H-NMR: 400 MHz; CDC13: b 1.80 - 2.31 (m's, 7H), 20 3.10 (m, 1H), 3.27 (m, 1H), 3.63 (m, 1H), 4.0 (m, 1H), 4.20 (m, 1H), 4.49 (m, 1H), 4.75 (m, 1H), 5.23 (m, 1H), 7.19 - 7.30 (m's, 5H), 7.52 (d, 1H, J = 6 Hz).
25 13C-NMR: 100 MHz; CDC13: b 26.4, 32.0, 32.6, 41.2, 44.2, 53.0, 59.4, 70.6, 89.47, 126.9, 128.4, 129.3, 137.4, 171.2, 171.6, 174.8.
Anal. calc'd. for C18H22N205S ~ 0.85 H20:
C, 54.91; H, 6.07; N, 7.12; S, 8.14 30 Found: C, 54.85; H, 5.68; N, 7.18, S, 8.14.
HPLC: tR = 13.5 min (96.7%, W 220); YMC S-3 ODS
(C-18) 6.0 x 150 mm; 30o B:A - 1000 B:A, 25 minute linear gradient (A = 90o water/methanol + 0.20 r~ ~~ n ~ ~ ~~ '' w. : =.J 1. ct ~ _i HA629a phosphoric acid B = 90o methanol/water +0.20 phosphoric acid) flow rate at 1.5 ml./min.

5 L4S f4a(R*> 7a 9a(3l1-Octahvdro-4-f(2-mercapto-1-oxo-ghenvlnropvl)aminol-5-oxopyrrolof2 1-bl f~ 31 h~azeoine-7-carbox5nlic acid a) fS-(R* R*)1-2-ff2-Phthalimido-4-(acetylthio)-1 oxobu yllaminol-5 5-dimetho~y~entanoic acid methyl 10 ester A OoC solution of triphenylphosphine (1.26 g., 4.79 mmol., 1.5 eq.) in dry tetrahydrofuran (15 ml.) was treated with diisopropyl azodicarboxylate (943 X11.. 4.79 mmol.). The resultant white slurry was 15 stirred for 30 minutes and then treated with a solution of [S-(R*,R*)]-2-[(2-phthalimido-4-hydroxy-1-oxobutyl)amino]-5,5-dimethoxypentanoic acid, methyl ester [prepared as described in Example 4(i), 1.35 g., 3.20 mmol.] in dry tetrahydrofuran (15 ml.) 20 followed by neat thiolacetic acid (343 ~1., 4.79 mmol.). The mixture was stirred at OoC for 1.5 hours and then partitioned between ethyl acetate (150 ml.) and 50o sodium bicarbonate (100 ml.). The ethyl acetate layer was washed with brine, dried over 25 magnesium sulfate, filtered, concentrated, adsorbed onto Celite~ and dried ~ vacuo. The crude material was purified by chromatography on a 2.5 x 15 cm silica gel column eluting with 1:1 ethyl acetate: hexane (11.) and 6:4 ethyl acetate: hexane 30 (11.1. The desired fractions were combined, concentrated and dried ~n_ vacuo affording 1.35 g. of title produce as an oil. TLC (E:2, ethyl acetate: hexane) Rf = 0.42.

«

, .4 :3 P, t f ; " n ~ 's ,., ~: U ., HA629a ~) fS-(R*,R*)1-2-f(2-Phthalimido-4-mercapto-1-oxobutvl)aminol-5,5-dimethoxypentanoic amid, methyl ester A de-oxygenated (argon bubbling) solution of 5 the product from part (a) (1.33 g., 2.76 mmol.) in methanol (25 ml.) at 0° C was treated with sodium methoxide (25o by weight in methanol, 1.52 ml., 6.63 mmol., 2.4 eq.). After 3 minutes, the mixture was quenched with saturated ammonium chloride (3 ml.), 10 diluted with water, and extracted with ethyl acetate (100 ml.). The ethyl acetate extract was washed with water (50 ml.) and brine (50 ml.), dried over sodium sulfate, filtered and concentrated. The residue was purified by chromatography on a 5 x 15 cm silica gel 15 column eluting with 1:1 (31.) followed by 8:2 (21.) ethyl acetate: hexane. The desired product. containing fractions were combined and concentrated to yield 853 mg. of title compound as an oil. TLC (8:2, ethyl acetate: hexane) Rf = 0.43.

c) f4S-(4a,7a,9a(3)1-Octahydro-4-nhthalimido-5-oxoovrrolof2,1-b1f1,31thiazeoine-7-carboxylic acid.
met)~1 ester A solution of product from part (b) (847 mg., 25 1.93 mmol.) in methylene chloride (20 ml.) was treated with Amberlyst~ 15 ion exchange resin (700 mg., pre-washed successively with 6N hydrochloric acid, water, tetrahydrofuran and methylene chloride).
After stirring at room temperature for 17 hours the 30 solution was filtered, concentrated and flash chromatographed on a 2.5 x 15 cm silica gel column eluting with 1:l ethyl acetate:hexane to afford 691 mg. of title product as a white foam.
TLC (8:2 ethyl acetate: hexane) Rf = 0.48.

~w~ ~s,~ n~;~
c;. -a.. Ha - . ~~! : :x HA629a d) f4S-(4a,7a.9af3)1-4-Amino-octahydro-5-oxopyrrolof2,1-b1f1,31thiazegine-7-carboxylic acid, methyl ester 5 The product from part (c) (899 mg., 2.40 mmol.) in methanol (17 ml.) was treated with hydrazine monohydrate (122 ~1., 2.52 mmol., 1.05 eq.) and the solution was stirred at room temperature for 3 days. The mixture was filtered and the solid was 10 washed with methanol. The filtrate was concentrated, triturated with methylene chloride, filtered again, concentrated, and dried ~ vacuo to yield 572 mg. of title product as a cloudy oil. TLC (10% methanol in methylene chloride) Rf = 0.13.

e) f4S-[4a(R*),7oc,9a(311-Octahvdro-4-ff2-cetylthio)-1-oxo-3-phenylprogyllaminol-5-oxoByrrolof2,1-b1f1,31thiazepine-7-carboxylic acid, methyl ester 20 A suspension of the dicyclohexylamine salt of (S)-2-(acetylthio)benzenepropanoic acid [prepared as described in Example 1 (h), 1.045 g., 2.58 mmol., 1.1 eq] in ethyl acetate (100 ml.) was washed with 50 potassium bisulfate (5 x 25 ml.), 50o brine (25 ml.), 25 and brine (25 ml.), dried (anhydrous sodium sulfate), filtered, concentrated and dried in vacuo for one hour to give (S)-2-(acetylthio)-benzenepropanoic acid.
This free acid was dissolved in dry methylene 30 chloride (10 ml.), cooled to OoC (ice-salt bath) and treated with triethylamine (360 ~tl., 2.58 mmol.), benzotriazol-1-yloxytris(dimethylamino)phosphonium hexafluorophosphate (1.141 g., 2.58 mmol.) and then a solution of the product from part (d) (57'? mg., 2.34 El ~ : ? ,r, n ~ r.
.~ a .:~
.....

HA629a mmol.) in methylene chloride (10 ml.). The resultant solution was stirred at OoC for 30 minutes then at room temperature for 2.5 hours. The reaction mixture was concentrated, diluted with ethyl acetate (100 5 ml.) washed with 0.5 N hydrochloric acid (50 ml.), water (50 ml.), saturated sodium bicarbonate (50 ml.), water (50 ml.) and brine (50 ml.), dried (anhydrous magnesium sulfate), filtered, and evaporated to dryness. The crude product was 10 adsorbed onto Celite~ and chromatographed on a silica gel column (5 x 10 cm), eluting with 25%(51.), 300(21.), 350(21.), and 40x(21.) ethyl acetate/hexane. The mixed fractions were combined and rechromatographed eluting with the same gradient.
15 The desired fractions were combined and concentrated, affording 490 mg. of pure title product.
TLC (1:1, ethyl acetate: hexane) Rf = 0.16.
f) f4S-f4a(R*),7a,9af311-Octahvdro-4-f(2-mercapto-1-20 oxo-3-phenylprogyl)aminol--5-oxo~yrrolo(2,1-bl(1.31 thiazepine-7-carbo~~lic acid A solution of the product from part (e) (490 mg., 1.09 mmol.) in methanol:tetrahydrofuran (8 ml.:
4 ml.) was purged with argon for 30 minutes, cooled 25 to OoC (ice-salt bath) then treated dropwise with a previously purged (argon, 30 minutes) solution of 1.0 N sodium hydroxide (10 ml.) maintaining the bubbling of argon throughout the addition and length of the reaction. The reaction mixture was stirred at 30 OoC for 3 hours, acidified at 0°C with 5o potassium bisulfate to pH 2 then extracted with ethyl acetate (3 x 75 ml.). The combined organic extracts were washed with brine (75 ml.), dried (anhydrous sodium sulfate), filtered, evaporated to dryness and dried ,... ~~c et HA629a 'fin vacuo to yield a white foam (489 mg.). The residue was purified by chromatography on a 2.5 x 15 cm silica gel column eluting with 9:1 ethyl acetate:heptane (400 ml.) and 0,5$ acetic acid in 9:1 5 ethyl acetate:heptane (11.). The desired fractions were concentrated, stripped with methylene chloride/heptane and dried in vacuo to yield 428 mg.
of product. The pure material was recrystallized from a mixture of ethyl acetate/methanol/hexane. The 10 crystals were collected by filtration, washing thoroughly with ethyl ether, and dried ~ vacuo overnight at 40°C over phosphorus pentoxide to yield 305 mg. of title product as white crystals; m.p. 206 - 208°C; [oc]D = -96.3° (c = 1.0, methanol) .
15 TLC (5o acetic acid in 9:1 ethyl acetate:heptane) Rf - 0.29.
1H-NMR: 400 MHz; CDC13 wi 2 drops CD30D: 8 1.94(m, 1H), 2.02(d, 1H, J = 9 Hz), 2.08(m, 1H), 2.20 -2.55(m's, 4H), 2.95(m, 1H), 3.08(m, 1H), 3.23 (m, 20 1H), 3.27 (m, 1H), 3.59 (m, 1H), 4.54 (t, 1H, J = 7.3 Hz), 4.60 (m, 1H), 5.23 (m, 1H), 7.18 - 7.34 (m's, 5H), 7.63 (d, 1H, J = 6 Hz).
13C_~g; 100 MHz; CDC13 w/ 2 drops CD30D: 8 27.6, 31.1, 32.1, 32.9, 41.1, 44.0, 52.8, 60.4, 62_2, 25 126.77, 128.3, 129.0, 137.4, 170.2, 171.4, 172.6.
Anal. calc'd. for C18H22N204S2 ~ 0.08 H20:
C, 54.60; H, 5.64; N, 7.07; S, 16.19 Found: C, 54.65; H, 5.59; N, 7.02, S, 15.80.
HPLC: tR = 13.0 min (98.80, UV 220); YMC S-3 ODS (C-30 18) 6.0 x. 150 mm; 40o B:A - 1000 B:A, 25 minute linear gradient (A = 90o water/methanol + 0.2~
phosphoric acid; B = 90o methanol/water + 0.2~
phosphoric acid); flow rate at 1.5 ml/min.

HA629a f 45- f 4a (R* ) 7a 9a(3) 1 1 -Octahyd~o-4- f (2-merc~to-1-oxo-~phenvlnrogyl)aminol-5-oxogyrrolof2 1-blfl 31 rh~azebine-7-carboxylic acid 5 The product of Example 5 was also prepared as follows:
a) N-f(Phenvlmethoxv)carbonyll-L-homoserine N-(Benzyloxycarbonyloxy)succinimide (23.57 g., 94.58 mmol.) was added to a solution of L-homoserine 10 (10.24 g., 85.98 mmol.) and sodium bicarbonate (7.95 g., 94.58 mmol., 1.1 eq.) in a mixture of water (100 ml.) and acetone (100 m1.1. The mixture was stirred at room temperature overnight. The acetone was removed under reduced pressure (rotovap) and the 15 aqueous solution was washed with methylene chloride (2 x 75 ml.). The aqueous layer was then acidified to pH 2 by addition of 6N hydrochloric acid and extracted with ethyl acetate (2 x 250 ml.). The combined ethyl acetate layers were washed with water 20 (2 x 100 ml.) and brine, dried over sodium sulfate, filtered, concentrated and dried ~ vacuo to afford 19.54 g. of title product as a white solid. TLC
(ethyl acetate:n-butanol:acetic acid:water; 2:1:1:1) Rf = 0.74 25 b) N-f(Phenylmethoxy)carbonyll-O-(triohenylmethvl)-L-homoserine To a suspension of the product from part (a) (19.51 g., 77.04 mmol.) in chloroform (250 ml.) was added triethylamine (12.35 ml., 88.59 mmol., 1.15 30 eq.). The homogeneous mixture was treated with triphenylmethyl chloride (24.70 g., 88.59 mmol.) and the reaction was stirred for 3 hours. The reaction mixture was concentrated under reduced pressure (rotovap), partitioned between ethyl acetate (400 ~~1 .~ ;~ ~ ~l ~ _.
E~ .~

HA629a ml.) and 5% potassium bisulfate (200 ml.). The ethyl acetate layer was washed with 5o potassium bisulfate (200 ml.), water (2 x 200 ml.), and brine (200 ml.), dried over sodium sulfate, filtered, and concentrated 5 to yield 45.4 g. material. The residue was chromatographed on a 10 x 30 cm silica gel column eluting with 6:4 ethyl acetate: hexane (21.) followed by to acetic acid in 8:2 ethyl acetate: hexane to give 8.76 g. of pure title compound.
10 c) (S)-2-Amino-5,5-dimethoxv~~n~nQ~ acid~.methvl ester (S)-2-Phthalimido-5,5-dimethoxypentanoic acid, methyl ester (prepared as described in Example 4 (f), 3.35 g., 10.43 mmol.) in methanol (70 ml.) was 15 treated with hydrazine monohydrate (531 (11., 10.95 mmol., 1.05 eq.) and the solution was stirred at room temperature for 6 days. The mixture was filtered and the solid was washed with methanol. The filtrate was concentrated, triturated with methylene chloride, 20 filtered again, concentrated, and dried in vacuo to yield 1.89 g. of title product as a cloudy oil.
TLC (loo methanol in methylene chloride) Rf = 0.39.
d) fS-(R*,R*)1-2-ff2-ff(Phenylmethoxy)-carbonyllaminol-4-(triphenylmethoxy)-1-oxobutvll-25 aminol-5,5-dimethoxynentanoic acid, methyl ester A solution of the product from part (b) (5.28 g., 10.65 mmol., 1.1 eq.) in dry methylene chloride (50 ml.) at Oo C was treated with triethylamine (1.48 ml., 10.65 mmol.), followed by the product from part 30 (c) (1.85 g., 9.68 mmol.) in dry methylene chloride (30 ml.) and benzotriazol-1-yloxytris(dimethylamino)-phosphonium hexafluorophosphate (4.71 g., 10.65 mmol., 1.1 eq.). The mixture was stirred for 1 hour at 0°C and then stirred at room temperature for 2 rl ~" :) r ~: ~ ~~ r~ J ~ ~.ax HA629a hours. The reaction mixture was partitioned between ethyl acetate (300 ml.) and water (150 ml.). The ethyl acetate layer was washed with 50o saturated sodium bicarbonate (200 ml.) and brine (2 x 200 ml.), 5 dried over magnesium sulfate, filtered, concentrated, adsorbed onto Celite~ and purified on a 7 x 20 cm silica gel column eluting with 40a ethyl acetate/hexane (31.), follawed by 500 (21.) ethyl acetate/hexane affording 4.84 g. of title product.
10 TLC (ethyl acetate: hexane, 1:1) Rf = 0.2'~.
e) fS-lR*,R*11-2-ff2-(f(Phenylmethoxy)carbonyll-aminol-4-hydroxy-1-oxobutyllaminol-5,5-dimethoxy-pentanoic acid. met y1 ester A solution of the product from part (d) (4.80 15 g., 7.18 mmol.) in methanol (70 ml.) was r_reated with p-toluenesulfonic acid monohydrate (300 mg.). After stirring at room temperature for 2 hours, the mixture was partitioned between ethyl acetate (400 ml.) and 25o saturated sodium bicarbonate (200 ml.). The 20 phases were separated and the aqueous layer was extracted again with ethyl acetate (100 ml.). The combined ethyl acetate extracts were washed with brine, dried over magnesium sulfate, filtered and concentrated. The residue was purified by 25 chromatography on a 5 x 20 cm silica gel column eluting with 7:3 (11.), 8:2 (11.) ethyl acetate: hexane followed by loo methanol in ethyl acetate (21.). The desired fractions were combined, concentrated and dried in vacuo to yield 2.92 g. of 30 title product. TLC (ethyl acetate: hexane, 8.2) Rf = 0.09.

.~ :9 Y ~'L f'%
iv .;r .:. ... ~ ; a HA629a f) fS-(R*.R*)1-2-ff2-ff(Phenylmethoxy)carbonyll-aminol-4-(acetylthio)-1-oxobutyllaminol-5-5-~;mPrhoxvnentanoic acid. methyl ester A Oo C solution of triphenylphosphine (3.06 5 g., 11.65 mmol., 1.7 eq.) in dry tetrahydrofuran (40 ml.) was treated with diisopropyl azodicarboxylate (2.29 ml., 11.65 mmol.). The resultant white slurry was stirred for 30 minutes and then treated with a solution of the product from part (e) (2.92 g., 6.85 10 mmol.) in dry tetrahydrofuran followed by neat thiolacetic acid (833 ~1., 11.65 mmol.). The mixture was stirred at Oo C for 2 hours and then partitioned between ethyl acetate (30C ml.) and 50o sodium bicarbonate (200 ml.). The ethyl acetate layer was 15 washed with brine. dried over magnesium sulfate, filtered, concentrated, adsorbed onto Celite~ and dried in vacuo. The crude material was purified by chromatography on a 5 x 20 cm silica gel column eluting with 1:1 ethyl acetate:hexane (31.). The 20 desired fractions were combined, concentrated and dried i~r vacuo affording 2.58 g. of title product as an off-white solid. TLC (ethyl acetate: hexane, 8:2) Rf = 0.40.
g) fS-(R*,R*)1-2-ff2-ff(Phenylmethoxv)carbonyll-25 aminol-4-mercagto-1-oxobutyllami~ol-5.5-dimethoxy~aentanoic acid, methyl ester A de-oxygenated (argon bubbling) solution of the product from part (f) (2.56 g., 5.28 mmol.) in methanol (50 ml.) ar_ Oo C was treated with sodium 30 methoxide (25o by weight in methanol, 3.62 ml., 15.84 mmol., 3 eq.). After 10 minutes, the mixture was quenched with saturated ammonium chloride (40 ml.), diluted with water (100 ml.), and extracted with ethyl acetate (300 ml.). The ethyl acetate extract t! A '~ F ~5 ,!
t~ .~. !-i ~-:Z ':.~ W

HA629a was washed with water (100 ml.) and brine (150 ml.), dried over magnesium sulfate, filtered and concentrated. The residue was purified by chromatography on a 5 x 20 cm silica gel column 5 eluting with 1:1 (31.) ethyl acetate:hexane. The desired compound was combined and concentrated to yield 1.99 g. of title product as an oil. TLC (ethyl acetate: hexane, 8:2) Rf = 0.43.
h) f 4S- (4a 7a 9a ) 1 -O ah~rdro-4- f f (phenylmethoxy) -10 ~arbonyllaminol-5-oxopvrrolof2 1-blfl 3lthiazegine-7-c~arboxvlic acid methyl ester A solution of the product from part (g) (2.16 g., 4.88 mmol.) in methylene chloride (50 ml.) was treated with Amberlyst~ 15 ion exchange resin (620 15 mg., pre-washed successively with 6N hydrochloric acid, water, tetrahydrofuran and methylene chloride).
After stirring at room temperature for 3 hours the solution was filtered, concentrated and flash chromatographed on a 5 x 20 cm silica gel column 20 eluting with 6:4 ethyl acetate: hexane to afford 1.34 g. of title product as a white foam. TLC (ethyl acetate: hexane, 8:2) Rf = 0.51.
i) f4S-l4a.7a.9a(3)1-4-Amino-octahvdro-5-25 oxogvrrolof2 1-blfl 3lthiazepine-7-carboxylic acid methyl ester A solution of the product from part (h) (1.20 g., 3.17 mmol., stripped with toluene three times and dried ~n vacuo overnight] in dry methylene chloride 30 (40 ml.) was treated with iodotrimethylsilane (632 ~tl., 4.44 mmol., 1.4 eq.) and stirred at room temperature under argon far 1.5 hours. The mixture was quenched with water (50 ml.), treated with l00 hydrochloric acid (5 ml., pH 1) and washed with ethyl ~'r ~ C~ !' r° f..,, .,..
G: .. F:~ '~ ;.~ ~ ~_' HA629a acetate (50 ml.). The aqueous phase was treated with with 10% sodium hydroxide and extracted with methylene chloride (three times). The pooled extracts were dried over sodium sulfate, filtered, 5 concentrated, and dried in vacuo to yield a 396 mg.
of title product as a clear oil. TLC (10% methanol in methylene chloride) Rf = 0.10.
i) ~4S-f4a(R*),7a,9af311-Octahydro-4-f(2-mercapto1-10 oxo-3-phenylgropyl)aminol-5-oxoRyrrolof2,1-b1f1,31thiazepine-7-carboxylic acid A solution of (S)-2-(acetylthio)benzene-propanoic acid in dry methylene chloride was treated with triethylamine. A solution of the product from 15 part (i) in methylene chloride was then added followed by benzotriazol-1-yloxytris-(dimethylamino)phosphonium hexafluorophosphate. The resultant solution was worked-up as described in Example 5(e) to give [4S-[4a(R.*),7a,9a(3]]-octahydro-20 4-[[2-(acetylthio)-1-oxo-3-phenylpropyl]amino]-5-oxopyrrolo[2,1-b][1,3]thiazepine-7-carboxylic acid, methyl ester.
A suspension. of this methyl ester product in methanol:tetrahydrofuran, purged with argon, was 25 cooled to 0° C and treated with a previously purged solution of 1.0 N sodium hydroxide. Work-up as described in Example 5(f) gave the title product.

30 f4S-f4a(R*),7a,9a(311-Octahydro-4-f(3-c~ clohexyl-2-mercapto-1-oxcZpro~~~.)aminol-5-oxogyrrolof<,l-b1f1,31-thiaz~ine-7-carboxylic acid ', ~. ~ "t r 1 b HA629a a) I4S-(4a,7a,.9a(3)1-4-Amino-octahvdro-5-oxogyrrolo-I2,1-b1f1,31thiazeRine-7-carboxylic acid, methyl ester, g-toluenesulfonic acid salt A solution of (4S-(4a,7oc,9a(3)]-octahydro-4-5 [[(phenylmethoxy)carbonyl]amino]-5-oxopyrrolo[2,1-b][1,3]thiazepine-7-carboxylic acid, methyl ester [prepared as described in Example 6(h), 738 mg., 1.95 mmol., stripped three times with toluene and dried ~ vacuo overnight) in dry methylene chloride 10 (25 ml.) was treated with iodotrimethylsilane (389 ~1., 2.73 mmol., 1.4 eq.) and stirred at room temperature under argon. After 2 hours the reaction was treated with additional amounts of iodotrimethyl silane (40 I11.) and stirred for 30 minutes. The 15 mixture was quenched with a 0.4 M hydrochloric acid solution of methanol:dioxane(9:1; 9.7 ml.) and stirred for 5 minutes. The volatiles were removed in vacuo (Rotovap) and the residue was partitioned between water and ethyl acetate. The separated ethyl 20 acetate layer was washed with water and the combined aqueous phase washed with ethyl acetate. The aqueous phase was cooled to Oo C and the pH adjusted to 10.3 (monitored with pH meter) with 1.0 N sodium hydroxide. The aqueous phase was extracted with 25 methylene chloride (three times) and the aqueous phase was then saturated with salt and extracted again with methylene chloride (three times). The pooled extracts were dried over sodium sulfate, filtered, concentrated, and dried in vacuo to yield 30 455 mg. of the free amine as a clear oil. TLC (10%
methanol in methylene chloride) Rf = 0.28.
This free amine was dissolved in ethyl acetate (5 ml.) and treated with a solution of p-toluenesulfonic acid monohydrate (354 mg., 1 eq.) in i 6 ,C C1 n' . .
<~:~E:.y~fa $J.r HA629a ethyl acetate (1 ml.). White crystals immediately formed. The cystals were stored in refrigerator (5°
C) for 30 minutes and then collected by filtration washing well with ethyl ether and drying overnight in 5 vacuo to yield 639 mg. of title product as a white solid.
b) (S)-2-(ACetylthio)-3-~yclohexylpropanoic acid,dicyclhexylamine salt 10 A solution of D-phenylalanine (5.20 g., 31.5 mmol.) in 2 M hydrochloric acid (75 ml.) in a 500 ml.
Parr hydrogenation flask was purged with nitrogen gas and treated with platinum oxide (640 mg., 2.82 mmol.). Hydrogenation was commenced at Po = 42.4 psi 15 in the sealed flask, refilling as necessary. Total hydrogen uptake was 83.4 psi (theory 83.8 psi) over 6 hours. The reaction was purged with nitrogen gas and filtered through Celite~, washing the filter cake with hot water. The filtrate was concentrated to 20 about 40 ml. and stored at 5°C overnight. The resulting solids were collected, washed with a small amount of cold water and dried in vacuo at 60° C to give 5.46 g. of (R)-2-amino-3-cyclohexylpropanoic acid, hydrochloride salt.
25 To a stirred solution of this hydrochloride salt (2.81 g., 13.5 mmol.) in 2.5 N sulfuric acid (32 ml.) at room temperature was added potassium bromide (10.0 g., 84 mmol.). The reaction mixture was cooled to -4° C and solid sodium nitrite (1.75 g., 25.4 30 mmol.) was added portionwise over one hour, maintaining the temperature below 0° C. The reaction foamed and an oil began to form. After addition was complete, the reaction was stirred for 1 hour and then warmed to room temperature and stirred for ~'lr 9 r, r~ ~ y _ .
) ~ .
E. , '.,~
_ 77 _ HA629a another hour. The reaction mixture was then extracted twice with ether, the extracts were dried (magnesium sulfate), filtered and evaporated to give 2.3 g. of (R)-2-bromo-3-cyclohexylpropanoic acid as a 5 colorless oil.
To a stirred slurry of potassium thioacetate (1.07 g., 9.36 mmol.) in dry acetonitrile (15 ml.) at 0°C under argon was added a solution of (R)-2-bromo-3-cyclohexylpropanoic acid (2.20 g., 9.36 mmol.) in 10 acetonitrile (3 ml.) over 10 minutes. The reaction was warmed to room temperature and stirred 16 hours.
The resulting slurry was filtered and evaporated.
The residue was redissolved in ethyl acetate, washed once with 5o potassium bisulfate solution, dried 15 (sodium sulfate) and evaporated. The oily yellow residue (2.21 g.) was dissolved in ether and treated with a solution of dicyclohexylamine (1.8 ml., 9.0 mmol.) in 5 ml. of ether. Scratching the flask surface with a glass rod provided 2.38 g. of white 20 crystalline title product; m.p. 159 - 161°C, [a]D =
-41.2° (c = 1.0, chloroform).
Anal. calc'd. for C23H41NSO3:
C, 67.11; H, 10.04; N, 3.40; S, '7.79 Found: C, 66.95; H, 10.12; N, 3.25; S, 7.89.

c) f4S-f4a(R*),7a,9a(311-Octahydro-4-ff2-(acetylthio)-3-cyclohexyl-1-oxoprogyllaminol-5-oxopyrrolof2,1-blfl.3lthiazey~ine-7-carboxylic acid, methyl ester 30 A suspension of the compound (S)-2-(acetylthio)-3-cyclohexylpropanoic acid, dicyclo-hexylamine salt (285 mg., 0.69 mmol., 1.05 eq.) in ethyl acetate (15 ml.) was washed with 5o potassium bisulfate (3 x 10 ml.), 50o brine (10 ml.), and brine ~~ rk e~ ~ v - 78 _ HA629a (10 ml.), dried (anhydrous magnesium sulfate), filtered, concentrated, stripped with methylene chloride (twice) and dried in vacuo for one hour to give (S)-2-(acetylthio)-3-cyclohexylpropanoic acid as 5 an oil.
This free acid of was dissolved in dry methylene chloride (5 ml.), cooled to 0° C (ice bath), and treated with triethylamine (96 ~1., 0.69 mmol., 1.05 eq.), then the product from part (a) (275 10 mg., 0.66 mmol.), triethylamine (92 ~tl., 0.66 mmol.) and finally benzotriazol-1-yloxytris(dimethylamino)-phosphonium hexafluorophosphate (305 mg., 0.69 mmol.). The resultant solution was stirred at 0°C
for 1 hour then at room temperature for 2 hours. The 15 reaction mixture was concentrated, diluted with ethyl acetate, washed with 5o potassium bisulfate (20 ml.), 50o saturated sodium bicarbonate (20 ml.), brine (20 m1.), dried (anhydrous magnesium sulfate), filtered, and evaporated to dryness. The crude product was 20 adsorbed onto Celite~ and chromatographed on a silica gel column (2.5 x 10 cm), eluting with 400 (11.) ethyl acetate/hexane. The desired fractions were combined and concentrated, affording 246 mg. of pure title product. TLC (ethyl acetate: hexane, 8:2) 25 Rf = 0.53.
d) f4S-f4a(R*).7a.9a(311-Octahvdro-4-f(3-Cyclohexyl-2-mercapto-1-oxobrogyl)aminol-5-oxogyrrolof2,1-bl-f1,31thiazepine-7-carboxylic acid 30 A solution o~ the product from part. (c) (245 mg., 0.54 mmol.) in methanol (6 ml.), purged with argon for 30 minutes, cooled to 0°C was treated dropwise with a previously purged (argon, 30 minutes) solution of 1.0 N sodium hydroxide (5 ml.) ~ ~ :~,~ n _. . _ ~j ~ ~) _ 79 _ HA629a maintaining the bubbling of argon throughout the addition and length of the reaction. The reaction mixture was stirred at 0°C for 2 hours, acidified at 0°C with 5% potassium bisulfate to pH 2 then 5 extracted with ethyl acetate (3 x 20 ml.). The combined organic extracts were washed with 50% brine (20 ml.), and brine (20 ml.), dried (anhydrous magnesium sulfate), filtered, and evaporated to dryness. The residue was purified by chromatography 10 on a 2.5 x 10 cm silica gel column eluting with 7:3 ethyl acetate:heptane (300 ml.) and to acetic acid in 7:3 ethyl acetate:heptane (500 ml.). The desired fractions were concentrated, stripped with methylene chloride and dried in vacuo to yield 172 mg. of 15 title product as a white foam; [a.]D = -1.16.9° (c =
0.5, methanol). TLC (1% acetic acid in ethyl acetate) Rf = 0.35.
1H-NMR: 400 MHz; CDC13: 8 G.91 (m, 2H), 1.22 (m, 3H), 1.44 (m, 1H), 1.55 (m, 1H), 1.68 (m's, 5H), 1.83 20 (m, 1H), 1.97 (m's, 2H), 2.12 (m, 1H), 2.19 - 2.40 (m's, 3H), 2.53 (m, 1H), 2.96 (m, 1H), 3.38 (m's, 2H), 4.62 (t, 1H, J = 6.8 Hz), 4.70 (m, 1H), 5.25 (m, 1H}, 7..55 (d, 1H, J = 6.4 Hz).
13C-~: 100 MHz; CDC13: 8 26.0, 26.1, 27.5, 31.5, 25 32.3, 33.0, 33.3, 35.2, 40.7, 43.0, 52.9, 60.6, 62.5,170.9, 172.7, 175.3.
Anal. calc'd. for C18H28N2o4S2:
C, 53.98; H, 7.05; N, 6.99; S, 16.01 Found: C, 53.97; H, 7.18; N, 6.84, S, 15.75.
30 HPLC: tR = 16 min (>99%, UV 217); YMC S-3 ODS (C-18) 6.0 x 150 mm; 50% B:A - 100% B:A, 25 minute linear gradient (A = 90% water/methanol + 0.2% phosphoric acid; B = 90% methanol/water + 0.2% phosphoric acid);
flow rate at 1.5 ml/min.

C i ~ : z .~ r~~ f"~ ....
a 1 (-.: 1. :.,: :2 C

HA629a f4S-f4a(R*).7a.9a(311-Octahydro-4-f(2-mercapto-1-oxohexyl)aminol-5-oxogyrrolof2.1-b1f1.31thiazepine-7-5 carboxylic acid a) (S)-2-Bromohexanoic acid Potassium bromide (15.9 g., 133 mmol.) was added to a stirred solution of D-norleucine (5.0 g., 10 38 mmol.) in 2.5 N sulfuric acid (77 ml.) at room temperature. The reaction. mixture was cooled to -10° C. and solid sodium nitrite (3.94 g., 57 mmol.) was added portionwise, maintaining the temperature between -10° and -5° C. After addition was complete, 15 the foamy reaction was stirred for 1 hour and then warmed to room temperature and stirred for another hour. The reaction mixture was then extracted twice with ether, the ether extracts were washed once with water, dried (magnesium sulfate), filtered and 20 evaporated to give 3.3 g. of crude title product.
b) (S>-2-(ACetylthio)hexanoic acid.
d~clohexLrlamine salt To a stirred slurzy of potassium thioacetate 25 (2.11 g., 18.5 mmol.) in 50 ml. of dry acetonitrile at room temperature under argon was added a solution of the product from part (a) (3.27 g., 16.8 mmol.) in 26 ml. of acetonitrile. The reaction was stirred 5 hours. The resulting slurry was filtered and 30 evaporated. The residue was redissolved in ethyl ether, washed once with 5o potassium bisulfate solution and once with brine, dried (magnesium sulfate) and evaporated. The residue was dissolved in ether (64 ml.) and treated with dicyclohexylamine ~ ~ ''~ ';

HA629a (3.4 ml., 16.8 mmol.). The ethereal solution was concentrated in vacuo, and triturated from hexanes to give a white solid which was recrystallized from ethyl ether/hexanes to give the title product. The 5 mother liquor was concentrated and recrystallized twice to provide a total yield of 2.2 g. of title product; m.p. 145 - 147° C'.; [a]D = -33.8° (c = 1.08, chloroform).
10 c) f4S-f4a (R*).7a,9a(311-Octahydro-4-ff2-lacetylthio )-1-oxohexyllaminol-5-oxogyrrolo-f2,1-b1f1,3 1thiazepine-7-carboxylic acid, methyl gster A suspension of the dicyclohexylamine salt 15 product from part (b) (255 mg., 0.69 mmol., 1.05 eq.) in ethyl acetate (15 ml.) was washed with 50 potassium bisulfate (3 x 5 ml.), and brine (10 ml.), dried (anhydrous magnesium sulfate), filtered, concentrated, stripped wit=h methylene chloride 20 (twice), and dried in vacuo for one hour too give the free acid as a oil.
This oil was dissolved in dry methylene chloride (6 ml.), cooled to 0° C. (ice bat-_h) and treated with triethylamine (96 ~,1., 0.69 mmol., 25 1.05 eq.), then [4S-(4a,7a,9a(3)]-4-amino-octahydro-5-oxopyrrolo[2,1-b][1,3]thiazepine-7-carboxylic acid, methyl ester, p-toluenesulfoni.c acid salt [prepared as described in Example 7(a), 275 mg., 0.66 mmol.], triethylamine (92 ~tl., 0.66 mmol.) and finally 30 benzotriazol-1-yloxytris(dimethylamino)phosphonium hexafluorophosphate (305 mg., 0.69 mmol.). The resultant solution was stirred at 0° C for one hour then at room temperature for 2 hours. The reaction mixture was concentrated, diluted with ethyl acetate, E" _s ~:, x J S ~a HA629a washed with 5o potassium bisulfate (20 ml.), 500 saturated sodium bicarbonate (20 ml.), brine (20 ml.), dried (anhydrous magnesium sulfate), filtered, and evaporated to dryness. The crude product was 5 adsorbed onto CeliteO and chromatographed on a silica gel column (2.5 x 10 cm), eluting with 40a (11.) ethyl acetate/hexane. The desired fractions were combined and concentrated, affording 258 mg of pure title product. TLC (ethyl acetate: hexane, 8:2) 10 Rf = 0.54.
d) f4S-f 4a(R*1,7a"9a(311-Octahydro-4-f(2-mercapto-1-oxohexyl)aminol-5-oxogyrrolof2,1-b1f1,31thiazegine-7-carboxylic acid 15 A solution of the product from part (c) (255 mg., 0.54mmol.) in methanol (5 ml.), purged with argon 30 minutes, cooled to 0C. was treated for dropwise with a previously purged (argon, 30 minutes) solution of 1.0 N sodium hydroxide (5 ml.) 20 maintaining the bubbling cf argon throughout the addition and length of the reaction. The reaction mixture was stirred at 0 C for 2 hours, acidified at 0 C with 5o potassium bisulfate to pH 2 then extractedwith ethyl acetate (3 x 20 ml.). The 25 combined organic extracts were washed with 50o brine (20 ml.) and brine (20 ml.), dried (anhydrous magnesiumsulfate), filtered, and evaporated to dryness. The residue was purified by chromatography on a 2.5 x 10 cm silica gel column eluting with 7:3 30 ethyl tate:heptane (300 ml.) and 1a acetic ace acid in 7:3 ethylacetate:heptane (500 m1.>. The desired fractionswere concentrated, stripped with methylene chloride and dried in vacuo to yield 170 mg.
of title prcduct as a white foam;
[a]p = -135.1 r# .j ;''1 i . _> i.~ .t c/ t c HA629a (c = 0.5, methanol). TLC (lo acetic acid in ethyl acetate) Rf = 0.32.
1H-NMR: 400 MHz; CDC13: ~ 0.89(t, 3H, J = 7 Hz), 1.32(m, 4H), 1.73(m, 1H), 1.96(m, 2H), 2.00(d, 1H, J
5 - 8.6 Hz), 2.11(m, 1H), 2.32 (m's, 3H), 2.52(m, 1H), 2.98(m, 1H), 3.32(m's, 2H), 4.61 (t, 1H, J = 7.1 Hz), 4.72 (m, 1H), 5.25 (m, 1H), 7.63 (d, 1H, J = 6.4 Hz).
13C-~: 100 MHz; CDC13: 8 13.8, 22.2, ~?7.6, 29.2, 31.4, 32.6, 33.1, 35.3, 43.0, 52.8, 60.5, 62.42, 10 170.7, 172.5, 174Ø
Anal. calc'd for C15H24O4N4S20 ~ 0.08 H20:
C, 49.79; H, 6.73; N, 7.74; S, 17.72 Found: C, 49.90; H, 6.92; N, 7.63, S, 17.57.
HPLC: tR = 9.4 min (>990, W 220); YMC S-3 ODS (C-15 18) 6.0 x 150 mm; 50o B:A - 100% B:A, 25 minute linear gradient (A = 90~ water/methanol + 0.20 phosphoric acid); B = 90o methanol/water + 0.2o phosphoric acid); flow rage at 1.5 ml/min.

j4~-f4a(R*) 7a 9a1311-Octahvdro-4-f(2-mercab2to-1-oxo-4-methyl~Znt~l) aminol -5-oxogyrrolo f 2. 1-bl f 1, 31 -thiazegine-7-carboxylic acid 25 al S)-2-Bromo-4-methylbentanoic acid Potassium bromide (9.5 g., 80 mmol.) was added to a stirred solution of D-leucine (3.0 g., 23 mmol.) in 2.5 N sulfuric acid (47 ml.) at room temperature.
The reaction mixture was cooled to -10° C. and solid 30 sodium nitrite (2.4 g., 34 mmol.) was added portionwise, maintaining the temperature between -10°
and -5° C. After addition was complete, the reaction was stirred for 1 hour and then warmed to room temperature and stirred for another hour. The a :'! :9 ~1 ' t'_ _~: }. .3 ~ a) HA6 2 9 a reaction mixture was then extracted twice with ether, the ether extracts were washed once with water, dried (magnesium sulfate), filtered and evaporated to give 2.7 g. of crude title product.

b) lS)-2-(Acetylthio)-4-methylpentanoic acid.
dicyclohexvlamine salt To a stirred slurry of potassium thioacetate (1.7 g., 15.0 mmol.) in 50 ml. of dry acetonitrile at 10 room temperature under argon was added a solution of the product from part (a) (2.6 g., 13 mmol.) in 17 ml. of acetonitrile. The reaction was stirred 4 hours. The resulting slurry was filtered and evaporated. The residue was redissolved in ethyl 15 ether, washed once with 5o potassium hydrogen sulfate solution and once with brine, dried (magnesium sulfate) and evaporated. The residue was dissolved in ether (64 ml.) and treated with dicyclohexylamine (2.7 ml., 14 mmol.). A white solid immediately began 20 precipitating from the solution. The solution was filtered and the white solid collected to give 2.0 g.
of title product; m.p. 153 - 158° C; [a]D = -54.5° C.
(c = 0.61, chloroform).
25 c ) f 4S- f 4oc (R* ) , 70c, 931 1 -Octahydro-4- f f 2-(acerylthio)-1-oxo-4-methyl entvllaminol-5-9xoByrrolof2,1-b1f1,31thiazepine-7-carbox~~lic acid, methyl ester A stirred suspension of the dicyclohexylamine 30 salt product from part (b) (234 mg., 0.63 mmol.) in ethyl acetate (15 ml.) was washed with 5o aqueous potassium bisulfate (3 x 5 ml.). The organic extract was dried (anhydrous magnesium sulfate), filtered and evaporated twice from hexane. The resulting oil was 'l !l i e.i HA629a dissolved in methylene chloride (6 ml.) and stirred under nitrogen at 0° C. To this solution was added triethylamine (88 ~1., 0.53 mmol.), then [4S-(4a,7a, 9a~3)]-4-amino-octahydro-5-oxopyrrolo[2,1-b][1,3]
5 thiazepine-7-carboxylic acid, methyl ester, p-toluenesulfonic acid salt [prepared as described in Example 7(a), 249 mg., 0.6 mmol.], an additional amount of triethylamine (84 ~1., 0.60 mmol.) and, after 10 minutes, benzotriazol-1-yloxytris(dimethyl-10 amino)phosphonium hexafluorophosphate (279 mg., 0.63 mmol.). After one hour, the reaction was warmed to room temperature and stirred 2 hours. The resulting colorless solution was evaporated at less than 30° C
and the oily residue redissolved in ethyl acetate.
15 The solution was washed once with 5$ potassium bisulfate solution, once with saturated sodium bicarbonate solution and once with brine. The organic layer was dried (magnesium sulfate), filtered and evaporated onto 5 g. of silica gel. Purification 20 by flash chromatography (2.5 x 15 cm column, eluting with 1:1 ethyl acetatelhexanes) provided 203 mg. of title product as a white solid; m.p. 101 - 103° C.
[a]D = -157.5° (c = 1.04, chloroform). TLC (ethyl acetate: hexane, 1:1) Rf = 0.19.

d) f4S-f4a(R*) 7a 9a~11-octahydro-4-f(2-mercapto-1-~co-4-methvlnen~yl)aminol-5-oxogyr.rolof2,i-blfl 3lthiaz~ine-7-carborylic acid A solution of the product from part (c) (184 30 mg., 0.44 mmol.) in 5 ml. of methanol was purged with nitrogen for 10 minutes and cooled to 0° C. To this solution was added dropwise 5 ml. of nitrogen-purged 1~I sodium hydroxide. Nitrogen was slowly bubbled through the solution during the reaction. After 2 C's ~ : A cy ?..t ~-h, .:~ ~~ 'r :.1 : a.) HA629a hours, the reaction was acidified with 2 ml. of 6 ~I
hydrochloric acid, extracted twice with ethyl acetate and the extracts combined, dried (magnesium sulfate) and evaporated. Re-evaporation from hexanes and 5 trituration of the residue in methanol/water provided 132 mg. of title product as a crystalline solid, m.p. 94 - 96° C.; falD = -158.6° (c = 0.42, methanol). TLC(ethyl acetate: hexane: acetic acid, 4:4:0.1) Rf = 0.13.
10 Anal. calc'd. for C15H24N2S204 ~ 0.75 H20:
C, 48.17; H, 6.87; N, 7.49; S, 17.15 Found: C, 48.33; H, 6.51; N, 7.37; S, 16.82.
HPLC: Rt = 17.6 min; (99.2%) YMC S-3 ODS (C-18) 6.0 x 150 mm; Oo to 1000 B:A, 25 min linear gradient and 15 15 min hold, 1.5 mL/min;
A = 90o water/methanol + 0.2o phosphoric acid;
B = 90o methanol/water + 0.2o phosphoric acid;
220 nm.

f4S-f4a(R*).7a.10aQ11-Octahydro-4-f(2-mercapto-1-oxo-3-ohenYl,~robyl)aminol-5-oxof1,41oxazinof3,4-b1f1,31-oxazenine-7-~arboxylic acid 25 ~) 2.2,2-Trichloroacetimidoic acid. 2-~penyl ester A suspension of 80o sodium hydride (945 mg., 31.5 mmol.; washed twice with 25 ml. of hexane) in dry ether (30 ml.) was treated dropwise with a solution of 2-propen-1-of (21.4 ml., 18.3 g., 315 30 mmol.), in dry ether (45 ml.), stirred for 20 minutes at room temperature under argon and then cooled to 0°
C (ice-salt bath). Trichloroacetonitrile (30 ml. or 42.3 g., 0.30 mole) was added over a period of 15 minutes and the brownish solution was stirred at 0° C

~'~-~~..) HA629a for 40 minutes, at 10° C for 10 minutes and at room temperature for 10 minutes. The reaction mixture was concentrated to a syrup, treated with a solution of methanol (1.2 ml.) in pentane (30 ml.) and stirred 5 vigorously for 5.0 minutes. The light brown precipitates were filtered off, washed with pentane (2 x 30 ml.) and the combined filtrates concentrated down to a light brown liquid. The liquid was re-dissolved in pentane (30 ml.), stirred for a few 10 minutes, and the resulting suspension filtered, and the precipitates obtained washed with pentane (30 ml.), repeating the procedure at least one more time.
The clear filtrate was concentrated and dried in vacuo to give 54.0 g. of title compound as a light 15 red-colored liquid. This material was stored as a solution in hexane at 10°C.
b) N-Phthaloyl-L-serine, methyl ester A suspension of L-serine, methyl ester, 20 hydrochloride, (25 g., 161. mmol.) in water (350 ml.) was diluted with dioxane ;250 ml.) and the resulting clear solution treated with solid sodium carbonate (17 g., 1.0 eq.) followed by N-carbethoxyphthalimide (37 g., 1.05 eq.). The reaction mixture was stirred 25 at room temperature for 2.5 hours under argon. The mixture was extracted with ethyl acetate (3 x 500 ml.) and the combined organic extracts were washed successively with So sodium bicarbonate (250 ml.), 50 potassium bisulfate (250 ml.) and brine (250 ml.), 30 dried (anhydrous sodium sulfate), filtered, evaporated to dryness and dried in vacuo. The product mixture was chromatographed on a silica gel column (Merck), eluting the column with ethyl acetate: hexane mixtures (1:3; 1:2) and the desired cr .1 :1 n ~ 1 v d .Y
i' ~
_ 88 -HA629a fractions were combined, evaporated to dryness and dried ~ vacuo to give 31 g. of title compound as a thick syrup. TLC (ethyl acetate: hexane, 1:1) Rf = 0.52.

c) N-Phthaloyl-O-(2-gronenyl)-L-serine, methyl ester A solution of the product from part. (b) (7.37 g., 29.5 mmol.) in dry methylene chloride (30 ml.) was treated with a solution of the product from part 10 (a) (11.97 g., 59.1 mmol., 2 eq.) in cyclohexane (60 ml.) followed by trifluoromethanesulonic acid (0.37 ml.) and the reaction mixture was stirred at room temperature for 20 hours under argon. The precipitates were filtered off, washed with a minimal 15 amount of methylene chloride and the combined filtrates were washed witri 5o sodium bicarbonate (30 ml.) and water (30 ml.), dried (anhydrous sodium sulfate), filtered, evaporated to dryness and dried in vacuo. The crude product mixture was 20 chromatographed on a silica gel column (Merck), eluting the column with ethyl acetate: hexane (1:9).
The desired fractions were combined, evaporated to dryness and dried in vacuo to give 7.56 g. of title compound as a clear thick syrup. TLC(ethyl acetate:
25 hexane, 1:1) Rf = 0.70.
d) N-Phthaloyl-0-(acetaldehyde)-L-serine, methyl A solution of the product from part (c) (2.5 30 g., 8.64 mmol.) in a mixture of dry methy'~ene chloride (46.4 ml.) and methanol (4.6 ml.) was cooled to -78° C (dry ice-acetone bath) and treated with ozone until a blue color persisted (about 15 minutes). The mixture was then purged with nitrogen f.. _~ ~.~ '~i" tB ~ r..e _ 89 _ Hp.629a for 10 minutes (until the blue color disappeared), treated with dimethylsulfide (14.0 ml., 0.19 mole, 22.1 eq.), warmed to room temperature and stirred for 2.5 hours under nitrogen, The reaction mixture was 5 evaporated to dryness and the residual syrup dissolved in ethyl acetate (50 ml.), washed with water (15 ml.) and brine (15 ml.), dried (anhydrous magnesium sulfate), filtered, evaporated to dryness and dried ',~,~n vacuo .
10 The crude product was chromatographed on a silica gel column (Merck ) eluting the column with ethyl acetate: hexane mixtures (1:9; 1:4; 1:2) to give 1.54 g. of title product. TLC(ethyl acetate: hexane, 1:1) Rf = 0.33.

e) N-Phthaloyl-O-(2 2-dimethoxyethyl)-L-serine methyl ester A solution of the product from part (d) (1.54 g., 5.29 mmol.) in a mixture of dry methylene 20 chloride (8.3 ml.) and dry methanol (8.3 ml.), was treated with trimethylorthoformate (0.84 ml., 7.68 mmol., 1.45 eq_) and p-toluenesulfonic acid monohydrate (92 mg.). The reaction mixture was stirred at room temperature under argon for 2.5 hours 25 then partitioned between ethyl acetate (50 ml.) and saturated sodium bicarbonate (15 ml.). The organic phase was washed with water (15 ml.) and brine (15 ml.), dried (anhydrous sodium sulfate), filtered.
evaporated to dryness and dried ~ vacuo. The crude 30 product was chromatographed on a silica gel column (Merck), eluting the column with ethyl acetate: hexane (1:4) to give 1.35 g. of title product as a thick clear syrup. TLC(ethyl acetate: hexane, 1:1) Rf ~ 0.58.

~, .. ., , ~ .~
t-: ..~ w.n ~t ~ ; ~i HA629a f) O-(2.2-Dimetho~yethyl)-L-serine, methyl ester A solution of the product from part (e) (2.0 g., 5.93 mmol.) in dry methanol (14 ml.) was treated 5 with hydrazine hydrate (0.30 ml., 6.1 mmol.) and stirred at room temperature for 4 days under argon.
The resulting suspension was filtered, washing the precipitates with methanol. (2 x 14 ml.) and the filtrate was concentrated to dryness. The syrup was 10 re-dissolved in methylene chloride and filtered two more times until no more precipitates were obtained.
The clear filtrate was concentrated to give 1.17 g.
of title product as a light yellow syrup.
TLC(methylene chloride: methanol, 9:1) Rf = 0.54.

g) N-f(Phenylmethoxy)carbonyll-O-((1,1 ~imethyleth~lldimethlsilyll-L-homoserine A solution of N-[(phenylmethoxy)carbonyl]-L
homoserine [prepared as described in Example 6(a), 20 3.0 g., 11.85 mmol.] in dzy dimethylformamide (65 ml.) was treated with [(1,1-dimethylethyl) dimethylsilyl chloride (10.72 g., 71.1 mmol.) and imidazole (9.65 g, 0.14 mol.) and stirred at room temperature under argon for 24 hours. The reaction 25 mixture was diluted with methanol (207 ml.), stirred for another 24 hours at room temperature and then concentrated to a syrup. The residual syrup was dissolved in ethyl acetate (200 ml.), washed with loo citric acid (2 x 75 ml) and brine, dried (anhydrous 30 sodium sulfate), filtered, evaporated to dryness and dried in vacuo. The crude product mixture was chromatographed on a silica gel column (Merck), eluting the column with ethyl acetate: hexane (l: l) followed by ethyl acetate: acetic acid (99.5: 0.5).

~

,a :. ~? a~v HA629a The desired fractions were combined, concentrated and evaporated several times from toluene to give 3.56 g.
of title compound as a wahy solid. TLC(ethyl acetate: acetic acid, 95:5) Rf = 0.82.

h) N-f0-f(1,1-Dimethylethyl)dimethylsi~yll-N-f ~nhenylmethoxv)carbonyll-L-homoseryll-0-(2.2-dimethoxyethyl)-L-serine, methyl ester A solution of the product from pare (g)(2.18 10 g., 5.93 mmol.) in dry methylene chloride was cooled to 0° C (ice-salt bath) and treated sequentially with a solution of the product from part (f) (1.71 g., 5.65 mmol.) in dry methylene chloride (5 rnl), tri-ethylamine (0.78 ml., 5.65 mmol.) and benzotriazol-15 1-yloxytris(dimethylamino)phosphonium hexafluorophosphate (2.63 g., 6.0 mmol.). The reaction mixture was stirred at 0° C for 30 minutes and at room temperature for one hour and 45 minutes.
The reaction mixture was partitioned between ethyl 20 ether (2 x 100 ml.) and water (30 ml.) and the combined organic extracts were washed with 50%
saturated sodium bicarbonate (20 ml.) and brine (25 ml.), dried (anhydrous sodium sulfate), filtered, evaporated to dryness and dried ~n vacuo. The crude 25 product mixture was chromatographed on a silica gel column (Merck), eluting the column with ethyl acetate: hexane mixtures (1:4; 1:3; 1:1) to give 2.38 g. of title product. TLCCethyl acetate: hexane, 1:1) Rf = 0.90.

i ) f 4S- ( 4a. 7a,. 10a~3> 1 -Octahydro-4- f f (phenylmethox~r> -carbonyllaminol-5-oxof1.41oxazinof3.4-b1f1.31-oxazepine-7-carboxylic acid, methyl ester ty, ~ .1 ~ s1 ..~ -..
i ~1 ~'_~ .h. .: -l c,) cr HA629a A solution of the product from part (h)(1.0 g., 1.8 mmol.) in dry methylene chloride (50 ml.) was treated with Amberlyst~ 15 ion exchange resin (acid form) and methanol (0.1 ml.) and the resulting 5 mixture was stirred at roam temperature under argon for three days. The resin was filtered off, washed with a small amount of methylene chloride and the filtrate concentrated to a syrup. The crude product mixture was chromatographed on a silica gel column, 10 eluting the column with ethyl acetate:hexane (1:1) to give 339 mg. of title product. TLC(ethyl acetate: hexane, 3:1) Rf - 0.53.
j) f4S-(4a 7a l0a(~l-Octah~dro-4-amino-5-15 Qxof1,41oxazinof3,4-b1f1,31axazepine-7-carboxylic acid, methyl ester A solution of the product prepared as described part (i)(771 mg., 2.04 mmol.) in dry methanol (25 ml.) was treated with 10o palladium on 20 carbon catalyst (125 mg.) and hydrogenated (balloon) at room temperature for 15 hours. The reaction mixture was filtered through a Celite~ pad and the pad was washed with methanol (2 x 25 ml.). The clear filtrate was evaporated to dryness and dried in vacuo 25 to give 448 mg. of title product as a syrup.
TLC(methylene chloride:methanal, 9:1) Rf = 0.22.
k) f4S-f4a(R*).7a.10a(311-Octahydro-4-ff2-lacer_y-lthio)-1-oxo-3-phenylprogyllaminol-5-30 oxofl.4loxazinof3.4-b1f1,31oxazegine-7-carboxylic acid, methyl ester The dicyclohexylamine salt of (S)-2-(acetylthio)benzenepropanaic acid (813 mg., 2.01 mmol.) was suspended in ethyl acetate (7C ml.), .~ ; , j ~, .
~. __ ; . .c ~l ~ a i HA 6 2 9 a washed with 5o potassiun bisulfate (5 x 9.3 ml.) and brine (9.3 ml.), dried (anhydrous magnesium sulfate), filtered, evaporated to dryness and dried ~ vacuo.
This free acid was dissolved in dry methylene 5 chloride (12 ml.), cooled to 0° C (ice-salt bath) and treated sequentially with a solution of the product from part (j) (448 mg., 1.84 mmol.) in dry methylene chloride (4.0 ml.), triethylamine (0.25 ml., 1.80 mmol.) and benzotriazol-1-yloxytris(dimethyl-10 amino)phosphonium hexafluorophosphate (823 mg., 1.86 mmol.). The reaction mixture was stirred at 0° C for one hour and at room temperature for 2 hours under argon. The reaction mixture was stripped to dryness and the syrup obtained was re-dissolved in 15 ethyl acetate (60 ml.), washed with 0.5 I~
hydrochloric acid (2 x 11 ml.), water (11 ml.) and brine (11 ml.), dried (anhydrous sodium sulfate), filtered, evaporated to dryness and dried ~ vacuo.
The crude product mixture was chromatographed twice 20 on a silica gel column (Merck), eluting each column with ethyl acetate: hexane mixtures (1:1; 1:2) to give 665 mg, of title product as a syrup. TLC(ethyl acetate: hexane, 3:1) Rf = 0.30.
25 1) f4S-(4a(R*) 7a 10a~311-Octahydro-4-f(2-mercaoto-1-oxo- -phen 'nropvl)aminol-5-oxof1.41oxazinof3.4-bl-~ '~lnxazeg~ine-7-carboxylic acid A solution of the product from part (k)(650 mg., 1.44 mmol.) in methanol (13 ml.), was purged 30 with argon for 30 minutes, cooled do,an tc 0° C (ice-salt bath) and treated dropwise with a solution of 1.0 Z1 sodium hydroxide (5.89 ml., previously purged with argon for 30 minutes), maintaining the bubbling of argon throughout the addition and lengr_h of the e, , . / d 9nt a..n w ~. ~ ~ ,...

HA629a reaction. The reaction mixture was stirred at 0°C
for 5.0 hours and quenched at 0° C with So potassium bisulfate (25.4 ml.). The mixture was warmed to room temperature, extracted with ethyl acetate 5 (3 x 50 ml.) and the combined organic extracts were washed with brine (15 ml.), dried (anhydrous sodium sulfate), filtered, evaporated to dryness and dried j~ vacuo. The crude product was triturated with hexane:methylene chloride (13C:7) and the solid 10 obtained chromatographed on a silica gel column (Merck), eluting the column with ethyl acetate: hexane mixtures (1:2; 1:1) followed by methylene chloride:methanol:acetic acid (100:4:0.2). The desired fractions were combined, evaporated to 15 dryness and evaporated several times from toluene to give 364 mg. of title product which was dried 'fin vacuo for 9.0 hours. The resulting product was then triturated with methylene chloride: hexane (1:10), hexane (50 ml.) and pentane (2 x 50 ml.), stirring 20 with the first 50 ml. for 4 hours and the next 50 ml.
of pentane overnight under argon. The solvent was decanted and the solid dried in vacuo for 6.0 hours to give pure title product as a solid amorphous foam;
[oc]D = -49.1° (c = 0.48, methanol). TLC
25 (toluene: acetic acid, 5:1) Rf = 0.17.
Anal. calc'd. for C18H22N206S ~ 0.56 H20:
C, 53.45; H, 5.76; N, 6.93; S, 7.92 Found: C, 53.45; H, 5.53; N, 6.75; S, 7.48.
HPLC: Rt = 10.45 min.; (98.30); YMS S-3 ODS
30 (c = 18) 6.0 x 150 mm; 440 (10o water - 900 methanol - 0.2o phosphoric acid)/S6o (90o water -10o methanol - 0.2o phosphoric acid), isocratic;
1.5 ml/min.

c:ø .: ~ :~ t5 ~ -.~
HA629a f4s-f4_a,lR*).7oc,l0alill-Octahydro-4-f(2-mercapto-1-oxo-3-g;henylprogyl)aminol-5-oxo-7H ~vridof2 1-blfl 31-thiazepine-7-carboxylic acid 5 The product of Example 3 was also prepared as follows:
a) N-f(Phenylmethoxy)carbonyll-O-f(1.1-dimethvl-ethyl)dimethylsilvll-L-homoserine 10 [(1,1-Dimethylethyl)dimethylsilyl]chloride (37.5 g., 249 mmol.) was added to a solution of N-[(phenylmethoxy)carbonyl]-L-homoserine [prepared as described in Example 6(a), 41.56 mmol.] in dimethyl-formamide (125 ml.), follcwed by imidazole (33.95 g., 15 498 mmol.). The resulting light yellow solution was stirred at room temperature for 22 hours. Methanol (500 ml.) was added, the reaction mixture was stirred for an additional 6 hours, and then the methanol and most of the dimethylformamide were removed ~n_ vacuo.
20 The remaining residue was taken up into ethyl acetate (800 ml.), washed with 10o citric acid (2 x 300 ml.), and the combined aqueous phase was extracted with ethyl acetate (300 ml.). The combined ethyl acetate phase was washed with water and brine, dried (sodium 25 sulfate), concentrated, and the residue was evaporated with hexane to form a white powder. This powder was dried in v a to give 12.942 g. of title product.
30 b) fS-(R*.R*)1-2-ff4-ff(1.1-Dimethylethyl)-dimethylsi X11 oxy 1 -~ -oxo-c- f f (ohenylmetho}y) -carbonyllaminolbut~llaminol-6.6-dimethoxyhexanoic acid, methyl ester ;'p .~! :1 ' c1 .... .r it! x ~ ~ C1 HA629a _.\
To a solution of~he product from part (a) (22.78 g., 61.97 din methylene chloride (100 ml.) cooled at 0° C was added N-methylmorpholine (6.81 ml., 61.97 mmol.), followed by hydroxy-5 benzotriazole (8.37 g., 61.97 mmol.), (S)-2-amino-6,6-dimethoxyhexanoic acid, methyl ester [prepared as described in Example 1(e), 10.6 g., 51.64 mmol.] in methylene chloride (50 ml.), and then 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (11.88 g., 61.97 10 mmol.). The reaction mixture was stirred at 0° C for one hour, then at room temperature overnight. The reaction mixture was concentrated in vacuo and the residue was diluted with ethyl acetate (600 ml.), washed with 5o potassium bisulfate (200 ml.), 0.5 N
15 sodium hydroxide (200 ml.), water, and brine, and dried (sodium sulfate). The filtrate was concentrated and the residue taken up in ethyl ether (150 ml.). The resulting suspension was filtered and the collected solid was washed thoroughly with ethyl 20 ether. The filtrate was concentrated ~ vacuo to dryness to afford 30 g. of crude title product as an oily compound which was used in the next reaction without purification. TLC (8:2, ethyl acetate: hexane) Rf = 0.55.

c1 fS-(R*.R*)1-2-ff4-Hydroxy-1-oxo-2-ff(phenyl-methoxvlcarbonyllaminolbutyllaminol-6,6-dimethoxy-hexanoic acid, methyl ester To a solution of the product from part (b) (30 30 g.) in methanol (150 ml.) cooled at 0° C was added para-toluenesulfonic acid monohydrate (1.96 g.). The reaction mixture was stirred at 0° C for 2 hours before quenching with aqueous sodium bicarbonate solution (1.3 g. of sodium bicarbonate in 100 ml. of k .y r~ '~
,. ~. ~i~=;
_ 97 _ HA629a water). The mixture was concentrated ~ vacuo and the residue partitioned between ethyl acetate (400 ml.) and water (150 ml.). The separated aqueous phase was extracted with ethyl acetate (2 x 150 ml.). The 5 combined ethyl acetate layers were washed with l00 sodium bicarbonate, brine (2 times), dried (sodium sulfate), filtered and evaporated to dryness. The residue was flash chromatographed on a 10 x 25 cm silica gel column eluting with 80o ethyl acetate in 10 hexane (51.), ethyl acetate (31.) and 2o methanol in ethyl acetate (51.). The desired fractions were combined and concentrated, and dried ~ vacuo to give 17.45 g. of title product as a pale yellow oil. TLC
(8:2, ethyl acetate: hexane) Rf = 0.17.

~1) fS-lR* R*)1-2-ff4-flMethanesulfonvl)oxvl-1-oxo-2-j~(phenylmethoxv)carbonyllaminolbutyllaminol-6 6-~limethoxvhexanoic acid, methyl ester To a solution of the product from part (c) 20 (17.40 g., 39.50 mmol.) (stripped with toluene three times and dried ~ yacuo overnight) in dry methylene chloride (250 ml.) cooled at -15° C (ice/acetone) was added triethylamine (8.26 ml., 59.28 mmol., freshly distilled), followed by methanesulfonyl chloride 25 (3.67 ml., 47.4 mmol.) dropwise. The reaction mixture was stirred at -15° C for 30 minutes, then quenched with saturated ammonium chloride solution (100 ml.).
After stirring for 5 minutes, the mixture was diluted with ethyl acetate (600 ml.) and washed with So 30 potassium bisulfate, brine, dried (sodium sulfate), filtered and evaporated to dryness. The residue was dried '1..)r vacuo to give 20.40 g. of title compound as a yellow oil which was used in the next reaction ~ 'f '? :'~ ''' '.
i.;.~;~-:J~~

HA629a without purification. TLC (8:2, ethyl acetate:
hexane) Rf = 0.35.
e) fS-(R*.R*)1-2-ff4-(Ac~ylthio)-1-oxo-2-ff(g envl-5 methoxv arho~llaminolbutyllaminol-6.6-dimethoxv-hPxano;~ acid methyl ester To a solution of thioacetic acid (5.09 ml., 71.10 mmol.) in methanol (100 ml.) was added cesium carbonate (10.81 g., 33.18 mmol.). The resulting 10 solution was concentrated in vacuo. The solid was triturated with dzy acetone (3 times) and then dried 'fin vacuo over phosphorus pentoxide overnight to give cesium thioacetate.
A solution of the product from part (d) (20.40 15 g., 39.50 mmol.) in dry dimethylformamide (150 ml.) was added via cannula to a suspension of cesium thioacetate (10.576 g., 50.85 mmol.) in dimethylformamide (50 ml.). The resulting yellow solution was stirred under argon at room temperature 20 overnight, then concentrated at high vacuum to remove most of the dimethylformamide. The residue was taken into ethyl acetate (11.) and washed with 10o sodium bicarbonate (200 ml.), water (4 x 200 ml.), brine (400 ml.) and dried (sodium sulfate). The filtrate 25 was concentrated and the residue evaporated with toluene (3 times), then dried in yaeuo to afford 20 g, of title compound as a light yellow solid which was used for the next reaction without purification.
TLC(8:2; ethyl acetate: hexane) Rf = 0.47.

f~ fS-(R*.R*)l.-.2-ff4-Mercagto-1-oxo-2-jjly~~nylmethoxy)carbonyllaminolbutvllaminol-6.6-c3;mPrhoxvhexanoic acid methyl ester A solution of the product from part (e) c, -~ :, °s; .~a _..
._ . . we HA629a (20 g., 39.50 mmol.) in methanol (250 ml.) cooled at 0°C. was purged with argon for 15 minutes. With continuous argon purging, a 250 (weight/weight, density = 0.945) sodium methoxide solution in 5 methanol (9.17 ml., 40 mmol.) was added dropwise.
After stirring for 5 minutes, the reaction was quenched with saturated ammonium chloride solution (200 ml.) and the mixture partitioned between ethyl acetate (11.) and water (200 ml.). The aqueous phase 10 was extracted with ethyl acetate (200 ml.). The combined ethyl acetate extract was washed with saturated ammonium chloride solution (400 ml.), brine (400 ml.), dried (sodium sulfate), filtered and concentrated ~ vacuo to give 17.5 g. of title 15 product as a yellow oil which was used for the next reaction without purification. TLC (8:2, ethyl acetate: hexane) Rf = 0.45.
cr) f4S-(4a,7a,l0a(3)1-Octahvdro-4-ff(ghenvl 20 methoxy)carbonyllaminol-5-oxo-7H-Ryridof2,1 bl(1,31thiazepine-7-carboxylic acid, methyl ester To a solution of the product from part (f) (17.5 g., 38.3 mmol.) in methylene chloride (600 ml.) was added Amberlyst~15 ion exchange resin (6 g., 25 pretreated with 6N hydrochloric acid, water, tetrahydrofuran, and methylene chloride arid dried).
The suspension was stirred under argon at room temperature for 18 hours and filtered. The filtrate was concentrated and the residue adsorbed on Celite0, 30 purified on a 10 x 30 cm silica gel column. eluting with 20-300 of ethyl acetate in hexane. The desired fractions were combined and evaporated ~ vacuo to dryness to afford 9.18 g. of title product as a yellow oil. TLC (1:1, ethyl acetate: hexane) 1 ~1 ~
f... ~,. a. ~.~ c.,.) t.i Rf = 0.32.
HA629a h) f4S-(4oc,7a,l0a[3)1-Octahvdro-4-amino-5-oxo-7H-pyridof2,1-blfl,3lthiazepine-7-carboxylic acid, 5 methyl ester To a solution of solution of the product from part (g) (9.1 g., 23.19 mmol., evaporated with toluene three times and dried ~ vacuo overnight) in dry methylene chloride (150 m1.> was added 10 iodotrimethylsilane (4.95 ml., 34.78 mmol.) dropwise.
The resulting yellow solution was stirred under argon at room temperature for 1.5 hours, then quenched with 0.4 N hydrochloric acid in methanol/dioxane (120 ml.). The volatiles were removed in vacuo and the 15 residue partitioned between ether (500 ml.) and water (700 ml.). The organic phase was extracted with 0.1 N hydrochloric acid (150 ml.) and the combined acidic aqueous extract cooled to 0°C, basified with 1 N
sodium hydroxide to pH 10.5 (monitored with a pH
20 meter), then extracted with methylene chloride (4 x 400 ml.). The combined organic extracts were washed with brine, dried (sodium sulfate), filtered and concentrated in vacuo to afford 6.45 g. of title product as a yellow oil, which was used for the next 25 reaction without further purification. TLC (1:9, methanol:methylene chloride) Rf = 0.20.
i ) f 4S- f 4a (R* ) , 7a, l0af~l 1 -Octahydro-4- f (?.-merca"y~to-1 oxo-3-ohen~lprogyl)aminol-5-oxo-7H-gyridof2.1-b1f1.31 30 thiazey~ine-7-carboxylic acid A cold (0°C) solution of (S)-(2-acetylthio)-benzenepropanoic acid and triethylamine in methylene chloride was treated with a solution of the product from part (h) in methylene chloride followed by _.. 45 a ' HA629a benzotriazol-1-yloxytris(dimethylamino)phosphonium hexafluorophosphate. The reaction was worked up according to the procedure described in Example 3 (c) to afford [4S-[4a(R*),7a,10a(3]]-octahydro-4-[[2-5 (acetylthio)-1-oxo-3-phenylpropyl]amino]-5-oxo-7H
pyrido(2,1-b][1,3]thiazepine-7-carboxylic acid, methyl ester.
A solution of this methyl ester product in deoxygenated methanol was treated with 1N sodium 10 hydroxide according to the procedure of Example 3(d) to afford the title product.

f4S-f4a(R*>,7a,10af311-Octahvdro-4-ff2-(mercaptomethyl)-15 1-oxo-3-Rhenyl rogyllaminol-5-oxo-7H-gyridof2,1-b1f1,31-thiazepine-7-carboxylic acid al (S)-2-f(Acetylthio)methyllbenzene ropanoic acid, ephedrine salt 20 A solution of (1R,2S)-(-)-ephedrine (17.3 g., 105 mmol.) in diethyl ether (175 ml.) was added in one portion to a solution of 2-[(acetylthio)methyl]benzene-propanoic acid (50.0 g., 210 mmol.) in diethyl ether (175 ml.). After standing at room temperature for 16 25 hours, the crystallized ephedrine salt wa;> collected by filtration (19.7 g.); m.p. 114 - 125°; [a]D = -40.6° (c - 1, methanol). An additional amount of solid (8.9 g, m.p. 121 - 126°; [a]D = -47.2° (c = 1, methanol)]
separated from the filtrate after remaining at room 30 temperature for 20 hours. The solids were combined and recrystallized from acetonitrile (1500 ml.). After 16 hours at room temperature, 20.8 g. of solid was collected; m.p. 125 - 130°C; [a]D = -98.9° (c = 1, methanol). This material was recrystallized in the same :"7 r.: a -. .:

HA629a manner from acetonitrile (300 ml.) to give 18.7 g., m.p.
128 - 130°; (a]D = -48.9° (c = 1, methanol). A third recrystallization from acetonitrile (225 ml.) afforded 17.4 g of solid (S)-2-((acetylthio)methyl]benzene-5 propanoic acid, ephedrine salt; m.p. 128 -- 129°; (a]D =
-50.1° (c = l, methanol).
Anal. calc'd. for C12H1403S ' C10H15N0:
C, 65.48; H, 7.24; N, 3.47; S, 7.95 Found: C, 65.46; H, 7.34; N. 3.21; S, 8.00.

b) f4S-f4a(R*),7a,10a(311-Octahydro-4-ff2-f(acetylthio)methyll-1-oxo-3-phenylpropyll-~minol-5-oxo-7H-gyridof2,1-b1f1,31thiazey~ine-7-carboxylic acid, methyl ester 15 A stirred suspensicn of the ephedrine salt from part (a) (333.1 mg., 0.822 mmol.) in ethyl acetate (5 ml) was washed three times with 5 ml portions of lI~ hydrochloric acid solution. The organic extracts were combined, washed with brine, 20 dried (magnesium sulfate), filtered, concentrated and dried in vacuo for 30 minutes. The resulting oil was dissolved in methylene chloride (2 ml) and stirred under nitrogen at 0°C. To this solution was added a solution of [4S-(4a,7a,l0a(3)]-octahydro-25 4-amino-5-oxo-7H-pyrido[2,1-b][1,3]thiazepine-7-carboxylic acid, methyl ester [200.0 mg, 0.774 mmol., prepared as described in Example 3(c)] in methylene chloride (6 ml), then triethylamine (0.113 ml, 0.813 mmol) and finally benzotriazol-1-yloxytris 30 (dimethylamino)phosphonium hexafluorophosphate (360.0 mg., 0.813 mmol.) The reaction was stirred at 0°C
and allowed to slowly warm to room temperature.
After 19 hours, the reaction was concentrated in vacuo and the residue was dissolved in ethyl acetate.

~a .1 !',. . ~ '. i . ~ f e;

HA629a The solution was washed once with a 5o solution of potassium bisulfate (20 ml), once with a saturated solution of sodium bicarbonate (20 ml), and once with brine. The organic layer was dried (magnesium 5 sulfate), filtered and concentrated to a yellow foam.
Purification by flash chromatography (silica gel, 230 - 400 mesh under 10 - 20 psi of nitrogen pressure) eluting with 4:3 ethyl acetate/hexane gave 303 mg of product as a clear oil.

c)f 4S-f4a.(R*) a..10a(311-0ctahydr o-4-f f2-.7 (mercay~tomethyl -oxo-3 =ghenylpro~y1-) l aminol-5-oxo-7H-gyridof2 .1-b1fl.31thiaze,B;~ne-7-carboxylic acid 15 A soltuion of the product from part (b) (303.1 mg., 0.635 mmol) in methanol (6.5 ml, deoxygenated via nitrogen bubbling) was cooled to 0°C and treated with 1I~ sodium hydroxide (6.5 ml, deoxygenated via nitrogen bubbling). After stirring for one hour at 20 0°C while purging continuously with nitrogen, the reaction was warmed to room temperature. After a total of three hours, the reaction was acidified to pH 1 with 5o potassium bisulfate and extracted with ethyl acetate. The organic layers were combined, 25 washed with water, brine, dried (sodium sulfate), filtered, and concentrated in vacuo to give 219 mg of title product as a white solid; m.p. 200°C (decomp.).
TLC (6:0.01: 3.99 ethyl acetate/acetic acid/hexane) Rf = 0.15.
30 HPLC: tR = 26.3 min, impurity at 27.0 min.; YMC S-3 ODS (C-18) 6.0 x 150 mm; Oo to 1000 B: A, 30 min.
linear gradient and 10 min. hold, 1.5 ml/min.; A =
90o water:methanol + 0.2o phosphoric acid, B = 900 methanol:water + 0.2o phosphoric acid; 220 nm.

HA629a Anal. calc~d for C2pH2604N2S2 ~ 0.11 C4H8o2 ~ 0.07 CH2C12:
C, 56.22; H, 6.21; N, 6.39; S, 14.63.
Found: C, 56.46; H, 6.28; N, 6.31; S, 14.59.

Bxamx~le 13 f4S-f4a(R*).7a.10a1311-Octahydro-4-fl2-mercapto4-methyl-1-oxopentyl)aminol-5-oxo-7H-gyridof2.1-b1f1.31 thiazeDine-7-carboxylic acid a) (R)-2-Bromo-4-methvlpentanoic acid Potassium bromide (9.5 g., 80 mmol) was added to a stirred solution of D-leucine (3.0 g., 23 mmol) in 2.5 N sulfuric acid (4~ ml) at room ternperature.
15 The reaction mixture was cooled to -10°C and solid sodium nitrite (2.4 g., 34 mmol) was added portionwise, maintaining the temperature between -10°
and -5°C. After addition was complete, the reaction was stirred for 1 hour and then warmed to room 20 temperature and stirred for another hour. The reaction mixture was then extracted twice with ether, the ether extracts were washed once with water, dried (magnesium sulfate), filtered and evaporated to give 2.7 g of crude title product.

b) (S)-2-lAcetylthio)-4-methyl~entanoic acid.
d~clohex~.lamine salt To a stirred slum. of potassium thioacetate (1.7 g, 15.0 mmol) in 50 ml of dry acetonitrile at 30 room temperature under argon was added a solution of the product from part (a) (2.6 g., 13 mmol) in 17 ml of acetonitrile. The reaction was stirred 4 hours.
The resulting slurry was filtered and evaporated.
The residue was redissolved in ethyl ether, washed ,'! ,~ c't ~~:~::~~~r HA629a once with 5o potassium bisulfate solution and once with brine, dried (magnesium sulfate) and evaporated.
The residue was dissolved in ether (64 ml) and treated with dicyclohexylamine (2.7 ml, 14 mmol). A
5 white solid immediately began precipitating from the solution. The solution was filtered and the white solid collected to give 2.0 g of title praduct; m.p.
153 - 158°C; (a]D = -54.5° (c = 0.61, chloroform).
10 c) f4S-f4a(R*),7a.10a!1311-Octahydro-4-ff2-(acetylthio)-4-methyl-1-oxopentyllaminol-5-oxo-7H-gvridof2.1-b1f1,31thiazepine-7-carboxylic acid, methyl ester A stirred suspension of the product from part 15 (b) (403.3 mg, 1.09 mmol) in ethyl acetate (5 ml) was washed three times with 5 ml portions of 5o potasium bisulfate solution. The organic extracts were combined, washed with brine, dried (sodium sulfate), filtered, concentrated and dried in vacuo for 30 20 minutes. The resulting oil (179.4 mg, 0.943 mmol) was dissolved in methylene chloride (2 ml) and stirred under nitrogen at 0°C. To this salution was added a solution of [4S- (4a, 7a, 10a(3)] -octahydro-4-amino-5-oxo-7H-pyrido[2,1-b](1,3]thia-25 zepine-7-carboxylic acid, methyl ester (232.0 mg, 0.898 mmol., prepared as described in Example 3(c)) in methylene chloride (6 ml), then triethylamine (0.131 ml., 0.943 mmol), and finally benzotriazol-1-yloxytris(dimethylamino)phosphonium 30 hexafluorophosphate (417.1 mg, 0.943 mmol.). The reaction was stirred at 0°C for one hour and 3.5 hours at room temperature. After a total of 4.5 hours, the reaction was cancentrated in vacuo and the residue was dissolved in ethyl acetate. The solution w ~ :1 ~ t? "'? : ~
F~; ':. td i:f CJ i V

HA629a was washed once with a 5o solution of potassium bisulfate (20 ml), once with a saturated solution of sodium bicarbonate (20 ml), and once with brine. The organic layer was dried (magnesium sulfate), filtered 5 and concentrated to a yellow foam. Purification by flash chromatography (silica gel, 230 - 400 mesh under 10 - 20 psi of nitrogen pressure) eluting with 2:3 ethyl acetate/hexane gave 209.4 mg. of title product as a clear oil.

d) f4S-f4a(R*) 7a 10a 11-Octahydro-4-f(2-mercapto-4-methyl-1-oxopertyllaminol-5-oxo-7H-gyri-dof2 1-blfl 3lthiazepine-7-carboxylic acid A solution of the product from part (c) (209.4 15 mg, 0.486 mmol) in methanol (5 ml, deoxygenated via nitrogen bubbling) was cooled to 0°C and treated with 11~ sodium hydroxide (5 ml, deoxygenated via nitrogen bubbling). After stirring for one hour at 0°C while purging continuously with nitrogen, the reaction was 20 warmed to room temperature. After a total of 2.5 hours, the reaction was acidified to pH 1 with 5%
potassium bisulfate and extracted with ethyl acetate.
The organic layers were combined, washed with water, brine, dried (sodium sulfate), filtered, and 25 concentrated in vacuo. Purification by flash chromatography (silica gel, 230 - 400 mesh under 10 -20 psi of nitrogen) eluting with nitrogen sparged 6:0.01:3.99 ethyl acetate~'acetic acid/hexane gave 142.0 mg of title product as a white solid. TLC
30 (6:0.1:3.9 ethyl acetate/acetic acid/hexane) Rf =
0.20. [a]D = -103.0° (c --.. 0.43, chloroform).
HPLC: tR = 26.7 min.; YMC S-3 ODS (C-i8) 6.0 x 150 mm; Oo to 1000 B: A, 30 min. linear gradient and 10 min. hold, 1.5 ml/min; A = 90~ water: methanol + 0.20 r. . 1., '3 c~ a HA629a phosphoric acid, B = 90o methanol:water + 0.20 phosphoric acid; 220 nm.
Anal. calc'd for C16H2604N2S2 ~ 0.19 C4H802 ~ 0.18 C7H16 ~ 0.9 H20:
5 C, 50.87; H, 7.63; N, 6.58; S, 15.07.
Found: C, 50.57; H, 7.20; N, 6.83; S, 14.75.
Example 14 f4S-f4a(R*).7a,9a1ill-Octahydro-4-f(2-merca~to-1-10 oxybutyllaminol-5-oxQpyrrolof2,1-b1f1.31thiazepine-7-carboxylic acid a) (R)-2-Bromobutanoic acid Potassium bromide (7.85 g, 65.94 mmol) was 15 added to a solution of (R)-2-aminobutanoic: acid (2.0 g, 19.40 mmol) in 2.5 N sulfuric acid (25 ml) and cooled to 0°C. Sodium nitrite (2.06 g, 29.87 mmol) was added slowly in several portions. The temperature was kept at less than 2°C during this 20 addition. The reaction was stirred at 0°C for one hour and at room temperature for 16 hours, then extracted with 3 - 50 ml portions of ethyl acetate.
The combined ethyl acetate layers were washed with 2 - 50 ml portions of water, 1 - 50 ml portion of 25 brine, dried (magnesium sulfate) and concentrated in vacuo to give 2.86 g of title product as a crude oil.
b) (S>-2-(Acer~ylthio)butanoic acid, dicyclo-h~lamine salt 30 To a slurry of 2.14 g 118.77 mmol) of potassium thioacetate in 15 ml of acetonitrile, stirred at room temperature, was added dropwise over 15 minutes a solution of iR)-2-bromobutanoic acid (2.83 g, 17.07 mmol) in 15 ml of acetonitrile. The ...
Pd _~ w ~, e.a e.r HA629a reaction was stirred at room temperature for 16 hours then filtered. The filtrate was concentrated in vacuo and the resulting oil was dissolved in 30 ml of ethyl ether. The ether layer was washed with 2 - 20 5 ml portions of 5% potassium bisulfate, 2 - 20 ml portions of water, 2 - 20 ml portions of brine, dried (magnesium sulfate) and filtered. To the filtrate was added 3.4 ml (17.07 mmol) of dicyclohexylamine.
After stirring at room temperature for 2 hours, the 10 slurry was filtered to give 1.24 g of the dicyclohexylamine salt product. A second crop of 724 mg of dicyclohexylamine salt product was obtained from the filtrate.
15 c) f4S-f4a(R*),7a,9a(311-Octahydro-4-ff2-f(acetyl-thio)-1-oxobutyllaminol-5-oxopyrrolof2,1-bl-f1.31thiazepine-7-carboxylic acid, methyl ester The dicyclohexylamine salt product from part (b) (227 mg, 0.66 mmol) was dissolved in 15 ml of 20 ethyl acetate and washed with three 10 ml portions of potassium bisulfate, one 10 ml. portion of brine, dried (magnesium sulfate), and concentrated in vacuo to give 108 mg of (S)-2-(acetylthio)butanoic acid as a clear oil.
25 To a solution of this free acid (108 mg, 0.66 mmol) in 5 ml of dry methylene chloride, cooled to 0°C, was added triethylamine (90 ~l, 0.66 mmol), followed by [4S-(4a,7a,9a~3)]-4-amino-octahydro-5-oxopyrrolo[2,1-b][1,3]thiazepine-7-carboxylic acid, 30 methyl ester, p-toluenesulfonic acid salt [250.0 mg, 0.66 mmol, prepared from the material described in Example 5(d)] and a second portion of triethylamine (90 ~1, 0.66 mrnol). The reaction was stirred at 0°C
for 20 minutes, then benzotriazol-1-yloxy-~ ~ C
YW

HA629a tris(dimethylamino)phosphonium hexafluorophosphate (292 mg, 0.66 mmol) was added in one portion. The reaction was stirred at 0°C for one hour, refrigerated for 56 hours, then stirred at room 5 temperature for 3 hours. The reaction mixture was then concentrated in vacuo, redissolved in 30 ml ethyl acetate and washed with 20 ml of 5o potassium bisulfate, 20 ml saturated sodium bicarbonate, 20 ml of brine, dried (magnesium sulfate), and concentrated 10 in vacuo to give a crude oil. The crude oil was flash chromatographed (Merck silica gel, 25 x 100 mm, 2:3 ethyl acetate/hexane) to give 208 mg of title product as a white foam.
15 d) [4S-[4a(R*),7a,9a(311-Octahydro-4-f(2-mercapto-1-~butyllaminol-5-oxogyrrolof2.1-b1f1,31thia-zenine-7-carboxylic acid A solution of the product from part: (c) (225 mg, 0.559 mmol) in methancl (5 ml) was purged with 20 argon for 30 minutes and cooled to 0°C. To this solution was added dropwise 5 ml of 1M sodium hydroxide, also purged with argon for 30 minutes and cooled to 0°C. The reaction was stirred at 0°C for 3 hours with continuous argon purging, then acidified 25 to pH 2 with 5o potassium bisulfate solution. The mixture was extracted with 3 - 40 ml portions of ethyl acetate, and the combined ethyl acetate layers were dried (magnesium sulfate), and concentrated in.
vacuo to give a crude foam. The crude product was 30 flash chromatographed (Merck silica gel, 25 x 180 mm, 3o acetic acid/ethy'. acetate) to give a white foam, which was dissolved in methylene chloride and triturated with hexane to give 176 mg of title product as a compact white foam; [a]D = -125.4° (c =

c ~ .~ : ~ ;7 $? ~t ° v i'. .i : .. e) t HA629a 1.0, chloroform). TLC (methanol/methylene chloride 1:9) Rf = 0.16.
HPLC: tR - 15.5 min. (97o total area, UV 220 nM);
YMC S-3 ODS (C-18, 120A) 6 x 150 mm; Oo B:A-100a B:A, 5 linear 25 minute gradient (A = 90% water/methanol +
0.2a phosphoric acid) B = 90o methanol/wat.er + 0.2%
phosphoric acid); flow rate = 1.5 ml/min.
Anal. calc'd for C13H2pN2S204 ~ 0.8 H20 0.2 C6H14 ~ 0.1 CH2C12:
10 C, 46.10; H, 6.66; N, 7.52; S, 17.21.
Found: C, 46.00; H, 6.17; N, 7.52; S, lEi.82.
Example 15 I4S-f4a(R*),7a,9a(~l-Octahydro-4-f(2-mercapto-1-15 oxopentyl)aminol-5-ox~yrrolof2 1-blfl 3lthiazepine-7-carboxylic acid a) (R)-2-Bromopentanoic acid Following the procedure of Example 14(a) but 20 employing D-norvaline in place of (R)-2-aminobutanoic acid, (R)-2-bromopentanoic acid was obtained as a clear liquid.
b) (S)-2-(Ace~vlthio>~entanoic acid dicvclo-25 hexylamine salt Reacting (R)-2-bromopentanoic acid with potassium thioacetate in acetonitrile followed by treatment with dicyclohex~~lamine according to the procedure of Example 14(b), (S)-2-(acetylthio)-30 pentanoic acid, dicyclohexylamine salt was obtained as a white solid.

;~y ~ :'~ I~, t-,. -.i °x e~ : i HA629a c) f4S-f4a(R*) 7a 9aa11-Octahydro-4-ff2-( cetvl-thio)-1-oxopent~llaminol-5-oxo~yrrolof2 1-bl-l '~~rhiazenine-7-carboxy,~ic acid methyl ester Reacting the free acid of the dicyclo-5 hexylamine salt from part (b) with [4S-(4a,7a,9a~3)]-4-amino-octahydro-5-oxopyrrolo-[2.1-b][1,3]thiazepine-7-carboxylic acid, methyl ester according to the procedure of Example 14(c), the title product was obtained as a white foam.

~~) f 4S- f 4a(R* ) . 7a. 9a(~l 1 -Octahvdro-4- f !2-merca~to-1-oxo~ntvl)aminol-5-oxo~yrrolo-f2 1-blfl 3lthiazepine-7-carboxylic acid A solution of the product from part. (c) in 15 methanol was treated with 1M sodium hydroxide according to the procedure of Example 14(d) and gave the title product as a compact white foam; [a]D =
-122.8° (c = 1.0, CDC13). TLC (methanol/methylene chloride 1:9) Rf = 0.15. HPLC: tr = 20.5 min.; (970 20 total area, UV 220 nM); YMC S-3 ODS (C-18, 120A) 6 x 150 mm; Oo B:A- 1000 B: A, linear 25 minute gradient (A = 90o water:methanol + 0.2~ phosphoric acid); s =
90o methanol: water + 0.2o phosphoric acid; flow rate _ 1.5 ml/min.
25 Anal. calc'd for C14H22N2S204 ~ 0.65 H20 0.20 C6H14:
C, 48.63; H, 7.01; N, 7.46; S, 17.08.
Found: C, 48.86; H, 6.70; N, 7.24; S, 16.74.
30 Exam8le 16 f4S f4a(R*) 7a 9a(311-Octahvdro-4-f(2-merc~to-4 4-dimettlyl-1-oxo~entyl)laminol-5-oxogyrrolof2.1-bl-f~.~~rhiazepine-7-carboxylic acid ,~ h! -l : a s -1 ~-tA6 2 9 a a) (R) 2-Bromo-4,4-dimethylgentanoic acid A solution of (R)-2-amino-4,4-dimethyl-pentanoic acid (950 mg, 6.55 mmol) in 2.5 N aqueous sulfuric acid (13 ml, 33 mmol) was cooled to -5°C and 5 treated with potassium bromide (2.72 g, 22.9 mmol) in one portion. The colorless solution was treated with sodium nitrite (680 mg, 9.86 mmol) portionwise, keeping the temperature between 0° and 3°C over a period of 25 minutes. The reaction mixture was 10 stirred at 0°C for one hour and at room temperature for 1.5 hours. The reaction mixture was poured into water (10 ml). The product was extracted with ether (60 ml), washed with water (20 ml) and brine (20 ml), dried (magnesium sulfate), and concentrated in vacuo 15 to give the title product as a colorless liquid.
b) (S)-2-(Acetylthio>-4,4-dimethylpentanoic acid A slurry of potassium thioacetate (750 mg, 6.58 mmol) and acetonitrile (10 ml, molecular sieves 20 dried) was cooled to 0°C and treated with a solution of (R)-2-bromo-4,4-dimethylpentanoic acid from part (a) in acetonitrile (2 ml) over 5 minutes. The reaction mixture was allowed to warm to room temperature and stirred for 2.5 hours. The slurry 25 was filtered. The filtrate was concentrated in vacuo. The residue was diluted in ether (50 ml), washed with two portions of 5o aqueous sodium thiosulfate (50 ml) and brine (25 ml), dried (magnesium sulfate), and concentrated in vacuo. The 30 pale yellow oil was purified by flash chromatography (Merck silica gel, 12 x 3 cm., loo methanol/methylene chloride) affording 575 mg of title product as a pale yellow oil.

Crt .a :~D _~ ~l ~"~
~a ~ h! JC

HA629a c) f4S-f4a(R*),7a,9a~i11-Octahvdro-4-ff2-(acetvlthio)-4~4-dimethyl-1-oxopentyllaminol-5-oxogyrrolof2,1-bl-f1.31thiazegine-7-carboxylic acid, methyl ester A clear solution of the product from part (b) 5 (148 mg, 0.72 mmol) in methylene chloride (5 ml, distilled from calcium hydride) was cooled to 0°C and treated with a solution of [4S-(4a,7a,9a(3)]-4-amino-octahydro-5-oxopyrrolo[2,1-b][1,3]thiazepine-7-car-boxylic acid, methyl ester, p-toluenesulfonic acid 10 salt [250.0 mg, 0.60 mmol, prepared from the material described in Example 5(d)] in methylene chloride (3 ml, distilled from calcium hydroxide), triethylamine (122 mg, 1.2 mmol), followed by benzotriazol-1-yloxytris(dimethylamino)phosphonium 15 hexafluorophosphate (319 mg, 0.72 mmol). The reaction mixture was stirred at 0°C for 24 hours and at room temperature for 5 hours. The crude reaction mixture was concentrated in vacuo. The residue was diluted in ethyl acetate (50 ml), washed with 5o aqueous 20 potassium bisulfate (50 ml), 50o saturated aqueous sodium bicarbonate solution (50 ml), and brine (50 ml), dried (sodium sulfate) and concentrated in vacuo.
The crude product was purified by flash chromatography (20g, Merck silica gel, ethyl acetate) to afford 244 25 mg of the title product as a white foam.
d) f 4S- ( 4a (R* ) , 7a, 9a(31 1 -Octahvdro-4- f (2-mercar~to-4 4-dimethvl-1-oxo~entyl)aminol-5-oxopyrrolof2 1-bl-f1,31thiazepine-7-carboxylic acid 30 A clear solution of the product from part (c) (240 mg, 0.56 mmol) in methanol (2 ml, nitrogen sparged) was cooled to 0°C and treated dropwise with 1N sodium hydroxide (2.27 ml, 2.24 mmol, argon sparged) with continuous sparging at 0°C. The mixture i ~ _i. ~;~ i el ~ s~' Hp, 6 2 9 a was allowed to stir at 0°C for 3 hours and at room temperature for 3 hours. The mixture was acidified to pH of 1 with a solution of 5o aqueous potassium bisulfate (argon sparged). The product was extracted 5 with methylene chloride (50 ml, nitrogen sparged), washed with brine, dried (sodium sulfate) and concentrated in vacuo. The crude product was recrystallized from methylene chloride/hexane to afford 75 mg of title product as a white solid; m.p.
10 124 - 126°C; [a]D = -175° (c = 0.25, methanol). TLC
(acetic acid/methanol/methylene chloride 1:5:94)Rf =
0.65.
HPLC: tR (YMC, S-3 ODS (C-18) 6.0 x 150 mm; 1.5 ml/min. linear gradient 0 - 100oB over 30 min., Buffer 15 A = methanol/water/phosphoric acid (10:90:0.2), Buffer B = methanol/water/phosphoric acid (90:10:0.2)) - 24.4 min., 950 of total peak area at 254 nm.
Analysis calc'd. for C16H26N204S2 ~ 0.13 C6H14:
C, 52.24; H,7.28; N, 7.26; S, 16.62 20 Found: C, 51.97; H,7.26; N, 7.09; S, 16.23.
Examgle 17 f4S-f4a(R*),7a,9ab11-Octahydro-4-f(2-mercapto-1-oxopropyl)aminol-5-Qxopyrrolof2,1-b11,31thiazeoine-25 7-carboxvlic acid a) (R>-2-Bromopropanoic acid Following the procedure of Example 14(a) but employing D-alanine in place of (R)-aminobutanoic 30 acid, (R)-2-bromopropanoic acid was obtained as a light yellow oil.

;~ a ~l :t _ i.r 't c~ ~~

HA629a b) (S)-2-(ACet~lthio)pro~~anoic acid To a light green solution of potassium thioacetate (3.94 g, 34.5 mmol) in acetonitrile (150 ml) was added a solution of (R)-2-bromopropanoic acid 5 (4.8 g, 31 mmol) in acetonitrile (12 ml) at room temperature under an argon atomosphere. The resulting white slurry was stirred at room temperature for 2 hours then filtered. The filtrate was concentrated in vacuo. The residue was diluted 10 in ethyl acetate (100 ml), washed with a 1.0o aqueous solution of potassium bisulfate (50 ml) and brine, dried (sodium sulfate), and concentrated in vacuo.
The crude product (4.61 g) was purified by flash chromatography (60 g - Merck silica gel, 1.:45:54 15 acetic acid/ethyl acetate/hexane) to afford 3.7 g of the title product as a light yellow oil; [a]D = -114°
(c = 0.50, methanol).
c) f4S-f4a(R*).7a,9a1,,'311-Octahydro-4-ff2-(acetyl 20 thio)-1-oxoprogyllaminol-5-oxopyrrolof2,1-b1f1.31 thiaze~ine-7-carboxylic acid, methyl ester A clear solution of (S)-2-(acetylthio)pro-panoic acid (86 mg, 0.58 mmol) in methylene chloride (5 ml, distilled from calcium hydride) wa~> cooled to 25 0°C and treated with a solution [4S-(4a,7a,9a(3)]-4-amino-octahydro-5-oxopyrrolo[2,1-b][1,3]thiazepine-7-carboxylic acid, methyl ester, p-toluenesulfonic acid salt (200.0 mg, 0.48 mmol, prepared from the material described in Example 5(d)] in methylene chloride (5 30 ml, distilled from calcium hydride), triethylamine (98 mg, 0.97 mmoi), followed by benzotriazol-1-yloxytris(dimethylamino)phosphonium hexafluorophosphate (255 mg, 0.58 mmol). The reaction mixture was stirred at 0°C for 22 hours and HA629a at room temperature for 2 hours. The crude reaction mixture was concentrated in vacuo. The residue was diluted in ethyl acetate (100 ml), washed with 50 aqueous potassium bisulfate (30 ml), 50o saturated 5 aqueous sodium bicarbonate solution, and brine, dried (sodium sulfate), and concentrated in vacuo. The crude product was purified by flash chromatography (40 g., Merck silica gel, ethyl acetate) to afford 180 mg of title product as a white solid; m.p. 143 -10 145°C .
d) f4S-f4a(R*),7a,9a~311-Octahydro-4-f(2-merca_pto--oxoprogyl)aminol-5-oxopyrrolof2,1-b1f1,31thiazepine-7-carboxylic acid 15 A clear solution of the product from part (c) (180 mg, 0.48 mmol) in methanol (2 ml) under an argon atmosphere was cooled to -10°C and treated dropwise with argon sparged 1N sodium hydroxide (1.95 ml, 1.95 mmol), keeping the temperature below 0°C. The mixture 20 was allowed to stir with argon sparging ar_ 0°C for 3 hours. The mixture was acidified to pH of 1 with a solution of So aqueous potassium bisulfate under an argon atmosphere. The product was extracted with nitrogen sparged ethyl acetate (100 ml), washed with 25 brine, dried (sodium sulfate), and concentrated in vacuo. The crude product was purified by flash chromatography (40 g, Merck silica gel, 1:5:94 acetic acid/methanol/methylene chloride) to afford 154 mg of title product as a white solid; m.p. 150 - 152°C;
30 [a]D = -156° (C = 0.50, methanol). TLC (1:5:94 acetic acid/methanol/methylene chloride) Rf = 0.28.
HPLC: tR (YMC, S-3 ODS (C-18) 6.0 x 150 mm; 1.5 ml/min. linear gradient 0-100oB over 30 minutes.
Buffer A = methanol/wateriphosphoric acid (10:90:0.2), _~ ,, r-, r~ iL
a : 1 .: x e.! , i.~

HA629a Buffer B = methanol/water/phosphoric acid (90:10:0.2)) - 14.69 min., more than 950 of total peak area at 254 mM.
Anal. calc'd. for C12H18N204S2~0.75CH3C02H:
5 C, 44.61; H, 5.82; N, 7.71; S, 17.64 Found: C, 44.76; H, 5.71; N, 7.81; S, 17.'76.
Example 18 f4S-f4a(R*),7a.9a(311-Octahydro-4-f3-cyclo~Ryl-2-10 mercapto-1-oxoprogyl>aminol-5-oxo~yrrolof2,1-blfl.31-~hiazepine-7-carboxylic acid a) !R>-2-ff(Phenylmethoxy>carbonyllaminol-4-pentenoic acid 15 A mixture of D-allylglycine (2.8 g, 24.3 mmol), 1 M aqueous sodium hydroxide solution (25 ml), and tetrahydrofuran (10 ml, distilled from ketyl) was stirred at room temperature until homogeneous then cooled in an ice-bath. To the resulting rapidly 20 stirred solution was added about 5 mL of 1.0 M
aqueous sodium hydroxide solution then dropwise about 1 g of benzyl chloroformate. This was repeated 4 additional times until a total of 28 mL of 1.0 M
aqueous sodium hydroxide soltuion and 4.80 g (95a, 27 25 mmol) of benzyl chloroformate were added. The reaction mixture was stirred for 15 minutes at 0°C
then 30 minutes at room temperature and then extracted with 50 mL of ether. The aqueous layer was acidified (pH = 1.5) the by addition of 6N
30 hydrochloric acid solution (about 10 mL) then extracted with three-50 mL, portions of ether. The three ether extracts were combined, dried (magnesium sulfate) and concentrated in vacuo to afford 6.01 g of title product as a colorless oil.

E~ ~ rff ;.~

HA629a b) (R)-2-lflPhenylmethoxv)carbonyllaminol-4-~pntPnnir- ar_i_d, ~henylmethyl ester Cesium carbonate (4.28 g, 13.1 mmol) was added 5 to a solution of the product from part (a) (5.96 g, 23.9 mmol) in anhydrous dimethylformamide (25 ml) at room temperature. The reaction mixture was stirred for 20 minutes then benzyl bromide (4.5 g, 26.3 mmol) was added rapidly (mildly exothermic). The mixture 10 was stirred for 30 minutes then partitioned between 100 ml of water and 100 ml of ether. The organic layer was separated, washed with three-100 mL
portions of water, 50 mL of brine, dried (magnesium sulfate) and concentrated .in vacuo to give an oil.
15 The crude material was purified by flash chromatography (Merck silica gel, 24 x 5.0 cm, 1:10 ethyl acetate/hexane then 1:4 ethyl acetate/hexane) to afford 6.13 g of title product as a colorless oil.
20 c) (R)-cc-f!(Phen~rlmethoxv)carbonvllaminolcvclo-p~g~ney~ropanoic acid ~h~nylmethvl ester Palladium(II)acetate (65 mg, 0.29 mmol) was added to a solution of the product from part (b) (5.78 g, 17.1 mmol) in anhydrous ether (60 ml) and 25 stirred for 10 minutes. The resulting mixture was cooled to 0°C was excess ethereal diazomethane (prepared from 12 g N-methyl-N'-nitro-N-nitroso-guanidinei120 ml ether) was added in portions over about 15 minutes. The reaction mixture was stirred 30 for 15 minutes then quenched by addition of 1 mL of glacial acetic acid. The solution was transferred to a separatory funnel, washed with 100 mL of saturated aqueous sodium bicarbonate solution, 50 mL of brine, dried (magnesium sulfate) and concentrated in vacuo i < ~ : 1 n ~l F." _.~ ! .i. t.~ ! C.~
~A629a to give a yellow oil. The crude material was purified by flash chromatography (Merck silica gel, 20 x 5.0 cm, 1:4 ethyl acetate/hexane) to afford 5.74 g of title product as a colorless oil.

d) (R)-(a-Amino)cvclo~ropanepropanoic acid Palladium on carbon catalyst (10a, 1.14 g) was added to a solution of the product from part (c) (5.71 g, 16.2 mmol) in methanol (75 ml) and stirred 10 under an atmosphere of hydrogen (balloon) at room temperature for 48 hours. The reaction mixture was filtered to remove the catalyst and the catalyst was rinsed with warm water. The filtrate was then passed through a 0.4 ~1M polycarbonate membrane filter. The 15 filtrate was concentrated in vacuo to give 2.03 g of title product as a white solid.
e) (S)-a,-(Acetvlthio)cyclopropanepropanoic acid A mixture of the product from part (d) (2.00 20 g, 15.5 mmol) in 2.5 N aqueous sulfuric acid (30 ml) was stirred at room temperature until homogeneous and then cooled to -5°C. Potassium bromide (6.50 g, 54.6 mmol) was added to this solution in one portion. The mixture was stirred until homgeneous. Sodium nitrite 25 (1.60 g, 23.2 mmol) was then added in small portions over about 25 minutes, maintaining the reaction temperature below 0°C. The reaction mixture was stirred for an additional 1 hour at 0°C then at room temperature for 1.5 hours. The resulting mixture was 30 diluted with 30 ml of water and extracted with three-30 mL portions of ether. The combined ether extracts were washed with 25 mL of brine, dried (magnesium sulfate) and concentrated in vacuo to give ;-y ~ :~ ~ ~.P .,t ...
+,~ ;. ': _e ~_~ : ;_ HA629a 2.82 g of crude (R)-(a-bromo)cyclopropanepropanoic acid as a pale yellow oil.
A solution of this crude (R)-(a-bromo)cyclo-propanepropanoic acid was added in acetonitrile (10 5 ml) over 5 minutes to a stirred slurry of potassium thioacetate (1.83 g, 16.1 mmol) in acetonitrile (20 ml) while cooling in an ice-bath. The reaction mixture was stirred at 0°C for 1 hour then at room temperature for 16 hours. The reaction mixture was 10 filtered and the filtrate concentrated in vacuo to give an oil. The oil was partitioned between 50 mL
of ether and 50 mL of 5% aqueous sodium thiosulfate solution. The organic layer was separated, washed with 25 mL of brine, dried (magnesium sulfate) and 15 concentrated in vacuo to give a yellow oi'~. The crude material was purified by flash chromatography (Merck silica gel, 12 x 5.0 cm, 1:19 methanol/methylene chloride) to afford 1.52 g of title product as a yellow oil.

f~ f4S-f4a(R*),7a,9a~311-Octahvdro-4-ff2-(acetvl-thio)-3-cvcloprogyl-1-oxoprogyllaminol-5-oxo-gyrrolof2,1-b1f1,31thiazepine-7-carboxylic acid.
methyl ester 25 Benzotriazol-1-yloxytris(dimethylamino)-phosphonium hexafluorophosphate (292 mg, 0.66 mmol) was added in one portion to a mixture of (4S-(4a,7a,9a(3)]-octahydro-4-amino-5-oxo-pyrrolo[2,1-b](1,3]thiazepine-7-carboxylic acid, 30 methyl ester, p-toluenesu'~fonic acid salt [250 mg, 0.60 mmol, prepared from the material described in Example 5(d)] in methylene chloride (3 ml, distilled from calcium hydride), triethylamine (121 mg, 1.20 mmol), and the product from part (e) (122 mg, 0.65 G'p .~ ~ .:. a ~ ~" '_~1 HA629a mmol) in methylene chloride (3 ml, distilled from calcium hydride). The reaction mixture was stirred for 0°C for 1 hour then at room temperature for 1.5 hours. The resulting mixture was partitioned between 5 20 ml of ethyl acetate and 20 ml of 1M aqueous potassium bisulfate solution. The organic layer was separated, washed with 20 ml of 5o aqueous sodium bicarbonate solution, 20 ml of brine, dried (magnesium sulfate) and concentrated in vacuo to give 10 an oil. The crude material was purified by flash chromatography (Merck silica gel, 12 x 3.U cm, 1:1 ethyl acetate/hexane) to afford 191 mg of title product as a solid white foam.
15 a) f4S-f4a(R*),7a,9a(311-octahvdro-4-f(3-cvclopropvl-2-merca~to-1-oxoRrogyl)aminol-5-oxopyrrolof2.1-bl-f1,31thiazeg~ine-7-carboxylic acid A solution of the product from part (f) (285 mg, 0.45 mmol) in methanol (3 ml) was sparged with 20 argon for 10 minutes at 0°C and then 1M aqueous sodium hydroxide solution (3 ml, freshly sparged with argon for 10 minutes) was added. The reaction mixture was stirred for 2.5 hours at room temperature with continuous argon sparge then acidified by 25 addition of 20 ml of 1M potassium bisulfate solution and extracted with 20 ml of ethyl acetate. The organic extract was washed with 20 ml of brine, dried (sodium sulfate) and concentrated in vacuo to give a gum. The gum was rinsed with anhydrous ether then 30 concentrated under oil pump vacuum to afford 121 mg of the title product as a white foam; (a]D = -103° (c - 0.23, methanol). TLC (1:10:90 acetic acidimethanol/methylene chloride) Rf = 0.46.

i : _A. . , ~ J E vi HA629a HPLC: tR (YMC S-3 ODS 6.0 x 150 mm; 1.5 mL/min, linear gradient 0-100oB over 30 minutes, Buffer A =
methanol/water/phosphoric acid (10:90:0.2), Buffer B
- methanol/water/phosphoric acid (90:10:0.2)) - 20.7 5 minutes greater than 97% of total peak area at 254 nm.
Anal. calc'd for C15H22N204S2 ~ 0.20 H20:
C, 49.77; H, 6.23; N, 7.74; S, 17.71 Found C, 50.01; H, 6.27; N, 7.50; S, 17.40.

Example 19 f4S-(4a,7a,9af3)1-Octahydro-4-ff(1-mercaptocyclo-8entyl)carbonyllaminol-5-oxooyrrolof2.1-b1f1.31-thiazepine-7-carboxylic acid a) 1-Mercagtocyclogentanecarboxylic acid A solution of lithium diisopropylamide was prepared under nitrogen from diisopropylamine (5.4 ml, 38.5 mmol) and n-butyllithium (2.5 M in hexanes, 20 15.4 ml, 38.5 mmol) in tetrahydrofuran (17.6 ml), maintaining the temperature between -3°C r_o 0°.
After stirring for 15 minutes, cyclopentanecarboxylic acid (2.0 g, 17.5 mmol) was added in tetrahydrofuran (2 ml) at 0°C to 3°C over 25 minutes. After 15 25 minutes at 0°C, the bath was removed and t:he reaction was stirred 15 minutes more, causing the temperature to rise to 15°C. The milky white solution was cooled to -78°C and sulfur (Sg, 618.0 mg, 19.3 mmol) was added as a solid, maintaining the temperature at 30 -78°C. The reaction was allowed to warm to room temperature in situ. After 70 hours, the reaction was cooled to 0°C, quenched with water (pH 8-9) and quickly acidified to pH 1 with 6I~ hydrochloric acid.
The aqueous solution was extracted with ethyl acetate i ~6 .f .~! ; ~1 ~'1 v w .w w1 L c.t : U

HA629a (3 x 30 ml), washed with brine, dried (magnesium sulfate), filtered and concentrated to give 2.62 g of title product as a yellow oil.
5 b) 1-(Acetylthi~~cloBentanecarboxylic acid To a solution of the product from part (a) (1.44 g, 9.89 mmol) in a nitrogen sparged solution of 11~I sodium hydroxide ( 20 ml , 19 . 7 mmol ) at 0°C was added acetic anhydride (0.93 ml, 9.89 mmol.).
10 Tetrahydrofuran (13 ml) was added in order' to solubilize the oil which formed. After stirring one hour at 0°C (pH 7), the reaction was warmed to room temperature and additional acetic anhydride (0.47 ml, 4.9 mmol) was added, as well as solid potassium 15 carbonate (2.04 g, 14.8 mmol) to pH 10 and tetra-hydrofuran (4 ml). After stirring overnight at room temperature, the reaction mixture was acidified to pH
1 with 1I~ hydrochloric acid and extracted with ethyl acetate. The ethyl acetate extracts were combined, 20 washed with brine, dried (magnesium sulfate) filtered and concentrated in vacuo to give a yellow solid (1.61 g). The solid was recrystallized twice from ethyl acetate/hexanes to give 614 mg of title product as a light brown solid; m.p. 119.5 - 121.5°C.

c) f4S-(4a.7a.9a(~ 1-Octahydro-4-ffl-f(ace~ylthio)-~yclopentyllcarbonyllaminol-5-oxopvrrolof2,1-b1f1.31-thiazenine-7-carboxylic acid, methyl ester To a solution of the product from part (b) 30 (94.5, 0.502 mmol) in methylene chloride (3.6 ml) at 0°C under nitrogen, was added triethylamir~e (70 X11, 0.502 mmol) followed by [9S-(4a,7a,9a(3)]-4-amino-octahydro-5-oxopyrrolo[2,1-b][1,3]thiazepine-7-i~ ~ a; '.~ J ~ ~.2 HA629a carboxylic acid, methyl ester, p-toluenesulfonic acid salt (prepared from the material described in Example 5(d), 198.9 mg, 0.478 mmol] in one portion, followed by triethylamine (66.6 ail, 0.478 mmol). The reaction 5 was stirred for 5 minutes at 0°C. Benzotriazol-1-yloxytris(dimethylamino)phosphonium hexafluoro-phosphate (222.0 mg, 0.502 mmol) was then added as a solid. The reaction was stirred at 0°C for one hour and then at room temperature for 2.25 hours. The 10 reaction was concentrated in vacuo and the residue partitioned between ethyl acetate and 5o potassium bisulfate (20 ml). The organic layer was washed with half saturated sodium bicarbonate and brine, dried (magnesium sulfate), filtered and concentrated to a 15 clear oil. Purification by flash chromatography eluting with 11:9 ethyl acetate/hexane gave 169.3 mg.
of title product as a clear oil.
d) f4S-(4a 7a 9a~3)1-Octahvdro-4-f (1-mercaptocvclo-20 p~nr,~rl ) carbonyl l aminol -S-oxogyrrolo f 2 1-bl f 1 31 -th~aze~ine-7-carboxylic acid A solution of the product from part (c) (167.3 mg., 0.404 mmol) in methanol (4 ml, deoxygenated via nitrogen bubbling) was cooled to 0°C and treated with 25 1~ sodium hydroxide (4 ml, deoxygenated via nitrogen bubbling). After stirring for 1.5 hours at 0°C while purging continuously with nitrogen, the reaction was warmed to room temperature. After a tot al of three hours, the reaction was acidified to pH 1 with 50 30 potassium bisulfate and extracted with ethyl acetate.
The organic layers were combined, washed with water (20 ml), brine, dried (sodium sulfate), filtered, concentrated in vacuo and re-evaporated from hexanes to give a white solid. The compound was dissolved in ~'p t : I ~' f~
~'.~ v ,;

HA629a dioxane (anhydrous) and lyophillized to give 110 mg, of title product as a white solid; [a]D = -106.5° (c - 0.68, chloroform). TLC (7:2.9:0.1, ethyl acetate/hexane/acetic acid)Rf = 0.12.
5 HPLC: tR = 21.5 min; YMC S-3 ODS (C-18) 6.0 x 150 mm;
Oo to 1000 B: A, 30 minutes linear gradient and 10 minutes hold, 1.5 ml/min.; A = 90o water/ 100 methanol + 0.2o phosphoric acid, B = 90o methanol/
10o water + 0.2o phosphoric acid; 220 nm.
10 Anal. calc'd for C15H22N204S2~0.15 C4H802~0.7 H20 ~,0.08C6H14:
C, 49.37; H, 6.63; N, 7.16; S, 16.39 Found: C, 49.03; H, 6.37; N, 7.21; S, 16.65.
15 Example 20 f4S-(4a,7a,10a~3)1-4-f(2-Carboxy-1-oxo-3-phenvl-progvl)aminoloctahydro-5-oxo-7H-pyridof2,1-b1f1,31-~hiazepine-7-carboxylic acid 20 a) 3-(Phenylmethyl)bropanedioic acid, monoethyl ester 3-(Phenylmethyl)propanedioic acid, diethyl ester (2.5 g, 10 mmol) in 10 ml of tetrahydrofuran was stirred overnight with 10 ml of 1N lithium 25 hydroxide. The reaction mixture was acidified with 11 ml of 1N hydrochloric acid and extracted with two 50 ml portions of ethyl acetate. The ethyl acetate extracts were washed with brine, dried (sodium sulfate), and concentrated in vacuo. The concentrate 30 was chromatographed through silica gel (80 g) using a 5o methanol:chloroform solvent system. The appropriate fractions were combined and concentrated to yield 1.23 g of title product.

k'i ~ ~2 ~ '~ ~ ~
, l.; _. i,.n '3 r,~ ; c ~

HA629a b~ f4S-(4a 7a l0a(~ 1-4-ff2-(Ethoxvcarbonvl)-1-oxo- -~~henvlnro8yllaminoloctahydro-5-oxo-7H-wrido-f2 ~-blfl 3lthiazenine-7-carboxylic acid, methyl ester 5 The product from part (a) (0.2228, 1 mmol) and [4S-(4a,7a,10a(i)]-octahydro-4-amino-5-oxo-7H-pyrido-[2,1-b][1,3]thiazepine-7-carboxylic acid, methyl ester [0.258 g., 1 mmol, prepared as described in Example 3(c)] were dissolved in methylene chloride (5 10 ml) and cooled to 0°C. Triethylamine (0.14 ml, 1 mmol) was added and the reaction mixture was stirred for one hour. Benzotriazol-1-yloxytris(dimethyl-amino)phosphonium hexafluorophosphate (0.442 g, 1 mmol) was added and the solution was stirred at 0°C
15 for 1 hour and at room temperature for 2.5 hours.
The reaction mixture was diluted with 50 ml of methylene chloride and washed with water, 10% sodium bisulfate, saturated aqueous sodium bicarbonate, dried (sodium sulfate), filtered and concentrated in 20 vacuo. The residue was chromatogaphed through silica gel using 30~ ethyl acetate in hexanes. The appropriate fractions were combined and concentrated in vacuo to yield 0.22 g of title product.
25 ~-~ f 4S- (4a 7a 10a i~"~ 1 -4- f (2-Carbox~-1-oxo-3-nhenvl-gr2gvl)aminoloctahvdro-5-oxo-7Hwridof2 1-blfl 31-thi zepine-7-carboxylic acid The product from part(b) (0.22 g, 0.476 mmol) was stirred with 1N lithium hydroxide (5 ml) in 30 tetrahydrofuran (5 ml) at room temperature for 3 hours. The reaction mixture was acidified to pH 2 with 1N hydrochloric acid and concentrated in vacuo.
The residue was dissolved in ethyl acetate and washed with water, brine, dried tsodium sulfate), and f ~ .~ "~ :' ~ r~ "' i ., '->; J ; ; ) HA629a concentrated in vacuo to 3 ml at which point product crystallized. After standing at 0°C overnight, the solid was filtered and dried to yield 0.16 g of title product as a white solid; m.p. 159 - 162°C; [a]D =
5 -84.92° (c = 0.7, methanol). TLC
(chloroform:methanol, 9:1) Rf = 0.23, 0.28.
HPLC: tR = 16.15, 16.35 min.; (UV 254 nm); YMC S-3 ODS (C-18) 6.0 x 150 mm, 3~ end capped column, linear gradient of 50 - 90o aqueous methanol containing 0.20 10 phosphoric acid, 20 min., 1.5 ml/min. (44.90, 55.1 isomer mixture).
Anal. calc'd for C2pH24N2S06~0.1 H20:
C, 56.89; H, 5.78; N, 6.66; S, 7.59 Found: C, 56.98; H, 5.68; N, 6.58; S, 7.15.

Example 21 L4S-I4a(R*) 7a 10a~311-Octahydro-4-I(2-mercaoto-1-Qxo-3-~henylpropyl)aminol-5-oxofl 4loxazinof3 4-bl-I1 3lthiazep~ne-7-carboxylic acid a) O-(2,2-Dimethoxyethyl)-N-fN-f(phenylmethox~,~)-S?2Y11-L-homoservll-L-serine methyl ester A solution of N-[O-[(1,1-dimethylet:hyl)-dimethylsilylJ-N-[(phenylmethoxy)carbonyl]-L-25 homoseryl]-0-(2,2-dimethoxyethyl)-L-serine, methyl ester [5.56 g, 10 mmol, prepared as described in Example 10(h)] in methanol (65 ml) was cooled to 0°C
(ice salt bath), treated with p-toluenesulfonic acid monohydrate (386 mg, 2.0 mmol) and stirred at 0°C for 30 1.5 hours. The reaction was quenched with sodium bicarbonate solution (198 mg. in 20 ml water), stirred for 5 minutes then evaporated to remove the methanol. The aqueous phase was extracted with ethyl acetate (2 x 200 ml) and the combined organic extract 4~ ~g :y a, c1 l _: . ~. F.r x. n HA629a was washed with water (110 ml), 5o sodium bicarbonate (80 ml) and brine (80 ml), dried (anhydrous sodium sulfate), filtered, evaporated to dryness and dried in vacuo. The crude product was chromatographed on 5 silica gel column (Merck), eluting the column with ethyl acetate: hexane (2:1) and ethyl acetate: methanol (98:2) to give 3.975 g of title product as a syrup.
TLC (ethyl acetate: hexane, 4:1) Rf = 0.17.
10 b) O-(2,2-Dimeth~loxyethyl)-N-f0-(methylsulfon~l)-N-f~ghenylmethoxylcarbonyil-L-homoseryll-L-serine.
methyl ester A solution of the product from part (a) (3.975 g, 8.98 mmol) in dry methylene chloride (52 ml) was 15 cooled to -15°C, treated with triethylamine (1.82 ml, 13.1 mmoles) and methanesulfonyl chloride (0.82 ml, 10.6 mmoles) and stirred at -15°C for 30 minutes.
The reaction mixture was quenched with 25o ammonium chloride (19 m1), warmed to room temperature and 20 diluted with ethyl acetate (750 ml). The organic phase was washed with 5o potassium bisulfate (100 ml), 50o saturated brine (100 ml) and saturated brine (100 ml), dried (anhydrous sodium sulfate), filtered, evaporated to dryness and dried in vacuo to give 4.9 25 g of title product as a waxy solid. TLC (ethyl acetate: hexane, 4:1) Rf = 0.32.
c) N-fS-Acetyl-N-f(phenylmethoxy)carbonyll-L-homocvsteinyll-O-(2,2-dimethoxyethyl)-L-serine.
30 methyl ester Cesium carbonate (5.56 g, 17.04 mmoles) was added to a solution of thiolacetic acid (2.6 ml) in dry methanol (40 ml), stirred for 10 minutes then evaporated to dryness. The resulting solid was :1 .! s, F ry r~~ _.
G: ..~ .;a v J ~

HA629a triturated with acetone (7 x 8 ml) and the off-white solids obtained were dried in vacuo to give 4.39 g cesium thiolacetic acid.
A suspension of cesium thiolacetic acid 5 (2.438, 1.3 eq.) in dry dimethylformamide (8.0 ml) was treated with a solution of the product from part (b) (4.9 g, 8.98 mmol) in dry dimethylformamide (24 ml) and stirred for 16 hours at room temperature under argon. The mixture was diluted with ethyl 10 acetate (1.0 L), washed successively with 5o sodium bicarbonate (2 x 150 ml), water (2 x 150 ml) and brine (150 ml), dried (anhydrous sodium sulfate), filtered, evaporated to dryness and dried in vacuo.
The crude product was chromatographed on a silica gel 15 column (Merck), eluting the column with ethyl acetate:hexane mixtures (1:1; 2:1) to give 3.93 g of the title product as a wah~y solid. TLC (ethyl acetate: hexane, 4:1) Rf = 0.63.
20 d) O- ( 2 . 2-Dimethoxyethyl ) -N- f N- f ~ghenylmethoxy ) -carbonyll-L-homocysteinyll-L-serine, methyl ester A solution of the product from part (c) (200 mg, 0.49 mmol) in methanol (8.0 ml) was purged with argon for 30 minutes, cooled to 0°C (ice-salt bath) 25 and treated with 25o sodium methoxide in methanol (0.11 ml, 0.5 mmol), maintaining the bubbling of argon throughout the addition and length of the reaction. After 5 minute- at 0°C, the mixture was quenched with 25o ammonium chloride (2.3 ml) and 30 partitioned between ethyl acetate (2 x 12 ml) and water (2.3 ml). The combined organic extracts were washed with 25o ammonium chloride (4.6 ml) and brine (4.6 ml), dried (anhydrous sodium sulfate), filtered, evaporated to dryness and dried in vacuo to give "~l ~ ~ 1 f~ fit a .' ~ ' 1 .. F., C.~ : cr HA629a 183.2 mg of title product as a white solid. TLC
(ethyl acetate: hexane, 4:1)Rf = 0.62.
e) f4S-(4a,7a,l0a(3)1-Octahvdro-5-oxo-4-ff(phenvl-5 r~rhoxv)carbonyllaminolfl 4loxazinof3 4-blfl 31-thiazegine-7-carboxylic acid A solution of the product from part. (d) (50 mg, 0.11 mmol) in dry methylene chloride (2.0 ml) was treated with Amberlyst~ 15 (H+ form; 13 mg), stirred 10 for 3 days at room temperature under argon, treated with more Amberlyst~ 15 (13 mg) and stirred for another 3 days. The solution was decanted and chromatographed on silica gel column (Merck), eluting the column with ethyl acetate: hexane mixtures (1:3;
15 1:1) to give 21.1 mg of title product as a syrup.
TLC (ethyl acetate: hexane, 4:1) Rf = 0.70.
f) f4S-(4a,7a,10a~3)1-Octahydro-4-amino-5-oxof1,41-oxazinof3 4-blfl 3lthiaze~ine-7-carboxylic acid 20 methyl ester A solution of the product from part (e) (421 mg, 1.01 mmoles) in dry methylene chloride (25 ml) was treated with trimethylsilyl iodide (0.72 ml, 5.06 mmoles) and stirred at roam temperature under argon 25 for 1.75 hours. The mixture was evaporated to dryness and the syrup obtained was partitioned between ethyl ether (50 ml) and 0.2 I~ hydrochloric acid (2 x 25 ml). The aaueous phase was brought to pH 10 with saturated sodium bicarbonate (25 ml), 30 treated with solid sodium chloride (2.0 g) and extracted with methyiene chloride (3 x 75 ml) to give 219 mg of title product as a syrup. A second treatment of the aqueous phase with sodium chloride (2.0 g) and reextraction with methylene chloride (2 x '..
~f l.~
~"~ ...... J.1 f Cl HA629a 100 ml) gave an additional 37 mg of title product.
TLC (methylene chloride: methanol, 9:1) Rf = 0.23.
g) f4S-f4a(R*)7a l0a(311-Octahvdro-4-ff2-(acetvl-5 rhio)-1-oxo-3-y?hen~lnroHyllaminol-5-oxof1,41oxazino-f'~_4-blfl 3lthiaz~gine-7-carboxylic acid, methyl ester (S)-2-(Acetylthio)benzenepropanoic acid, dicyclohexylamine salt (516 mg, 1.32 mmol, 1.2 eq.) 10 was suspended in ethyl acetate (42 ml), washed with 5o potassium bisulfate (5 x 6.0 ml) and brine (6.0 ml), dried (anhydrous magnesium sulfate), filtered, evaporated to dryness and dried in vacuo.
The free acid was dissolved in dry methylene 15 chloride (9.5 ml), cooled to 0°C (ice-salt bath) and treated sequentially with a solution of the product from part (f) (285.5 mg, 1.09 mmol) in dry methylene chloride (4.2 ml), triethylamine (0.14 ml, 1.15 mmol) and benzotriazol-1-yloxytris(dimethylamino)phos-20 phonium hexafluorophosphate (484 mg, 1.09 mmol). The reaction mixture was stirred at room temperature for 1.0 hour and at room temperature for 2.0 hours under argon, then stripped to dryness. The residual syrup was dissolved in ethyl acetate (40 ml), washed with 25 0.5 ~ hydrochloric acid (2 x 6.6 ml), water (6.6 ml) and brine (6.6 ml), dried (anhydrous sodium sulfate), filtered, evaporated to dryness and dried in vacuo.
The crude product was chromatographed on silica gel column (Merck), eluting with ethyl acetate: hexane 30 mixtures (1:2; 1:l) to give 382.9 mg of title product as a syrup. TLC (ethyl acetate:hexane, 1:1) Rf =
0.28.

W a :1 . ~ 'F? y'y "' 6" .I~ ,'~ t, e.~

HA629a h) t4S-f4a(R*),7a,10afill-Octahvdro-4-f(2-mercanto-1-oxo-3-pheny~pr~wll,aminol -5-oxo f 1 , e~oxazino f 3 . 4-bl -f1.31thiazepine-7-carboxylic acid A solution of the product from part(g) (382.9 5 mg, 0.82 mmoI) in methanol (9.0 ml) was purged with argon for 30 minutes, cooled to 0°C (ice-salt bath) then treated with 1.0 ~ sodium hydroxide (3.32 ml, 4.0 eq; previously purged with argon for 30 minutes), maintaining the bubbling of argon throughout the 10 addition and length of the reaction. The reaction mixture was stirred at 0°C for 5.0 hours and at room temperature for 1.0 hour, brought to pH 2.0 with 50 potassium bisulfate (14.5 ml), warmed to room temperature and extracted with ethyl acetate (2 x 50 15 ml). The combined organic extracts were washed with brine (10 ml), dried (anhydrous sodium sulfate).
filtered, evaporated to dryness and dried in vacuo.
The syrup obtained was evaporated twice from hexane (25 ml) and the solid foam obtained was 20 chromatographed on a silica gel column (Merck), eluting the column with toluene: acetic acid mixtures (100:1; 50:1; 20:1) to give 212 mg of title product as a solid; m.p. 224 - 226°C; [a]D = -50.2° (c =
0.45, methanol). TLC (toluene:acetic acid, 5:1) Rf =
25 0.28.
HPLC: tR = 5.37 min. (W 220 nm) (98.90 ; YMS S-3 ODS
(C-18) 6 x 150 mm; 600 (10o water-90a methanol -0.2~
phosphoric acid) / 400 (90% water-loo methanol -0.2$
phosphoric acid), isocratic.
30 Anal. calc'd for C1gH22N2o5S2 ~ 0.19 H20:
C, 52.34; H, 5.44; N, 6.78; S, 15.53 Found: C, 52.58; H, 5.57; N, 6.44; S, 15.16.

HA629a Example 22 f4S-f4a(R*) 7a 10a(311-Octahydro-4-fl2-merca~to-1-nxn- -phenylbroBvl)aminol-5-oxo-7H ~vridof2.1-bl-f~ 'ilth~azep~ne-7-carboxylic acid 5 The product of Examples 3 and 11 was also prepared as follows:
a) f4S-(4a 7a l0a~i» -Octahydro-4-amino-5-oxo-7H-gyr~dof2 1-b1f1.31thiaze~ine-7-carboxylic acid.
10 merhyl ester, p-toluenesulfonic acid salt [4S-(4a,7a,10a(3)]-Octahydro-4-amino-5-oxo-7H-pyrido[2,1-b][1,3]thiazepine-7-carboxylic acid, methyl ester (6.11 g) was dissolved in ethyl acetate (about 100 m1) and treated with a solutior_ of 15 p-toluenesulfonic acid monohydrate (4.52 g) in methanol (3 ml) and ethyl acetate (20 ml). A
precipitate formed immediately. The mixture was diluted with additional ethyl acetate and the solid was collected by filtration. The solid was washed 20 with ethyl ether and dried in vacuo to give 7.908 g of the title product as a pale yellow solid in 980 purity; m.p. 179 - 181°C (decomp.).
b) f4S-f4a(R*) 7a l0a(311-Octahydro-4-ff2-(acetyl-25 thio)-1-oxo-3-phenvlpro~yllaminol-5-oxo-7H-gyrido-f2 1-blfl 3lthiazepine-7-carboxylic acid methyl ester A slurry of the product from part (a) (636 mg, 1.48 mmol) in methylene chloride (5 ml) and dimethyl-30 formamide (1 ml) was treated with N-methylmorpholine (163 [t1, 150 mg, 1.48 mmol) followed by I-hydroxy-7-azabenzotriazole (208 mg, 1.52 mmol).
The bright yellow solution was then treated with (S)-2-(acetylthio)benzenepropanoic acid (333 mg, 1.48 , y ,c r~ ' s'1 M~ ...
a v _. ._ : t, a '. ; f HA629a mmol) in methylene chloride (5 ml) and cooled in an ice-bath. Ethyl-3-(dimethylamino)propyl carbodiimide, hydrochloride salt (2.88 mg, 1.50 mmol) was added and the mixture was stirred at 0°C for 1 5 hour and at room temperature for 1.5 hours. The solvent was removed by rotary evaporation and the residue was partitioned between ethyl acetate and 0.5 N hydrochloric acid. The ethyl acetate extract was washed successively with water (twice), SCIo saturated 10 sodium bicarbonate, and brine, then dried (sodium sulfate), filtered, and stripped to give 651.2 mg of title product as a white foam.
~) f4S-f4a(R*) 7a 10a(x.11-Octahydro-4-f(2-mercabto 15 1-oxo-3-ghenyloroy~yl)aminol-5-oxo-7H-pyridof2.1-bl f~ 3lthiazegine-7-carbox~ic acid A solution of the methyl ester product from part (b) in deoxygenated methanol was treated with 1N
sodium hydroxide according to the procedure of 20 Example 3(d) to afford the title product.
Example 23 f4S-f4alR*) 7a l0a~i11-Octahy~ro-4-f(2-mercapto-1-oxo-~-phen~lprogyl)aminol-5-oxo-7H=pyridof2 1--blfl 31-25 ,~hiazex~ine-7-carboxylic acid The product of Examples 3, 11 and 22 was also prepared as follows:
a) N-f(Phenylmethoxv)carbonyll-L-methionine 30 In a 2L flask equipped with a mechanical stirrer and internal thermometer, sodium ;hydroxide (61.65 g, 1.541 mol) was dissolved in distilled water (1000 ml). To this solution, L-methionine (100.0 g, 0.670 mol) was added at room temperature. The ;1 A r? r~ ..
~. .j r., ':t J i :t HA629a solution was cooled in an ice bath (internal temperature 3°C) and benzyl chloroformate (110 ml, 0.737 mol) was added over 10 minutes. After a 15 minute induction period, the internal temperature 5 rose from 3°C to 12°C over 30 minutes and then dropped to 0°C over 15 minutes. The reaction was stirred at 0°C for 2 hours, during which time the initially cloudy reaction mixture became homogeneous.
The ice bath was removed, and the reaction was 10 allowed to warm to room temperature over 1 hour. The reaction mixture was transferred into a separatory funnel and washed with hexane (2 x 300 ml). The aqueous layer was acidified with 6N hydrochloric acid to pH 5 and diluted with ethyl acetate (600 ml). The 15 mixture was further acidified to pH 2. The organic layer was separated, and the aqueous layer was extracted with ethyl acetate (3 x 600 ml). The organic extracts were combined and washed with brine (750 ml), dried (magnesium sulfate), filtered and 20 concentrated in vacuo to produce a light yellow oil.
The crude product (oil) was dissolved in toluene (1500 ml), and the solution was concentrated to half of its volume. A second portion of toluene (750 ml) was added, and concentrated again such that 630 ml of 25 toluene remained. This solution was stored at 5°C
overnight, during which time some of the product crystallized from solution. The solid was redissolved by warming to room temperature. Toluene (134 ml) was then added (a few seed crystals 30 remained). with mechanical stirring, heptane (500 ml) was added in 30 ml portions at 10 minute intervals (approximately 3 hours total addition time). At this point, the product started to crystallize from solution. An additional portion of 4 't .~ : ! ? f'~, r~
r i :S
~~. r. ~ I I~~.A ~~ 1 u.

HA629a heptane (1020 ml) was added over 1.5 hours, and the resulting slurry was stirred for 2 hours. The product was collected by vacuum filtration, washed with 1:2 toluene:heptane (3 x 150 ml) and heptane (3 5 x 500 ml) and air-dried to give 158.6 g of title product as a white solid; m.p. 66°C; [oc]D = -1.5° (c - 1, 95~ ethanol). TLC (ethanol:water, 3:1) Rf =
0.78.
Anal, calc'd for C13H17N04S:
10 C, 55.11; H, 6.05; N, 4.94 Found: C, 54.96; H, 6.20; N, 4.83.
b) N-f(Phenylmethoxy)carbonyll-L-methionine. methyl ester 15 In a 3 L flask equipped with a mechanical stirrer and an argon inlet, the product from part (a) (100.0 g, 0.353 mol) was dissolved in methanol (2L), and p-toluenesulfonic acid monohydrate (6.71 g, 0.035 mol) was added. The reaction mixture was stirred 20 under argon for 21 hours. Triethylamine (4.9 ml, 0.035 mol) was added, and the reaction mixture was stirred for an additional 15 minutes. The reaction mixture was concentrated in vacuo to a pa-~e yellow oil. The oil was dissolved in ethyl acetate (900 25 ml), and the solution was washed with 1N hydrochloric acid (740 ml), saturated sodium bicarbonate (2 x 740 ml) and brine (740 ml). The organic layer was dried (magnesium sulfate), filtered and concentrated in vacuo to a light yellow oil. The oil was 30 concentrated from hexane i2 x 100 ml) to obtain 98.22 g of title product as a white solid.
c> N-f(PhenYlmethoxy)carbonyll-L-methionine.
sulfoxide. methyl ester G'x -i .~t 9 '~'~ Y'j ."
' - ~ :e ;:, .' ,... _t c.) H.~629a In a 3L flask equipped with mechanical stirrer, the product from part (b) (97.95 g, 0.329 mol) was dissolved in methanol (1675 ml) and distilled water (215 ml). The solution was cooled in 5 an ice bath, and sodium bicarbonate (28.5 g, 0.339 mol) was added. N-Chlorosuccinimide (44.0 g, 0.329 mol) was added in small portions over 25 minutes so that the internal temperature did not exceed 7°C.
The mixture was stirred in an ice bath for 1 hour and 10 then was allowed to warm to room temperature over 1 hour. The mixture was concentrated in vacuo by about 75o to remove the methanol, diluted with ethyl acetate (1000 ml) and washed with brine (500 ml).
The brine layer was back-extracted with ethyl acetate 15 (2 x 200 ml). The organic extracts were combined, dried (magnesium sulfate), filtered, and concentrated in vacuo to a clear, viscous oil. The oil was concentrated from toluene (3 x 100 ml) and residual solvents were removed under high vacuum to produce 20 crude title product as a clear oil, which solidified to a white solid (131.4 g). The crude product contained 12 weight percent succinimide and 9 weight percent toluene by NMR. The product was a mixture of sulfoxide diastereomers.

d~ S-f(ACetyloxy)methvll-N-f~henylmethoxy)-carbonyll-L-homocysteine, methyl ester To a 1 liter flask containing the product from part (c) (102.8 g corrected weight, 0.328 mol) was 30 added toluene (480 ml), sodium acetate (32.3 g, 0.394 mol) and acetic anhydride (186 ml, 1.970 mol). The resulting mixture was refluxed (118°C) under argon for 18 hours. The dark brown reaction mixture was allowed to cool to room temperature. After an hour sy a ; v ' sy r~ y-4. f ~ . l, t.e HA629a at room temperature the reaction mixture became very thick with solids. The solids were dissolved with ethyl acetate (100 ml), and the mixture was partially concentrated in vacuo to a viscous brown residue.
5 The residue was concentrated from toluene (240 ml) to remove acetic anhydride, diluted with ethyl acetate (1000 ml), and carefully washed with saturated sodium bicarbonate (4 x 680 ml). The organic layer was washed with brine (450 ml), dried (magnesium 10 sulfate), filtered and concentrated in vacuo.
Residual solvents were removed under high vacuum to produce a light brown solid. The crude product was dissolved in n-butyl acetate (450 ml) with warming (35°C) and stirring. After cooling to room 15 temperature, hexane (200 ml) was added slowly to the solution with stirring over 15 minutes. At this point the product crystallized from the solution. An additional portion of hexane (700 ml) was added over 30 minutes, and the resulting slurry was stirred for 20 3 hours. The product was collected by filtration and washed with 1:2 n-butyl acetate:hexane (200 ml), 1:4 n-butyl acetate:hexane (2 x 240 ml), and hexane (2 x 250 ml). The product was air-dried, then dried under high vacuum to give 87.7 g of title product as a pale 25 brown solid; m.p. 73°C; [a]D = -1.6° (c = 1, 950 ethanol). TLC (5o methanol/methylene chloride) Rf =
0.80.
Anal. calc'd for C16H21N~6S:
C, 54.07; H, 5.95; N, 3.94 30 Found: C, 53.48; H, 5.74; N, 3.82.
e) S-Acetyl-N-f(phenylmethoxy)carbonyll-L-homo-~ysteme e ~1 r.S . ~ ::, e~
a _t ~..

HA629a In a 1 L flask, a solution of the product from part (d) (83.0 g, 0.233 mol) in tetrahydrofuran (415 ml) was sparged with argon for 30 minutes. In a separate 2L flasked equipped with a mechanical 5 stirrer and an argon inlet, a solution of 86.8 potassium hydroxide (62.7 g, 0.969 mol) in distilled water (280 ml) was sparged with argon for 15 minutes.
The tetrahydrofuran solution was added to the potassium hydroxide solution (internal temperature 10 20°C) rapidly, via cannula, wish vigorous stirring under argon. The flask containing the product from part (d) was rinsed with 20 ml of tetrahydrofuran (sparged with argon for 15 minutes) and the rinse was added to the reaction mixture. After 30 minutes, the 15 reaction was clear and biphasic, and an exotherm to 28°C had occurred.
After an additional 2 hours, the reaction was cooled to 1°C (internal) and sodium borohydride (2.75 g, 0.073 mol) was added in one portion (exotherm to 20 6.8°C). The reaction mixture was stirred for an additional 20 minutes at 0°C and then allowed to warm to 11°C over 30 minutes. The reaction mixture was cooled to 1°C, and acetic anhydride (68.6 ml, 0.727 mol) was added over 10 minutes. An exotherm to 10°C
25 occurred during the addition. The internal temperature dropped back to 4°C before the addition was complete. The cooling bath was removed, and the reaction was stirred at ambient temperature for 45 minutes.
30 The reaction mixture was concentrated in vacuo to approximately half of its volume, acidified to pH
2 with 6N hydrochloric acid (175 ml), and extracted with ethyl acetate (2 x 1.1 L). The combined organic extracts were washed with brine (560 ml). The ~.:c.w~~~~~?

HA629a organic layer was treated with activated carbon and anhydrous magnesium sulfate, filtered, and concentrated in vacuo to a yellow oil. n-Butyl acetate (380 ml) was added, and the solution was 5 concentrated in vacuo (45°C) to half of its volume.
A second portion of n-butyl acetate (190 ml) was added and concentrated again such that 190 ml of n-butyl acetate remained. Heptane (300 ml.) was added slowly with stirring to haziness, and seed crystals 10 were added. After 15 minutes a white solid crystallized from the solution. A second portion of heptane (570 ml) was added slowly over 30 minutes, and the resulting slurry was stirred at room temperature overnight. The product was collected by 15 filtration, washed with 1:3 n-butyl acetate:heptane (2 x 275 ml) and hexane (2 x 275 ml), air-dried, and then dried under high vacuum to produce 50.1 g of title product as a white solid; m.p. 73 - 74°C; [aJD
- -1.3° (c = 1, 95o ethanol). TLC (ethanol: water, 20 3:1) Rf = 0.83.
Anal. calc'd for C14H17N05S:
C, 54.01; H, 5.50; N, 4.50 Found: C, 53.88; H, 5.45; N, 4.44.
The filtrate was concentrated so that 100 ml 25 of butyl acetate remained. This solution was treated with 310 ml of heptane as described above to obtain a second crop of 8.4 g of title product as a white solid for a total yield of 58.5 g.
30 f~ fS-(R* R*)-2-ff4-(Acetylthio)-1-oxo-2--ff(nhenvl-methoxv)carbon~llaminolbutyllaminol-6 6-dimethoxv-hexanoic acid, methyl ester S-Acetyl-N-[(phenylmethoxy)carbony.l]-L-homo-cysteine (0.456 mol) was dissolved in a mixture of r. f'= ~ ....
_w .. h ~.3 i ~_a HA629a methylene chloride (600 ml) and dimethylformamide (90 ml), and hydroxybenzotriazole hydrate (64.72 g, 0.479 mol) was added. The mixture was cooled in an ice-bath and a solution of (S)-2-amino-6,6-dimethoxy 5 hexanoic acid, methyl ester [prepared as described in Example 1(e), 93.7 g, 0.456 mol) dissolved in methylene chloride (600 ml) was added. Finally, ethyl-3-(dimethylamino)propylcarbodiimide, hydrochloride salt (91.83 g, 0.479 mol) was added and 10 the reaction was stirred for one hour at 0°C, then for 2 hours at room temperature. At the end of that time, the reaction mixture was concentrated in vacuo and the residue was partitioned between ethyl acetate (3 L) and saturated aqueous sodium bicarbonate (1 L).
15 The organic extract was washed with water (1 L), 50 potassium bisulfate (1 L), water (1 L), and brine (1 L), then dried (sodium sulfate) and concentrated in vacuo to 238 g of crude product. The crude product was dissolved in ethyl acetate:methylene chloride 20 (1:1, 300 ml) and applied to a 10 x 15 cm pad of Merck silica gel. Elution with 8:2 ethyl acetate:hexane (7L) followed by ethyl acetate (4 L) provided 205.28 g of title product.
25 g) f 4S- (4a 7a 10a13» -Octahydro-4- f f ~phenylmethoxy) -c-arhonyllaminol-5-oxo-7H-p~ridof2 1-blfl 3lthiazey~ine -7-carboxylic acid, methyl ester A solution of the product from part (f) [205.28 g, 0.412 mol, dried by evaporating in 30 methylene chloride/toluene) in methanol (2 LI was cooled to 0°C (ice bath) and purged with argon for 30 minutes. A 25a by weight solution of sodium methoxide in methanol (95.1 ml, 1.01 eq.) was added rapidly with continued argon parging, and the '~ ~l !"1 y ~";

HA629a reaction was stirred for 10 minutes longer, then quenched by the addition of 1L of saturated ammonium chloride solution, diluted with 0.5 L of water, and treated with 3 L of ethyl acetate. The resulting 5 mixture was divided into two portions which were each separately concentrated in vacuo to remove organics (ethyl acetate and methanol). The concentrated residues were recombined and treated with 1 L of ethyl acetate. The organic layer was separated and 10 rinsed with 0.5 L of saturated ammonium chloride.
The combined aqueous solutions were reextracted with 1 L of ethyl acetate. The organic extracts were combined and washed with 1 L of water and two 1 L
portions of brine, dried (sodium sulfate), filtered 15 and concentrated. The residue was further evaporated with methylene chloride and dried in vacuo to give 182.65 g of free sulfhydryl of the product from part (f) .
This free sulfhydryl intermediate (0.400 mol) 20 was dissolved in methylene chloride (4 L) and treated with 30.8 ml (0.400 mol) of trifluoroacetic acid.
The reaction mixture was refluxed for 16 hours, then cooled and concentrated in vacuo. The resulting residue was dissolved in 2 L of ethyl acetate, then 25 washed with 400 ml of 0.1 N hydrochloric acid, 1 L of water, 1 L of saturated sodium bicarbonate, 1 L of water, and 1 L of brine, dried (sodium sulfate), filtered and concentrated. The residue was evaporated with methylene chloride and dried in vacuo 30 to afford 166.24 g of title product.
h~ f4S-(4a 7a, 10a~11-Octahydro-4-amino-5-oxo-7H-g5r~dof2 1-blfl 3lthiazegine-7-carboxylic acid methyl ester ~ ~ ~" f ~ ~ ~-a r. ~ i,~ ~s_ HA629a Iodotrimethylsilane (76.6 ml, 0.538 mol) was added to a solution under argon containing the product from part (g) (162.43 g, 0.414 mol) dissolved in methylene chloride (1.5 L). After stirring for 5 1.5 hours, the reaction mixture was concentrated in vacuo and the residue was partitioned between 1 L of ethyl acetate and 700 ml of 1N hydrochloric acid (evolution of C02 occurs. pH 1.2). The ethyl acetate layer was separated and extracted with 300 ml of 1 N
10 hydrochloric acid. The combined acidic aqueous extracts were washed with a further 1 L of ethyl acetate, then cooled to 0°C and basified with 4 N
sodium hydroxide (about 275 ml) to pH 10Ø The aqueous layer was saturated with solid sodium 15 chloride, then extracted with five 1 L portions of methylene chloride. The combined organic extracts were dried (sodium sulfate), filtered and concentrated in vacuo. The residue was redissolved in 1 L of methylene chloride and rinsed with 0.5 L of 20 brine, dried (sodium sulfate), filtered and concentrated to give 98.8 g of title product.
~ f4S-f4a(R*) 7a. 10a~311-Octahydro-4-ff2-(acetyl-th~o)-1-oxo-3-phenylpropyllaminol-5-oxo-7H-nvrido-25 « 1-blfl 3lthiazegine-7-carboxy~~~ acid methyl ester (S)-2-(ACetylthio)benzenepropanoic acid, dicyclohexylamine salt (173.1 g, 0.427 mol) was partitioned between ethyl acetate (1 L) and l00 30 potassium bisulfate (800 ml). The organic: layer was separated and washed with 5o potassium bisulfate (1 L), 50o brine (1 L) and brine (1 L), dried tsodium sulfate), filtered and concentrated in vacuo. The residue was evaporated several times with methylene 4 ; .C : l .''~ ~;'~ '~
i. hl r ."

HA629a chloride, then dried overnight in vacuo to yield 97.3 g of crude (S)-2-(acetylthio)benzenepropanoic acid.
A solution of this (S)-2-(acetylthio)benzene-propanoic acid (0.427 mol) dissolved in methylene 5 chloride (900 ml) was cooled in an ice-bath and treated with a solution of the product from part (h) (100.28 g, 0.388 mol) in methylene chloride (600 ml), triethylamine (154.1 ml, 0.388 mol), and finally benzotriazol-1-yloxytris(dimethylamino)phosphonium 10 hexafluorophosphate (188.9 g, 0.427 mol) added in one portion. After one hour at 0°C and 2 hours at room temperature, the reaction mixture was concentrated in vacuo and dissolved in 2 L of ethyl acetate. The organic solution was concentrated in vacuo and 15 dissolved in 2 L of ethyl acetate. The organic solution was washed with 0.5 L of brine, ? L of 0.5 N
hydrochloric acid, 1 L of water, 2 L of saturated sodium bicarbonate, 1 L of water, and 1 L of brine, dried (sodium sulfate), filtered and concentrated.
20 At this point, those aqueous rinses which contained product (TLC indication) were reextracted with ethyl acetate. The ethyl acetate extracts were worked up in the usual manner and all combined to give a crude yellow oil product. The yellow oil was applied to a 25 15 x 15 cm silica gel pad prepared in 1:1 ethyl acetate:hexanes and eluted with 7L of 1:1 ethyl acetate:hexanes followed by 4L of 6:4 ethyl acetate:hexanes and finally 2L of 7:3 ethyl acetate:hexanes. The filtrates containing the 30 desired product were concentrated to give 123.57 g of title product.
j) f4S-4a(R*),7a,10a~311-Octahydro-4-f(2-mercapto-1-c-.F- ~.-~ .~. ~ ~~ 'y HA629a Qxo-3-ohenvlnrQpvl)aminol-5-oxo-7H~vri f2 1-bl-f1.31thiazP~pine-7-carboxylic acid Into a 12 1 three-necked flask, fitted with an additional funnel and mechanical stirrer, was placed 5 a solution of the product from part (i) (96.0 g, 0.207 mol) in methanol (1.1 1). The solution was purged with argon for 30 minutes then cooled in an ice-bath until the internal temperature was +7°C. A
total of 1.45 L of 1N sodium hydroxide solution 10 (previously sparged with argon for 30 minutes) was added over 1 hour. The reaction mixture was continuously sparged with argon during the addition.
The reaction temperature rose to +12°C and was maintained during the addition. The reaction mixture 15 was stirred for an additional 30 minutes, then warmed to room temperature with an ambient water bath and stirred with sparging for 2.5 hours. About 250 ml of 6 ~ hydrochloric acid was added dropwise over 15 - 20 minutes to adjust the pH to 2. A gummy precipitate 20 formed during the acidification. After continual stirring for a further 2 hours, the precipitate changed to a fine white solid, with the presence of some larger chunks of solid product. The product was collected on a 600 ml sintered glass funnel. Washing 25 the collected solid with 1L of water followed by 2 L
of anhydrous ether and final drying in vacuo afforded 70.3 g of title product as a fine white solid; m.p.
218 - 220°C (dec.). TLC (1:99 acetic acid/ethyl acetate) Rf = 0.48.
30 HPLC: tR(YMC S-3 ODS 6.0 x 150 mm; 1.5 mLimin., isocratic 60o B, Buffer r. _- methanol/water%phosphoric acid (10:90:0.2), Buffer B =
methanol/water/phosphoric acid (90:10:0.2>) - 9.33 min., 99.30 of total peak area at 220 nm.

c~.K :1;~';1~.~
a'.. ~ ~.',~ vx ,.~ i :.
HA629a Anal. calc~d for C19H24N204S2:
C, 55.86; H, 5.92; N, 6.86; S, 15.70 Found: C, 55.83; H, 5.83; N, 6.96; S, 15.70.

F ,.~W ,.. '~: e~ ~ a HA629a Example 24 J~ S-f4a(R*) 7a l0~ill-Octahydro-4-ff2-(acetylthio)-~-oxo-3-ohenylpropvllaminol-5-oxo-7H-Ryridof2.1-bl-y1 '~lrhiazPZ~ine-7-carboxylic acid methyl ester 5 The coupling reaction described in Examples 3(c), 11(i), 22(b), and 23(i) was also carried out as follows:
A solution of (S)-2-(acetylthio)benzenepro-panoic acid (1.83 g, 8.14 mmol) and 10 [4S-(4a,7a,10a~3)]octahydro-4-amino-5-oxo-7H-pyrido[2,1-b][1,3]thiazepine-7-carboxylic acid, methyl ester (2.11 g, 8.17 mmol) in dry methylene chloride (20 ml) was cooled to 0°C and ethyl-3-(dimethylamino)propyl carbodiimide, hydrochloride 15 salt (1.77 g, 9.32 mmol) was added in a single portion. The reaction mixture was stirred at 0°C for 6 hours and then was concentrated to an oily foam.
The residue was then partitioned between ethyl acetate (100 ml) and 1N hydrochloric acid (50 ml).
20 The organic phase was washed with 1N hydrochloric acid (50 ml), saturated aqueous sodium bicarbonate (2 x 50 ml), and saturated aqueous sodium chloride (50 ml), dried (anhydrous sodium sulfate), filtered and concentrated in vacuo to give 3.43 g of title product 25 as a white foam.
Example 25 1n~-f4a(R*) 7a l0a~i11-Octahydro-4-f(2-mercapto-1-oxo--phenylnrQg~ll~minol-5-oxo-7H-pvridof2 1-blfl 31-30 rh~azepine-7-carboxv~ic acid 1 1-dimethylethylamine salt A 15 ml, 3-necked flask equipped with a reflux condenser was evacuated and refilled with argon three times. [4S-[4a(R*),7a,10a~3]-Octahydro-4-[(2-mercap-ca o2izas~s aooa-os-os - 148 _-~,.629a to-1-oxo-3-phenylpropyl)amino7-5-oxo-Jl~~pyxida-[2,1-b1I1.37thiazepine-7-carboxylic acid (0.20 g) and a 1:1 solution of degassed absolute ethanol and acetonitrile (1.0 ml) were charged into the flask.

As the heterogeneous mixture was stirred., tent-butylamine (53.0 ~t3, 1.03 eq.) was added dropwise. The solution became homogeneous within three minutes after the amine addition was completed.

The solution (internal temperature of 30Cwas diluted slowly by the dropwise additiars cf acetonitrile to a final -volume of 10 ml.
A ter an additional 2 hours of starring, the solids were filtered, washed once wish 100% acetonitrii.e (5 ml), air dried, and placed under high vacuum for 2 hours to remove residual solvents to give 0.2 g of title product as a white crystalline sand.

The above material was combined with material from other runs and recrystal:lized as fallo~as.

ml, 3-necked flask equipped with a ref~~ax condenser, magnetic stirrer bar, and addition funnel was SEC110N8CORRECT!n~~evacuated and refilled w:~th argon thxee times. The SEECERTIFO~,Tr batches of 1.1-dirnethylamine salt product 10.37 g) and ~ORR~CTIOP:
-A91-'CLE =i VQiRCERrIFIC.:~T59$ acetonitrile/ethanol (2.2tml) were added to the flask. The flask and contents were warmed to 29 -32C to dissolve the solids. 'the soluta~an was diluted with acetonitrile t2' ml). The heating bath was removed, and the flask was allowed to cao:1 to room temperature t20C). Af:e:~ one hour ~f additional stirring, the mixture was filtered, and the solids were washed ordce with acetontx-ii~:
t10 ml)"

air-dried, and placed under high vacuum to :~emove residual solvents and give 0.29 g of tit:l.e laroduct as a white crystalline solid; m.p. shrinks at 160C and slowly melts and decomposes as the tempexat~~re is {.,; ,9 : ~ tr. ~ Wt ,''F
r': ~ .., HA629a increased to 190-191°C (at 190 - 191°C, the remaining glossy material melts rapidly).
Example 26 5 j4S-!4a 7a l0a(3)1-Octahydro-4-amino-5-oxo-7H-gyridof2 1-blfl 3lthiazepine-7-carboxylic acid, methyl ester This intermediate of Examples 3(c), 11(h) and 10 23(h) was also prepared as follows:
~) 2-(Acetylamino)-2-f4-(acetyloxy)butyllpropane-dioic acid, diethyl ester A stirred suspension of 95o sodium hydride 15 (60.8 g, 2.532 mol) in anhydrous dimethylformamide (500 ml) under an atmosphere of argon was cooled to 0°C (ice bath). A solution of diethyl acetamido-malonate (500 g, 2.302 mol) in anhydrous dimethyl-formamide (1.2 1) was added over a period of 45 20 minutes while keeping the reaction temperature below 18°C. After the addition was complete, the turbid solution was gradually warmed to room temperature.
After stirring for one hour at room temperature, 4-bromobutyl acetate (471.5 g, 2.417 mol) was added.
25 The mixture was then stirred at 59 - 60°C for 18 hours. The resulting slurry was cooled to room temperature, quenched with absolute ethanol (40 ml) and glacial acetic acid (4 ml), stirred for about 15 minutes, poured into a l00 lithium chloride solution 30 and extracted with ethyl acetate (2 x 3 1). The combined ethyl acetate extracts were washed with 100 lithium chloride (3 x 3 1), dried (anhydrous sodium sulfate), and evaporated in vacuo to give 750 g of title product as an oil.

1 ., c , r a-, r~ ~..
- .~ ; .: :J

HA629a b) 2-(Acetylamino>-6-hvdroxyhexanoic acid The product from part (a) (730 g, 2.2 mol) was weighed into a 5 1. 3-neck flask (equipped with a 5 thermometer, magnetic stirrer and air cooled condenser) and diluted with absolute ethanol (300 ml) followed by the addition of aqueous 6N sodium hydroxide (1.6 1, 9.6 mol). The reaction mixture was heated at 68 - 70°C for 5 hours and a homogenous 10 solution was obtained. The reaction was cooled to room temperature, and 6N hydrochloric acid (1.32 1) was added slowly to pH 1.3. The flask was equipped with a short path still head to distill off the ethanol as the temperature was slowly increased to 87 15 - 90°C and maintained at this temperature for 8.5 hours. Slow carbon dioxide evolution was observed.
The total volume of distillate was 600 ml. The pH of the final solution was 3Ø The reaction mixture was concentrated in vacuo until all of the water 20 evaporated off and then concentrated from toluene (2 x 500 ml). The semi-solid mass was triturated with absolute ethanol (1 1), filtered, and rinsed with additiona2 absolute ethanol (500 ml). The filtrate was concentrated in vacuo to yield 509 g of crude oil 25 (82a purity) which contained ethanol and toluene.
c~ (S)-2-Amino-6-hvdroxyhexanoic acid The crude product from part (b) (443 g, includes same toluene and ethanol, starting material 30 weight estimated to be 394 g) was dissolved in water (3.3 1) and 1 N lithium hydroxide was added until the pH was 7.5 (1.53 1 required). The mixture was heated to 35°C and acylase (grade 1 from porcine kidney, 0.4 g) was added and the reaction mixture was stirred for G'k ,~ :r a ;,~ 7 HA629a 24 hours. At the end of this time period the pH was 7.33. The pH was readjusted to 7.5 with 1N lithium hydroxide (about 2 ml), additianal acylase (0.4 g) was added, and the reaction was stirred for 17 more 5 hours (pH 7.3). The pH of the solution was adjusted to 5.9 with acetic acid. Celite~ (20 g) and charcoal (20 g) were added and the reaction was heated to 92°C
and maintained for 5 minutes. The reaction was filtered through a pad of Celite~ and concentrated in 10 vacuo to a semi-paste (441 g). This was triturated with 900 ml of 1:5:10 water:ethanol:dimethylformamide. Some warming was required to break up the original cake. The reaction mixture was refrigerated overnight, filtered, and 15 washed with 200 ml. of the above solvent mixture to yield 214 g of crude material (about 40% N-acetyl material). This material was suspended in methanol (500 ml), warmed on a steam bath, allowed to stand for 2 hours, and filtered. This procedure was 20 repeated a second time to yield 108 g of title product; [a]D = +22° (c = 1.44, 6 N hydrochloric acid).
Alternatively, steps (b) and (c) were also performed as follows:

b) 2-(Acetylamino)-6-hydrox~hexanoic acid A 5 1, 3-necked flask, equipped with a mechanical stirrer and thermocouple thermometer, was charged with the product from part (a) (631 g, 1.933 30 mol) and tetrahydrofuran (259 ml). A 6 N sodium hydroxide solution (1385 ml, 8.31 mol) was added to the stirred solution over 40 minutes. A strong exotherm occurred and it was necessary to cool the reaction mixture in an ice bath to keep the v 9 ~a : ~ R ~.~ I~ -.
3 , t.,. ._. .~ :: t~ r ...

HA629a temperature under 60°C. The reaction mixture was then heated to slight reflux (pot temperature at 67 -68°C) for 5.5 hours.
The mixture was stirred at room temperature 5 overnight (16.5 hours). The pH was brought from 12.75 to 1.30 with the gradual addition of 6 N
hydrochloric acid solution (1150 ml, 6.9 mol), maintaining the temperature at about 25°C. The mixture was heated gradually with a short 10 distillation head until distillation and gas (carbon dioxide) evolution started (72.3° C pot temperature, 70°C head temperature) and until distillation stopped and gas evolution became very slow (94.1°C pot temperature, 50°C head temperature). Total 15 distillate collected was 410 m:1 and the pot residue had a pH of 3.9. Heating was continued for another ten minutes with no additional gas evolution. Total heating time from the start of distillation was 7.5 hours.
20 After stirring at room temperature overnight, the clear reaction mixture (pH 3.50) was stripped in the rotary evaporator under vacuum in a 60°C bath and the pasty residue was stirred with absolute ethanol (750 ml). The resulting crystalline suspension was 25 stripped in the rotary evaporator (pump vacuum, 60°C
bath) and the pasty residue was chased with absolute ethanol (2 x 750 ml). To the final residue, absolute ethanol (1500 ml) was added and the mixture was stirred in a 60°C bath until it became a fine 30 crystalline suspension, about 20 minutes, and then stirred at room temperature for 20 minutes. The suspension was filtered and the cake was washed with absolute ethanol (2 x 300 ml). The filtrates appeared hazy and were further clarified by .. .:. ~ ,i j HA629a filtration through a pad of Celite~. The new, clear filtrate was stripped in the rotary evaporator to give 434.6 g of title product as an amber-colored thick syrup. TLC (10:1:1, methanol: acetic 5 acid: water) Rf = 0.59.
c) (S)-2-Amino-6-hydro~yhexanoic acid A 5 1, 3-necked flask, equipped with a mechanical stirrer and thermometer, was charged with 10 the product from part (b) (434 g ,1.93 mol), and water (3 1). The pH of the hazy solution was adjusted from 4.05 to 7.50 by the addition of 1 N
lithium hydroxide (705 ml). The solution was warmed to 36°C and porcine kidney acylase I (0.710 g) was 15 added. The mixture was stirred at 35° to 36°C for 23.5 hours, The reaction mixture was cooled to room temperature and the pH was brought from 7.0 to 5.9 by the addition of glacial acetic acid (4.4 ml).
Celite~ (29 g) and charcoal (29 g) were added and the 20 temperature was raised with stirring to 91.°C. The heating was removed and the mixture was allowed to cool to room temperature. The suspension was filtered through an 18.5 cm filter paper disc and the cake was thoroughly washed with water. Th.e colorless 25 filtrates (about 3.9 1) were concentrated in a rotary evaporator at 60°C to give 476 g of a clear, thick oil. Absolute ethanol (720 ml) was added and the mixture was stirred until it became a homogeneous crystalline suspension. The solvent was again 30 stripped off and absolute ethanol (1584 mli was added to the white solid residue. The suspension was rolled in the rotary evaporator at room temperature overnight (15 hours) and filtered through 18.5 cm paper. The cake was washed with absolute ethanol (7 k A ~ :1 f <~ ~ .u i-.H ..~ ~.1~ t~ f Cf HA629a x 100 ml) and dried to constant weight under vacuum to give 85.8 g of white, crystalline title product.
TLC (methanol: water: acetic acid, 10:1:1) R.f = 0.62.
Anal. calc'd for C6H13N03:
5 C, 48.25; H, 8.94; N, 9.38 Found: C, 48.66; H, 8.77; N, 9.43.
d) fS-(R* R*)-2-ff4-(ACetylthio)-1-oxo-2-ff(phenvl-mPrroxy)carbonvllaminolbutyllaminol-6-hvdroxyhexanoic 10 acid, methyl ester A slurry of (S)-2-amino-6-hydroxyhexanoic acid (1.0 g, 6.8 mmol) in methanol (20 ml) was stirred under argon at room temperature and treated with trimethylsilyl chloride (1.9 ml, 15 mmol). The 15 resulting solution was stirred at room temperature for 18 hours. The solvent volume was reduced to about 3.5 ml under reduced pressure. Acetonitrile (5 ml) was added and the solution was cooled to -10°C. N,N-Diisopropylethylamine (4.15 m1, 23.8 20 mmol) was then added and the solution was cooled to -40°C to give a solution containing (S)-2--amino-6-hydroxyhexanoic acid, methyl ester.
In a separate flask, a solution of S-acetyl-N-[(phenylmethoxy)carbonyl]homocysteine 25 [prepared as described in Example 23(e), 2.117 g, 6.8 mmol] in acetonitrile (5 ml) at 0°C was treated with N,N-diisopropylethylamine (1.20 ml, 6.8 mmol). In another flask, hydroxybenzotriazole hydrate (0.104 g, 0.68 mmol) and methanesulfonyloxybenzotriazole (1.450 30 g, 6.8 mmol) were dissolved in acetonitrile and cooled to -18°C. The previously formed S--acetyl-N-[(phenylmethoxy)carbonyl]homocysteine was then added dropwise to this solution while maintaining the internal temperature at less than -10°C. After ~, >) .,t ;,j .. -f: :3 .

HA629a stirring at -18° to -12°C for three hours, the resulting solution was added dropwise to the above solution containing (S)-2-amino-6-hydroxyhexanoic acid, methyl ester at -40°C. The mixture was allowed 5 to slowly warm to 16°C over 18 hours. The reaction was then poured into ethyl acetate (50 ml) and 1N
hydrochloric acid (50 ml). The mixture was transferred into a separatory funnel and the layers were separated. The aqueous layer was extracted with 10 ethyl acetate (2 x 50 ml). The organic layers were combined and then washed with 1N hydrochloric acid (100 ml), saturated sodium bicarbonate (100 ml), and saturated sodium chloride (100 ml). The solution was dried over magnesium sulfate, filtered, and 15 concentrated to a white solid. To this solid was added tert-butyl methyl ether (20 ml) and the resulting slurry was stirred at room temperature for 4 hours and filtered. The product was washed with tert-butyl methyl ether and dried to yield 2.087 g of 20 title product; m.p. 89 - 90°C.
P1 fS-(R*,R*)1-2-ff4-(Acetylthio)-1-oxo-2-ffphenvl-methoxy)carbonyllaminolbutyllaminol-6-oxohexanoic acid, methyl ester 25 To a solution of oxalyl chloride (546 ~1, 6.27 mmol) in dry methylene chloride (16 ml) at -65°C
(internal temperature) was. added dropwise a solution of dimethylsulfoxide (905 )11, 12.54 mmol) in methylene chloride (13 ml) over 12 minutes while 30 maintaining an internal temperature between -65° and -60°C. A solution of the product from part (d) (1.90 g, 4.18 mmol) in methylene chloride (7 ml) was added to the reaction flask over 20 minutes producing a turbid mixture. Additional methylene chloride (1 ml) ;3 .~ :-~ ~ ~ '",f ,-.
~. ... ~o ~r ~.,~ L

HA629a was used to complete the transfer of the alcohol into the reaction flask and the reaction was allowed to stir at -65°C for 40 minutes. Next N,N-di.iso-propylethylamine (3.7 ml, 20.90 mmol) was added thus 5 producing a clear solution. After stirring an additional 30 minutes at -65°C, the reaction was allowed to warm to -18°C over 2 hours. The reaction was quenched with loo aqueous potassium bisulfate (30 ml) and then warmed to room temperature. The 10 reaction mixture was diluted with 25 ml of water, mixed, and the phases were separated. The aqueous fraction was back-extracted with methylene chloride (2 x 25 ml). The combined organic extracts were washed with loo aqueous potassium bisulfate (25 ml), 15 saturated aqueous sodium bicarbonate (2 x 25 ml), brine (25 ml), dried (magnesium sulfate), filtered and concentrated in vacuo to give 1.84 g of title product as a white solid.
20 f) f4S-(4a,7a"10a~)1-Octahydro-4-ff(phenylmethoxv)-~arbonYllaminol-5-oxo-7H-~yridof2,1-b1f1,31thiaze-y~;nP-7-carboxylic acid methyl ester A dried flask under argon was charged with the product from part (e) (1.76 g, 3.89 mmol) and 25 methanol (17 ml). The so'~.ution was cooled to 0°C and sparged with argon for 25 minutes. Sodium methoxide solution (25o by weight in methanol, 983 ~1, 4.28 mmol) was added to the reaction mixture over about 15 seconds. The reaction was quenched after one hour 30 with 1N hydrochloric acid solution (20 ml) and then allowed to warm to room temperature. Ethyl acetate (35 ml) was added and after mixing, the layers were separated. The aqueous fraction was back-extracted with ethyl acetate (2 x 15 ml). The combined organic 'a .0 : ?~ ~ 6', ;S °~
... ..... ° ~ '.C'. ,_f ~

HA629a fractions were washed with 1N hydrochloric acid solution (15 ml), brine, dried (magnesium sulfate), filtered, and concentrated in vacuo to give 1.69 g of [S-(R*,R*)]-2-[[4-mercapto-1-oxo-2-[[(phenylmethoxy)-5 carbonyl]amino]butyl]amino]-6-oxohexanoic acid, methyl ester as a white foam.
A solution of this white foam and trifluoroacetic acid (305 ~1, 3.95 mmol) in methylene chloride (17 ml) was refluxed for 2.25 hours. After 10 cooling to room temperature, the reaction was concentrated and the residue was dissolved in ethyl acetate (25 ml), washed with saturated sodium bicarbonate solution (2 x 20 ml) and brine, dried (magnesium sulfate), filtered and concentrated in 15 vacuo to yield 1.50 g of title product as a white foam.
a) f4S-(4a,7a,10a(3)1-Octahvdro-4-amino-5-oxo-7H-gyrido~2,1-b1f1,31thiaze~ ne-7-carboxylic acid, 20 methyl ester Treatment of the product from part (f) with iodotrimethylsilane according to the procedure of Example 23(h) or 11(h) removes the N-protecting group and yields the desired 4-amino product.

Example 27 (S)-2-Phthalimido-6-hydroxyhexanoic acid This intermediate of Example 1(c) was also 30 prepared as follows:
To a solution of 2-(acetylamino)-2-[4-(acetyl-oxy>butyl]propanedioic acid, diethyl ester [730 g, 2.2 mol, prepared as described in Example 24(a)] in absolute ethanol (300 ml) was added 6 N sodium HA629a hydroxide solution (1.6 1). The reaction was heated at 70 - 75°C for 5 hours, then at 90° to 95°C to distill off most of the ethanol. The reaction was cooled and acidified to pH 1.3 using 6N hydrochloric 5 acid (about 1.3 1), then heated at 90° - 100°C to achieve decarboxylation. Upon completion, the crude reaction mixture was cooled to room temperature.
The above crude reaction mixture was heated to 35°C and treated with about 600 ml of 6N sodium 10 hydroxide followed by 1N sodium hydroxide to adjust to pH of 7.5 (final volume was about 5.3 L). To this mixture was added 0.6 g of porcine kidney acylase z.
After stirring overnight at 35°C the pH was 7.25.
The pH was adjusted to 7.5 and an additional 300 mg 15 of acylase was added. After stirring overnight, the reaction appeared to be about 90o complete. The reaction mixture was next treated with 20 g of charcoal and 20 g of Celite~, then heated. to 85°C and maintained at that temperature for 10 minutes, then 20 cooled to 50°C and filtered. At this point, the total volume of the filtrate was about 4.9 1. The filtrate was cooled to 5°C and solid sodium carbonate was added to adjust the pH to 9.3. N-Carbethoxy-phthalimide (263.04 g, 1.2 mol) was added in one 25 portion and sodium carbonate was added as needed to keep the pH at 9.3. After' 2 hours at 5°C followed by 3 hours at room temperature, the pH dropped to 8.5 and most of the reagents had dissolved. The reaction mixture was filtered, cooled t.o 5°C and acidified to 30 pH 2.3 with 6N hydrochloric acid. The precipitated solid was collected by filtration and washed with 200 ml of cold water, then dried in vacuo to yield 220 g of title product.

y .~ :r ! r1 r~ ..
i_. L :.. _. c3 HA629a Example 2$
f 4S-~4a. 7a, 10a(31 1 -Octahydro-4- f f 2-mercagt:o-3-(1-n~hthalenyl)-1-ox~~ropyllaminol-5-oxo-7H-pyrido-j2,1-b1f2,31 iazenine-7-carboxylic acid a) lAcetvlamino)(1-naDhthaleHylmethyl)proganedioic.
ietj~rl ester To a solution of sodium ethoxide (21o in ethanol, 4.613 gm, 67.8 mmol) in ethanol (100 ml) was 10 added diethyl acetamidomalonate (14.74 gm, 67.8 mmol), then 1-(bromomethyl)napthalene (10.0 gm, 45.2 mmol). The solution was stirred at room temperature for one hour, The reaction mixture was then concentrated to an orange oil. The oil was dissolved 15 in ethyl acetate and washed with 50o saturated ammonium chloride water and brine, then dried over sodium sulfate, filtered and concentrated to afford an orange solid. The solid was recrystallized from ethyl acetate and hexane to afford beige crystals 20 contaminated with diethylacetamido malonate. The solid was dissolved in 50o ethyl acetate in hexane and purified by flash chromatography on Merck silica gel in 50% ethyl acetate in hexane. Those fractions containing pure product were combined and 25 concentrated to afford 10.225 g. of product as a white solid; m.p.
105-108°C; Rf = 0.57 (50o ethyl acetate in hexane).
b) a-Amino-1-naz~hthaleneproz~anoic acid 30 A solution of the product from part (a) (16.182 gm., 47.5 mmol) was suspended in 48o hydrogen bromide (100 ml) and refluxed under argon for 14 hours. The hydrogen bromide salt of the product was filtered out of solution as a white solid, then taken up in hot ,'..Y ..1 ~ :,i !."r -,.
..: , . ._ -:.~Y y , HA629a (50 °C) water (500 ml) and the solution neutralized with concentrated ammonium hydroxide. The product precipitated out of solution as a fine white solid.
Upon filtration and drying under high vacuum 5 overnight (18 hours>, 8.335 g. of product was obtained as a fluffy white solid; m.p. 264 °C.
c) a-Bromo-1-nanhthalenenropanoic acid To a solution of the product from part (b) 10 (4.000 g., 18.6 mmol) and potassium bromide (7.63 g., 63.2 mmol) in 2.5 N sulfuric acid (35 ml) kept at 0 °C was added sodium nitrite (:1.92 g., 27.8 mmol) over one hour. The mixture was stirred for an additional hour at 0° C, then was warmed t.o room 15 temperature and stirred for 2.5 hours. The reaction mixture was then extracted with ether (3x). The ether layers were combined and washed with water and brine, then dried over sodium sulfate, filtered and concentrated to give an orange oil. The oil was 20 purified by flash chromatography on r2erck silica gel in 70% ethyl acetate in hexane with 1o acetic acid added to reduce tailing. Those fractions containing the bromide were combined and concentrated to afford slightly contaminated product as an orange oil which 25 solidified upon sitting overnight. Rf = 0.40 (400 ethyl acetate in hexane with 1% acetic acid).
d) a-(Acetylthio)-1-naphthalenenropanoic acid To a slurry of potassium thioacetate (0.912 30 g., 8.00 mmol) in acetonitrile (300 ml) at 0°C was added the product from part (c) (2.030 g., 7.2? mmol) as a solution in acetonitrile (3 ml). The solution was stirred for one hour at 0°C, then was warmed to room temperature and stirred for 15 hours. Potassium i't o y-. w t 1 ...~ ,.
.. .. .. .n, :a '.~
- lbl -HA629a bromide was then filtered out of the reaction mixture and the filtrate concentrated to afford an orange oil. The oil was dissolved in ethyl acetate and washed with 10~ potassium bisulfate and brine, then 5 dried over sodium sulfate, filtered and concentrated to afford an orange oil. The oil was purified by flash chromatography on Merck silica gel in 50% ethyl acetate in hexane with 1% acetic acid added to reduce tailing, Those fractions containing product were all 10 contaminated with a compound with an Rf = 0.43.
Those fractions were pooled and concentrated to give an orange oil. The crude product was purified via the dicyclohexylamine salt by dissolving the orange oil in ether and adding an equivalent of 15 dicyclohexylamine (1.32 g., 7.27 mmol) to the solution. The dicyclohexylamine salt was obtained in 2 crops of brown crystals (1.450 gm) still slightly contaminated with impurity. The crystals were suspended in ethyl acetate and shaken with 10%
20 potassium bisulfate (3x). The organic layer was then washed with water and brine, then dried over sodium sulfate filtered and concentrated to afford 875 mg.
of product as a yellow oil; Rf = 0.40 (40% ethyl acetate in hexane with 1% acetic acid).

e) f4S-(4a.7a,10a(3)1-Octahydro-4-ff2-(acetvlthio)-3-(1-naphthalenvl)-1-oxo~rogyllaminQ,l-5-oxo-7H-g3rrido f~,. 1-bl f 1. 31 thiazP~~ine-7-carboxvlic acid.
methyl. ester 30 A solution of the racemic acid product from part (d) in methylene chloride and a solution of ( 4S- (4a, 7a, 10a(3) J -octahydro-4-'amino-5-oxo-7H-pyrido(2,1-b](1,3]thiazepine-7-carboxylic acid, methyl ester in methylene chloride are reacted in the k ~ y ~~ ~,~ 1n1 w~
,. . ._ _ _.
~a HA629a presence of triethylamine and benzotriazol-1-yloxy-tris(dimethylamino)phosphonium hexafluorophosphate according to the procedure of Example 23(i) to give the title product.

f) f4S-14a,7a,10a~3)1-Octahvdro-4-ff2-merc~pto-3-(1-nanhthalenyl)-1-oxogropvllaminol-5-oxo-7Hwri f2.1-b1f1.31-thiazepine-7-carbox~rlic acid A solution of the product from part. (e) in 10 methanol is treated with 1N sodium hydroxide according to the procedure of Example 23(j) to give the title product.
ExamBle 29 15 L4S- f 4oc (R* ) , 7a" 10a(31 1 -OCtahvdro-4- f f 2-mercapto-1-~0-3-(2-thienyl)~rogyllaminol-5-oxo-7H-gyrido-J2 1-b 1j1 3lthiazepine-7-carboxylic acid al (S)-oc-(ACetvlthio)-2-thiQphenepro~anoic acid 20 Potassium chloride (3.0 g., 40.1 mmol.) was added to a solution of (3-(2-thienyl)-D-alanine (1.37 g., 8.03 mmol.) in 2.5 N hydrochloric acid (25 ml.) at room temperature under argon. After stirring for 10 minutes, the resulting mixture was cooled to 0°C
25 and treated with sodium nitrite (720 mg., 10.44 mmol.). After 2.5 hours, the reation mixture was warmed to room temperature and was stirred 1 hour.
The mixture was partitioned between water and ethyl acetate and the organic layer was dried (sodium 30 sulfate), filtered, and concentrated. The residue was flash chromatographed (Merck silica gel) eluting with to acetic acid in 3:1 hexaneiethyl acetate to give 760 mg. of (R)-a.-chloro-2-thiophenecarboxylic acid as a yellow oil.

6 .. .r ~ < t-~ r'.~
... _... _.. i.7 ; ..

HA629a Cesium thioacetate (2.95 g., 14.19 mmol.) was added to a solution containing the above chloride (750 mg., 4.73 mmol.) in dimethylformamide (15 ml.) at room temperature under argon. After stirring for 5 2 hours, the reaction mixture was partitioned between loo potassium bisulfate and ethyl acetate. The organic layer was washed with brine, dried (sodium sulfate), filtered, and concentrated and the residue was flash chromatographed (Merck silica gel) eluting 10 with 1o acetic acid in 4:1 hexane;ethyl acetate to give 500 mg. of the title product as an oil.
TLC (2o acetic acid in 3:1 ethyl acetate/hexane) Rf 0.73.
15 b~ f4S-f4a(R*),7oc,l0a(311-Octahvdro-4-ff2-(acetvl-thio)-1-oxo-3-(2-thienyl)progyllaminol-5-oxo-7H-gyridof2.1-blfl,3lthiazepine-7-carboxylic acid, methyl ester A solution of the acid product from part (a) 20 in methylene chloride and a solution of (4S- (4a" 7a" 10a~3) ] -octahydro-4-amino-5-oxo-7H-pyrido[2,1-b][1,3]thiazepine-7-carboxylic acid, methyl ester in methylene chloride are reacted in the presence of triethylamine and benzotriazol-1-yloxy-25 tris(dimethylamino)phosphcnium hexoflurophosphate according to the procedure of Example 23(i) to give the title product.
c ) f 4S- f 4a, (R* ) . 70c, 10.a(31 1 -Octahydro-4- f f 2-merca~to-30 1-oxo-3-(2-thien~,l)~rogyllaminol-5-oxo-7H-pvrido-f2,1-blfl.3lthiazeoine-7-carboxylic acid A solution of the product from part (b) in methanol is treated with 1.N sodium hydroxide HA629a according to the procedure of Example 23(j) to give the title product.
Examg~e 30 5 j.4S-f4a(S*) 7a 10a(ill-Octahvdro-4-f(2-mercanto-1-oxo-3 ohenvlnroovl)aminol-5-oxo-7Hwridof2 1 ~lfl 31-~hiazepine-7-carboxvlic acid a~ (R)-2-(Acetylthio)benzeneRropanoic acid, dicv~
10 ~Pxvlamine salt Following the procedure of Example 1(hl but substituting L-phenylalanine for the D-phenylalanine, (R)-2-(acetylthio)benzenepropanoic acid, dicyclo-hexylamine salt was obtained.

~) f4S-f4a(S*) 7a l0a(3l1-Octahvdro-4-ff2-(acetyl-~]hio)-1-oxo-3-phenylprogyllaminol-5-oxo-7H-l,vrido-,L2 1-bill 3lthiazenine-7-carboxy~~~ acid methyl gster 20 A stirred suspension of (R)-2-(acetylthio)-benzenepropanoic acid, dicyclohexylamine salt (353.5 mg, 0.872 mmol) in ethyl acetate (5 ml) was washed with 5~ potassium bisulfate solution (3 x 5 ml). The organic extracts were combined, washed with brine, 25 dried (magnesium sulfate), filtered, concentrated, dried in vacuo and stripped twice from hexanes to obtain (R)-2-(acetylthio)benzenepropanoic acid as an oil.
The resulting free acid (181.4 mg, 0.809 mmol) 30 was dissolved in methylene chloride (2 ml) and stirred under nitrogen at 0°C. To this solution was added a solution of [4S-(4a,7a,l0a(3)]-octahydro-4-amino-5-oxo-7H-pyrido[2,1-b][1,3]thiazepine-7-i~ ~ Cs~ ~ et r) ~.
m it .;,. i., ';, c~ 1 a HA629a carboxylic acid, methyl ester (200 mg, 0.774 mmol) in methylene chloride (6 ml), then triethylamine (0.113 ml, 0.813 mmol) and finally benzotriazol-1-yloxytris(dimethylamino)phosphonium 5 hexafluorophosphate (360 mg, 0.813 mmol). The reaction was stirred at 0°C and then slowly allowed to warm to room temperature. After a total of 20 hours, the reaction was concentrated in vacuo. The residue was dissolved in ethyl acetate and the 10 solution was washed with a 5o solution of potassium bisulfate, a saturated solution of sodium bicarbonate, and brine. The organic layer was dried (magnesium sulfate), filtered, and concentrated to a yellow solid. Purification by flash chromatography 15 (eluting with 2:3 ethyl acetate/hexane) gave 261.7 mg of title product as a clear oil.
c) f4S-f4a(S*),7a,10a~ill-Octahvdro-4-f(2-mercapto 1-oxo-3-phenvlprogyl)aminol-5-oxo-7H-gyridof2,1-bl 20 f1,31thiazegine-7-carboxylic acid A solution of the product from part. (b) (261.1 mg, 0.562 mmol) in methanol (6 ml, deoxygenated via nitrogen bubbling) was cooled to 0°C and treated with 1N sodium hydroxide (6 ml, deoxygenated vi.a nitrogen 25 bubbling). After stirring for one hour at 0°C while purging continuously with nitrogen, the reaction was warmed to room temperature. After stirring for 30 minutes at room temperature, a clear solution was obtained. After 5.5 hours, the reaction was 30 acidified, to pH 1 with 5o potassium bisulfate and extracted with ethyl acetate. The organic: layers were combined, washed with water and brine, dried (sodium sulfate), filtered and concentrated in vacuo.
Purification by flash chromatography (6:0.01:3.99 HA629a ethyl acetate: acetic acid:hexane) gave 190 mg of title product as a white solid; [a]D = -87.5° (c =
0.51, chloroform). TLC (6:0.01:3.99, ethyl acetate: acetic acid: hexane) Rf = 0.20.
5 HPLC: tR = 25.3 min; YMC S-3 ODS (C-18) 6.0 x 150 mm;
0% to 100oB:A, 30 min. linear gradient and 10 min.
hold, 1.5 ml/min; A=90% water: methanol + 0.20 phosphoric acid, B = 90o methanol: water + 0.20 phosphoric acid; 220 nm.
10 Anal. calc'd for C19H2404N2S2~0.15 C4H802~0.15 C7H16 ~ 0.39 H20:
C, 55.89; H, 6.45; N, 6.31; S, 14.45 Found: C, 56.19; H, 6.50; N, 6.71; S, 13.96.
15 Example 31 I4S-(4a,7a,9aj3)1-Octahvdro-4-ff2-mercapto-1-oxo-3-(4-thiazolyl)propyllaminol-5-oxogyrrolof2,1-bl-f1.31thiazepine-7-carboxylic acid 20 a) (R)-2-Amino-3-(4-thiazolyl)p~~anoic acid A solution of 4N hydrochloric acid in dioxane (10 ml) was added to a solution of (R)-2-:[(1,1-dimethylethoxy)carbonyl]amino]-3-(4-thiazolyl)propa-noic acid (2.0 g, 7.3 mmol) in dioxane (2 ml). The 25 reaction mixture was stirred at room temperature for 3 hours, concentrated in ~~acuo and the residue was dissolved in water (3 ml). The pH was adjusted to 6.5 with 1N sodium hydroxide and this solution was passed through 20 ml of DowexO AG50(H+). The column 30 was eluted with water (25C3 ml) followed by 20 pyridine in water (300 ml). The product containing fractions were concentrated ir_ vacuo to yield 0.94 g of title product.

4': A ':R 9 ~'I ~ '~
r .. ...,. , , L t ...

HA629a b1 (R)-2-Bromo-3-(4-thiazolyl)~?ro~anoic acid A solution of the product from part: (a) (0.516 g, 3 mmol) and potassium bromide (1.19 g, 10.1 mmol) in water (5.94 ml) and sulfuric acid (0.43 ml) was 5 stirred at -10°C for 5 minutes followed by the portionwise addition of sodium nitrite (0.318 g, 4.61 mmol) over a 10 minute period. The reaction mixture was stirred an additional 10 minutes at 0°C and at room temperature for one hour, and then e~aracted 10 with ether (3 x 100 ml). The ether extracts were washed with brine (2 x 20 ml), dried (sodium sulfate), filtered, and concentrated in vacuo to yield 0.37 g of title product; (oc]D = +37.35° (c =
0.7, methanol). A second run was carried out 15 starting with 2.67 mmol of the product from part (a) using the same procedure to yield an additional 0.35 g of title product.
c) (S)-2-lAcetylthio)-3-(4-thiazol5rl)propanoic acid 20 The product from part (b) (0.72 g, 3.05 mmol) and potassium thioacetate (0.35 g, 3.05 mmol) were stirred in acetonitrile (9 ml) overnight at room temperature and at 30°C for one hour. The reaction mixture was diluted with ethyl acetate (100 ml) and 25 filtered. The filtrate was concentrated in vacuo.
The residue was redissolved in ethyl acetate (100 ml), washed with water (2 x 50 ml) and brine (20 ml), dried (sodium sulfate), filtered and concentrated in vacuo to yield 0.52 g of title product; (a)D =
30 -15.89° (c = 0.6, methanol).

tz p, :7 r - :L68 -HA629a ~) f4S-(4a.7a.9a(3)1-Octahvdro-4-ff2-(acetvlthio)-~-oxo-3-(4-thiazolyl)proy~yllaminol-5-oxopyrrolo-j2.1-b1f1.31thiazepine-7-carboxylic acid, methyl ester 5 [4S-(4a,7a,9a(~)]-4-Amino-octahydro-5-oxo-pyrrolo[2,1-b][1,3]thiazepine-7-carboxylic acid, methyl ester, p-toluenesulfonic acid salt [0.367 g, 0.882 mmol, prepared from the material described in Example 5(d)] was dissolved in methylene chloride (5 10 ml) 0°C, followed by the addition of triethylamine (0.12 ml, 0.868 mmol). The product from part !c) (0.2 g, 0.865 mmol) was added to this solution followed by a second portion of triethylamine (0.12 ml, 0.865 mmol). Benzotriazol-1-yloxytris-15 (dimethylamino)phosphonium hexafluorophosphate (0.383 g, 0.865 mmol) was added and the reaction mixture was stirred at 0°C for one hour and a room temperature for 4 hours. The reaction mixture was concentrated in vacuo and the residue was dissolved in ethyl 20 acetate (60 ml). The organic extract was washed with 5o aqueous potassium bisulfate (10 ml) and brine (2 x 10 ml), dried (sodium sulfate), filtered and concentrated in vacuo. This crude material was chromatographed through 100 g of Merck silica gel 25 using 0.2o methanol in ethyl acetate. The fractions enriched in the slower isomer were concentrated in vacuo to yield 0.134 g of title product.
e) f 4S- (4a, 7a. 9a~3) 1 -Octahydro-4- f f 2-mercaoto-1-30 oxo-3-(4-thiazolyl)grogyllaminol-5-oxogyrrolo-f2,1-blfl.3lthiazenine-7-carboxylic acid The product from part (d) (0.135 g, 0.29 mmol) was dissolved in methanol (3 ml) and argon was bubbled into the solution for 30 minutes at 0°C. 1N

f : .,r ; . ,rt to ,.,~ __ s. ,. , s n a ._ HA629a Sodium hydroxide (1.32 ml) also purged with argon was added to the above solution and the reaction mixture was stirred at 0°C with argon bubbling through the solution for one hour and at room temperature for 2 5 hours. The reaction was quenched by the addition of 5~ aqueous potassium bisulfate (20 ml) and the organics were extracted with ethyl acetate (3 x 50 ml). The ethyl acetate solution was washed with brine, dried (sodium sulfate), filtered, and 10 concentrated in vacuo. The concentrate was chromatographed through 40 g of Merck silica gel using chloroform containing 5o methanol and 0.5~
acetic acid. The appropriate fractions were combined, concentrated and partitioned between 20 ml 15 of ethyl acetate and 5$ aqueous potassium bisulfate.
The ethyl acetate solution was washed with water and brine, dried (sodium sulfate), and concentrated in vacuo. The residue was lyophilized from dioxane (4 ml) to yield 36 mg of title product as a 70:30 20 mixture of isomers; m.p. 95 - 115°C; [a]D = -191.7°
(c = 0.06, chloroform). TLC
(chloroform: methanol: acetic acid, 8:2:0.2) Rf = 0.59.
HPLC: tR = 3.06 min; YMC ~~-3 ODS (C-18) 6.0 x 150 mm, 3~1 end capped column, isocratic 60o aqueous methanol 25 containing 0.2o phosphoric acid, 25 min, 1.5 ml/min.
(95.40) .
Anal. calc~d for C15H1gN304S3~0,2 C4Hg02 ~ 0.9 H20:
C,43.59; H, 5.19; N, 9.65; S, 22.09 Found: C,43.54; H, 4,89; N, 9.44; S, 21.90.

CA 02129375 20~a2~06-05 HA629a xam~
1000 tahlets each containing the following ingredients:

(4S-(4a(R*),'Ja,lOap)]-Octahydro-4-[(2-mercapto-1-oxo-3-phenylprapyl)-amino]-5-oxo-7H-gyrido[2,1-b,i[1,3)thia-zepiae-7-carboxylic acid 1610mg.
srcnoN a caRR~crlu~l SEECERTiFh,aTE Cornstarch 1(#0mg.

CORR~CTIOP:._ARTICL~:9Gelatin 20 mg.

VOiRCERTiFfc;ATAvieel''"' (microcrystalline cellulose)50 mg.

Magnesium stearate 5 mg.

275 mg.
are prepared from sufficient bulk quant:it.ies by mixing the product of Example 3 and cornstarch~with an agueous solution of ttze gelatin. Thr~ mixture is dried and ground to a fine powder. The ~vic.elT"' and then the magnesium stearate are admixed ~rith granulation. The mixturEa is then compre:~sed in a tablet press to form 100(1 tablets each containing 100 mg. of active ingredient.
In a similar manner, tablets contain.fng 200 mg. of the product of Examples 1 2, 4 to 23.. 25, and 28 to 3I can be prepared.
Similar procedures can be employed to form tablets or capsules containing from 20 mg. to 500 mg.
of active ingredient.

Claims (17)

What we claim is:
1. A compound of the formula including a pharmaceutically acceptable salt thereof wherein:
X is O or S-(O)t;
R1 and R12 are independently selected from the group consisting of hydrogen, alkyl, alkenyl, cycloalkyl, substituted alkyl, substituted alkenyl, aryl, substituted aryl, heteroaryl, cycloalkyl-alkylene-, aryl-alkylene-, substituted aryl-alkylene-, and heteroaryl-alkylene- or R1 and R12 taken together with the carbon to which they are attached complete a cycloalkyl ring or a benzofused cycloalkyl ring;
R2 is hydrogen, , or R11-S- ;
R3, R5 and R7 are independently selected from the group consisting of hydrogen, alkyl, substituted alkyl, aryl-(CH2)p-, substituted aryl-(CH2)p-, heteroaryl-(CH2)p- , R4 is alkyl, cycloalkyl-(CH2)p-, substituted alkyl, aryl-(CH2)p-, substituted aryl-(CH2)p-, or heteroaryl-(CH2)p-;
R6 is alkyl, substituted alkyl, cycloalkyl-(CH2)p-, aryl-(CH2)p-, substituted aryl-(CH2)p-, or heteroaryl-(CH2)p-;
R8 is hydrogen, lower alkyl, cycloalkyl, or phenyl;
R9 is hydrogen, lower alkyl, lower alkoxy, or phenyl;
R10 is lower alkyl or aryl-(CH2)p-;
R11 is hydrogen, alkyl, substituted alkyl, cycloalkyl-(CH2)p-, aryl-(CH2)p-, substituted aryl-(CH2)p-, heteroaryl-(CH2)p-, or -S-R11 completes a symmetrical disulfide wherein R11 is m is zero or one;
Y is CH2, S-(O)t or O provided that Y is S-(O)t or O only when m is one;
n is one or two;
p is zero or an integer from 1 to 6;
q is zero or an integer from 1 to 3;
r is zero or one; and t is zero, one, or two.
2. A compound of Claim 1 having the formula wherein:
A is ;
R2 is hydrogen, , or R11-S-;
R3 is hydrogen or lower alkyl of 1 to 4 carbons;
r is zero or one;

R11 is lower alkyl or 1 to 4 carbons;
R1 is aryl-CH2-, substituted aryl-CH2-, heteroaryl-CH2-, cycloalkyl-CH2- wherein cycloalkyl is of 3 to 7 carbons, or straight or branched chain alkyl of 1 to 7 carbons and R12 is hydrogen; or R1 and R12 taken together with the carbon to which they are attached complete a cycloalkyl ring of 5 to 7 carbons;
R6 is lower alkyl of 1 to 4 carbons or phenyl;
n is one or two;
m is zero or one;
X is O or S; and Y is CH2, O, or S provided that Y is O or S
only when m is one.
3. A compound of Claim 2 wherein: ~
R2 is hydrogen or , R3 is hydrogen;
r is zero or one;
R1 is benzyl, cyclopropylmethyl, or straight or branched chain alkyl of 3 to 5 carbons;
R12 is hydrogen;
n is one or two;
m is zero or one;
X is O or S; and Y is CH2, O, or S provided that Y is O or S
only when m is one.
4. A compound of Claim 3 wherein:
X is S;
Y is CH2;
n is two;
m is one;
r is zero or one;
R2 is hydrogen;

R1 is benzyl or isobutyl; and R12 is hydrogen; or X is S;
Y is CH2;
n is one;
m is one;
r is zero;
R2 is hydrogen;
R1 is benzyl; and R12 is hydrogen; or X is S;
Y is CH2;
n is two;
m is zero;
r is zero;
R2 is hydrogen;
R1 is benzyl, cyclopropylmethyl, n-butyl, isobutyl, n-propyl, or -CH2C(CH3)3; and R12 is hydrogen; or X is O;
Y is CHI;
n is two;
m is one;
r is zero;
R2 is hydrogen;
R1 is benzyl; and R12 is hydrogen; or X is O;
Y is CH2:
n is two;
m is zero;
r is zero;
R2 is hydrogen;
R1 is benzyl; and R12 is hydrogen; or X is O;
Y is O;
n is two:
m is one;
r is zero;
R2 is hydrogen;
R1 is benzyl; and R12 is hydrogen; or X is S;
Y is O;
n is two:
m is one:
r is zero;
R2 is hydrogen;
R1 is benzyl; and R12 is hydrogen.
5. The compound of Claim 4 which is:
[4S-[4.alpha.(R*),7.alpha.,10.alpha..beta.]]-octahydro-4-[(2-mercapto-1-oxo-3-phenylpropyl)amino]-5-oxo-7H-pyrido[2,1-b][1,3]thiazepine-7-carboxylic acid;

[4S-[4.alpha.(R*),7.alpha.,10.alpha..beta.]]-octahydro-4-[(2-mercapto-1-oxo-3-phenylpropyl]amino]-5-oxo-7H-pyrido[2,1-b][1,3]-thiazepine-7-carboxylic acid, 1,1-dimethylethylamine salt;

[4S-[4.alpha.(S*),7.alpha.,10.alpha..beta.]]-octahydro-4-[(2-mercapto-1-oxo-3-phenylpropyl]amino]-5-oxo-7H-pyrido[2,1-b][1,3]-thiazepine-7-carbaxylic acid;

[4S-[4.alpha.(R*),7.alpha.,10.alpha..beta.]]-octahydro-4-[[2-(mercapto-methyl)-1-oxo-3-phenylpropyl]amino]-5-oxo-7H-pyrido-[2,1-b][1,3]thiazepine-7-carboxylic acid;

[4S-[4.alpha.(R*),7.alpha.,10.alpha..beta.]]-octahydro-4-[(2-mercapto-4-methyl-1-oxopentyl)amino]-5-oxo-7H-pyrido[2,1-b][1,3]thiazepine-7-carboxylic acid;

[3R-[3.alpha.(S*),6.alpha.,9a.beta.]]-hexahydro-3-[(2-mercapto-1-oxo-3-phenylpropyl)amino]-4-oxo-2H,6H-pyrido[2,1-b]-[1,3]thiazine-6-carboxylic acid;

[4S-[4.alpha.(R*),7.alpha.,9a.beta.]]-octahydro-4-[(2-mercapto-1-oxo-3-phenylpropyl)amino]-5-oxopyrrolo[2,1-b][1,3]-thiazepine-7-carboxylic acid;

[4S-[4.alpha.(R*),7.alpha.,9a.beta.]]-octahydro-4-[(3-cyclo-propyl-2-mercapto-1-oxopropyl)amino]-5-oxopyrrolo-[2,1-b][1,3]thiazepine-7-carboxylic acid;

[4S-[4.alpha.(R*),7.alpha.,9a.beta.]]-octahydro-4-[(2-mercapto-1-oxohexyl)amino]-5-oxopyrrolo[2,1-b][1,3]-thiazepine-7-carboxylic acid;
[4S-[4.alpha.(R*),7.alpha.,9a.beta.]]-octahydro-4-[(2-mercapto-1-oxo-4 -methylpentyl)amino]-5-oxopyrrolo[2,1-b][1,3]-thiazepine-7-carboxylic acid;

[4S-[4.alpha.(R*),7.alpha.,9a.beta.]]-octahydro-4-[(2-mercapto-1-oxopentyl)amino]-5-oxopyrrolo[2,1-b][1,3]-thiazepine-7-carboxylic acid;

[4S-[4.alpha.(R*),7.alpha.,9a.beta.]]-octahydro-4-[(2-mercapto-4,4-dimethyl-1-oxopentyl)amino]-5-oxopyrrolo[2,1-b]-[1,3]thiazepine-7-carboxylic acid;

[4S-[4.alpha.(R*),7.alpha.,10a.beta.]]-octahydro-4-[(2-mercapto-1-oxo-3-phenylpropyl)amino]-5-oxo-7H-pyrido[2,1-b)[1,3]oxa-zepine-7-carboxylic acid;

[4S-[4.alpha.(R*),7.alpha.,9a.beta.]]-octahydro-4-[(2-mercapto-1-oxo-3-phenylpropyl)amino]-5-oxopyrrolo[2,1.-b][1,3]oxa-zepine-7-carboxylic acid;

[4S-[4.alpha.(R*),7.alpha.,10a.beta.))-octahydro,4-[(2-mercapto-1-oxo-3-phenylpropyl)amino]-5-oxo[1,4)oxazino[3,4-b)[1,3]-oxazepine-7-carboxylic acid; or [4S-[4.alpha.(R*),7.alpha.,10a.beta.]]-octahydro-4-[(2-mercapto-1-oxo-3-phenylpropyl)amino]-5-oxo[1,4]oxazino[3,4-b][1,3]-thiazepine-7-carboxylic acid.
6. The compound of the formula including a pharmaceutically acceptable. salt thereof.
7. A pharmaceutical composition useful in the treatment of cardiovascular disease comprising a pharmaceutically acceptable carrier and one or more compounds of the formula including a pharmaceutically acceptable salt thereof wherein A, x, Y, n, m and R3 are as defined in Claim 1.
8. A compound of the formula including a salt thereof wherein:
X is O or S;
n is one or two;
m is zero or one;
Y is CH2, O, or S provided that Y is O or S
only when m is one;
R3 is hydrogen, lower alkyl, or aryl-(CH2)p-;
and p is zero or an integer from 1 to 6;
provided that when X is O, n is one, and Y is CH2, then m is one.
9. A process for preparing the compounds of the formula which comprises:

a) when A is and R3 is hydrogen, coupling the acylmercapto sidechain of the formula or an activated form thereof with the amine of the formula in the presence of a coupling reagent wherein X, Y, m, n, R6, r, R1,and R12 are as defined in Claim 1 and R3 is hydrogen or an acid protecting group followed by removal of the aryl group and the R3 acid protecting group;
b) when A is coupling the carboxylic acid of the formula or an activated form thereof with the amine of the formula in the presence of a coupling reagent wherein X, Y, m, n, R1 and R12 are as defined in Claim 1, and R3 and R7 are acid protecting groups;

c) when A is and R3 is hydrogen, reacting the keto acid or ester of the formula under reducing conditions or the triflate of the formula with the amine of the formula wherein X, Y, m, n, R7 and R1 are as defined in Claim 1 and R3 is an acid protecting group followed by removal of the R3 acid protecting group; and d) when A is and R3 is hydrogen, coupling a phosphonochloridate of the formula with the amine of the formula wherein X, Y, m, n, and R4 are as defined in Claim 1 and R3 and R5 are acid protecting groups followed by removal of the R3 and R5 acid protecting groups.
10. A process for preparing the compounds of the formula wherein:
X is O or S;
n is one or two;
m is zero or one;
Y is CH2, O or S provided that Y is O or S
only when m is one; and R3 is an acid protecting group;
which comprises:
a) coupling an amino acid of the formula with the amino acid ester of the formula to give the dipeptide wherein:
P1 is an amino protecting group or a group which together with the N-atom forms a protecting group; and P2 is a hydroxy or mercapto protecting group;
b) selectively removing the P2 protecting group from the product of part (a);
c) cyclizing the product of part (b) to give and d) removing the P1 protecting group of the product of part (c) to give the desired product.
11. A process of Claim l0 wherein:
x is S;
n is one or two;
Y is CH2;
m is zero or one;
which comprises:
a) coupling an amino acid of the formula with the amino acid ester of the formula to give the dipeptide of the formula wherein:
P1 is an amino protecting group or a group which together with the N-atom forms a protecting group; and P2 is a hydroxy protecting group;
b) selectively removing the P2 protecting group from the product of part (a) to give the corresponding hydroxy compound;
c) converting the hydroxy product from part (b) to the mercaptan of the formula d) cyclizing the mercaptan product of part (c) to give and e) removing the P1 protecting group from the product of part (d) to give the desired product.
12. A process of Claim 10 wherein:
x is S;
n is two;
Y is S or O; and m is one;
which comprises;
a) coupling an amino acid of the formula with the amino acid ester of the formula to give the dipeptide of the formula wherein:
P1 is an amino protecting group or a group which together with the N-atom forms a protecting group; and P2 is a hydroxy protecting group;
b) selectively removing the P2 protecting group from the product of part (a) to give the corresponding hydroxy compound;
c) converting the hydroxy product from part (b) to the mercaptan of the formula d) cyclizing the mercaptan product of part (c) to give and e) removing the P1 protecting group from the product of part (d) to give the desired product.
13. A process for preparing the compounds of the formula wherein:
X is O or S;
n is one or two;
m is zero or one; and R3 is an acid protecting group;
which comprises:
a) coupling an amino acid of the formula with the hydroxy amino acid ester of the formula to give the dipeptide of the formula wherein:
P1 is an amino protecting group or a group which together with the N-atom forms a protecting group; and P2 is a hydroxy or mercapto protecting group;
b) oxidizing the hydroxy product of part (a) to the aldehyde of the formula c) selectively removing the P2 protecting group from the aldehyde product of part (b);
d) cyclizing the product of part (c) to give and e) removing the P1 protecting group of the product of part (d) to give the desired product.
14. A pharmaceutical composition for use in the treatment of cardiovascular disease in a patient comprising an effective amount of a compound as claimed in Claim 1, 2, 3, 4, 5 or 6, or a pharmaceutically acceptable salt there-of, together with a pharmaceutically accept-able carrier therefor.
15. A pharmaceutical composition for use in the treatment of hypertension or congestive heart failure in a patient comprising an effec-tive amount of a compound as claimed in Claim 1, 2, 3, 4, 5 or 6, or a pharmaceutically ac-ceptable salt thereof, together with a pharma-ceutically acceptable carrier therefor.
16. The use of a compound, as claimed in Claim 1, 2, 3, 4, 5 or 6, or a pharmaceutically acceptable salt thereof, in the treatment of cardiovascular disease in a patient.
17. The use of a compound, as claimed in Claim 1, 2, 3, 4, 5 or 6, or a pharmaceutically acceptable salt thereof, in the treatment of hypertension or congestive heart failure in a patient.
CA002124375A 1993-06-15 1994-05-26 Compounds containing a fused bicyclic ring and processes therefor Expired - Fee Related CA2124375C (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7797893A 1993-06-15 1993-06-15
US077,978 1993-06-15

Publications (2)

Publication Number Publication Date
CA2124375A1 CA2124375A1 (en) 1994-12-16
CA2124375C true CA2124375C (en) 2003-01-28

Family

ID=22141128

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002124375A Expired - Fee Related CA2124375C (en) 1993-06-15 1994-05-26 Compounds containing a fused bicyclic ring and processes therefor

Country Status (38)

Country Link
US (5) US5508272A (en)
EP (1) EP0629627B1 (en)
JP (1) JP3569550B2 (en)
KR (1) KR100395604B1 (en)
CN (1) CN1046525C (en)
AT (1) ATE266032T1 (en)
AU (1) AU672899B2 (en)
BG (1) BG62139B1 (en)
BR (1) BR1100970A (en)
CA (1) CA2124375C (en)
CY (1) CY2492B1 (en)
CZ (1) CZ289488B6 (en)
DE (1) DE69433752T2 (en)
DK (1) DK0629627T3 (en)
EE (1) EE03178B1 (en)
EG (1) EG20537A (en)
ES (1) ES2219644T3 (en)
FI (3) FI106464B (en)
GE (1) GEP19981301B (en)
HK (1) HK1001814A1 (en)
HU (1) HU216791B (en)
IL (2) IL109924A (en)
LT (1) LT3626B (en)
LV (1) LV10622B (en)
MY (1) MY123673A (en)
NO (1) NO306405B1 (en)
NZ (1) NZ260736A (en)
PH (1) PH30830A (en)
PL (1) PL178469B1 (en)
PT (1) PT629627E (en)
RO (1) RO112870B1 (en)
RU (1) RU2125056C1 (en)
SG (1) SG46510A1 (en)
SK (1) SK282529B6 (en)
TW (1) TW329423B (en)
UA (1) UA39924C2 (en)
UY (1) UY23787A1 (en)
ZA (1) ZA944163B (en)

Families Citing this family (120)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5552397A (en) * 1992-05-18 1996-09-03 E. R. Squibb & Sons, Inc. Substituted azepinone dual inhibitors of angiotensin converting enzyme and neutral exdopeptidase
US5646276A (en) * 1992-05-13 1997-07-08 Bristol-Myers Squibb Co. Diazepine containing dual action inhibitors
US5504080A (en) * 1992-10-28 1996-04-02 Bristol-Myers Squibb Co. Benzo-fused lactams
NZ267161A (en) * 1993-06-11 1996-12-20 Eisai Co Ltd Dipeptidic benzazepine derivative with ace inhibiting activity
US5508272A (en) * 1993-06-15 1996-04-16 Bristol-Myers Squibb Company Compounds containing a fused bicycle ring and processes therefor
US5525723A (en) * 1993-11-18 1996-06-11 Bristol-Myers Squibb Co. Compounds containing a fused multiple ring lactam
US5587375A (en) * 1995-02-17 1996-12-24 Bristol-Myers Squibb Company Azepinone compounds useful in the inhibition of ACE and NEP
US5877313A (en) 1995-05-17 1999-03-02 Bristol-Myers Squibb Benzo-fused azepinone and piperidinone compounds useful in the inhibition of ACE and NEP
US5650408A (en) * 1995-06-07 1997-07-22 Karanewsky; Donald S. Thiazolo benzazepine containing dual action inhibitors
US5635504A (en) * 1995-06-07 1997-06-03 Bristol-Myers Squibb Co. Diazepine containing dual action inhibitors
US6777550B1 (en) 1996-04-12 2004-08-17 Bristol-Myers Squibb Company N-formyl hydroxylamine containing compounds useful as ACE inhibitors and/or NEP inhibitors
DE59808284D1 (en) 1997-03-14 2003-06-12 Basf Ag CYCLOALKYLALCANCARBOXYLIC ACID AMIDES, THEIR PRODUCTION AND USE
US6133002A (en) 1997-09-25 2000-10-17 Dsm N.V. Process for preparing optically active 2-amino-ω-oxoalkanoic acid derivatives
US6340752B1 (en) 1998-01-06 2002-01-22 Bristol-Myers Squibb Co. Deprotection and recrystallization processes
IT1298267B1 (en) * 1998-02-18 1999-12-20 Zambon Spa PROCEDURE FOR THE PREPARATION OF (S) -2-ACETYLTIO-3-PHENYL-PROPIONIC ACID AND ITS SALTS
IT1298268B1 (en) * 1998-02-18 1999-12-20 Zambon Spa PROCEDURE FOR THE PREPARATION OF THE (S) -2-BROMO-3-PHENYL-PROPIONIC ACID
DE69926750T2 (en) 1998-06-17 2006-06-29 Bristol-Myers Squibb Co. PREVENTING THE BRAIN INFINE BY COMBINED ADMINISTRATION OF ADP RECEPTOR ANTIBLE PLATES AND ANTI-HYPERTENSIVE MEDICAMENTS
EP1357109B1 (en) 1998-06-18 2008-07-23 F. Hoffmann-La Roche Ag Process for aryl alkyl sulfide
US6174711B1 (en) 1998-07-05 2001-01-16 Mitsubishi Gas Chemical Company Method for producing L-allysine acetal
US6162913A (en) * 1998-07-15 2000-12-19 Bristol-Myers Squibb Co. Preparation of [4S-(4α,7α,10aβ)]-4-amino-octahydro-5-oxo-7H-pyrido[2,1 -b] [1,3]thiazepine-7-carboxylic acid, methyl ester and salts thereof via novel disulfides
EP1097236A4 (en) * 1998-07-15 2006-10-04 Bristol Myers Squibb Co Stereoselective reductive amination of ketones
US6468781B1 (en) 1999-07-08 2002-10-22 Bristol-Myers Squibb Company Stereoselective reductive amination of ketones
IL140861A (en) * 1998-07-15 2004-06-01 Bristol Myers Squibb Co Dioxolane pentanoic acid and processes for the preparation thereof
AU758062B2 (en) 1998-09-03 2003-03-13 Bristol-Myers Squibb Company Enzymatic oxidative deamination process
EP1129066B1 (en) 1998-11-11 2005-02-02 Novartis AG Production of 2-amino-2- 2-(4-c 2-20?-alkyl-phenyl)ethyl]propane-1,3-diols
MXPA01009654A (en) * 1999-03-29 2002-05-14 Squibb Bristol Myers Co Use of vasopeptidase inhibitors to treat angina pectoris.
SE9903028D0 (en) 1999-08-27 1999-08-27 Astra Ab New use
MXPA02001694A (en) * 1999-08-30 2002-08-06 Aventis Pharma Gmbh Use of inhibitors of the renin-angiotensin system in the prevention of cardiovascular events.
US6300503B1 (en) 1999-12-17 2001-10-09 Dixie Chemical Company Hydantoin intermediates for the synthesis of omapatrilat and methods for producing and using the same
NL1014354C2 (en) * 2000-02-11 2001-08-14 Dsm Nv Process for the preparation of (S) -2-acethylthio-3-phenylpropanoic acid.
NL1014353C2 (en) * 2000-02-11 2001-08-15 Dsm Nv Process for the preparation of (R) -2-bromo-3-phenylpropanoic acid.
US6509330B2 (en) 2000-02-17 2003-01-21 Bristol-Myers Squibb Company Hydroxamic acid containing compounds useful as ACE inhibitors and/or NEP inhibotors
DE60105216T2 (en) 2000-03-30 2005-03-24 Ajinomoto Co., Inc. Production process for an aromatic carboxylic acid derivative
US6620600B2 (en) * 2000-09-15 2003-09-16 Bristol-Myers Squibb Co. Enzymatic resolution of aryl and thio-substituted acids
EP1324975B1 (en) 2000-09-29 2005-11-16 Bristol-Myers Squibb Company Dynamic resolution of isomers and resolved isomers
US8168616B1 (en) 2000-11-17 2012-05-01 Novartis Ag Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension
US7119188B2 (en) * 2001-01-04 2006-10-10 Bristol-Myers Squibb Company N-carbobenzyloxy (N-CBZ)-deprotecting enzyme and uses therefor
US6828119B2 (en) * 2001-01-04 2004-12-07 Bristol Myers Squibb Company Enzymatic deprotection of amines and hydroxides
WO2003055856A2 (en) * 2001-10-17 2003-07-10 Bristol-Myers Squibb Company BICYCLIC LACTAM DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES AND/OR TNF-α CONVERTING ENZYME (TACE)
US7107198B2 (en) * 2001-11-02 2006-09-12 Sun Microsystems, Inc. Automatic generation of reduced-size circuit models including inductive interaction
US6984645B2 (en) 2001-11-16 2006-01-10 Bristol-Myers Squibb Company Dual inhibitors of adipocyte fatty acid binding protein and keratinocyte fatty acid binding protein
JP2005516940A (en) * 2001-12-20 2005-06-09 ブリストル−マイヤーズ スクイブ カンパニー Reduction of pulse pressure and vascular stiffness by administration of vascular peptidase inhibitor to hypertensive patients
ATE409466T1 (en) * 2002-01-11 2008-10-15 Novo Nordisk As METHOD AND COMPOSITION FOR TREATING DIABETES, HYPERTENSION, CHRONIC HEART FAILURE AND CONDITIONS ASSOCIATED WITH FLUID RETENTION
US20070197552A1 (en) * 2002-01-11 2007-08-23 Novo Nordisk A/S Method and composition for treatment of diabetes, hypertension, chronic heart failure and fluid retentive states
EP1383042B1 (en) * 2002-07-19 2007-03-28 STMicroelectronics S.r.l. A multiphase synchronous pipeline structure
US6842358B2 (en) * 2002-08-01 2005-01-11 Netlogic Microsystems, Inc. Content addressable memory with cascaded array
US7045653B2 (en) * 2002-12-23 2006-05-16 Pfizer, Inc. Pharmaceuticals
CL2004000544A1 (en) * 2003-03-18 2005-01-28 Pharmacia Corp Sa Organizada B USE OF A PHARMACEUTICAL COMBINATION, OF AN ALGOSTERONE RECEIVER ANTAGONIST AND A NEUTRAL ENDOPEPTIDASE INHIBITOR, USEFUL FOR THE TREATMENT AND PREVENTION OF A PATHOLOGICAL CONDITION RELATED TO HYPERTENSION, RENAL DYSFUNCTION, INSULINOPATI
US7459474B2 (en) 2003-06-11 2008-12-02 Bristol-Myers Squibb Company Modulators of the glucocorticoid receptor and method
US20050054731A1 (en) * 2003-09-08 2005-03-10 Franco Folli Multi-system therapy for diabetes, the metabolic syndrome and obesity
US7371759B2 (en) 2003-09-25 2008-05-13 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
US7420059B2 (en) 2003-11-20 2008-09-02 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
GB0327839D0 (en) 2003-12-01 2003-12-31 Novartis Ag Organic compounds
US7273881B2 (en) 2004-01-16 2007-09-25 Bristol-Myers Squibb Company Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
WO2005089731A2 (en) 2004-03-17 2005-09-29 Novartis Ag Use of renin inhibitors in therapy
US7888381B2 (en) 2005-06-14 2011-02-15 Bristol-Myers Squibb Company Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity, and use thereof
EP1906934A4 (en) * 2005-07-14 2012-03-07 Franco Folli Daily dosage regimen for treating diabetes, obsity, metabolic syndrome and polycystic ovary syndrome
GT200600381A (en) 2005-08-25 2007-03-28 ORGANIC COMPOUNDS
US7390789B2 (en) * 2005-09-13 2008-06-24 William H Simmons Thio-containing inhibitors of aminopeptidase P, and compositions thereof
US7400236B2 (en) 2005-10-21 2008-07-15 Gm Global Technology Operations, Inc. Vehicular lane monitoring system utilizing front and rear cameras
US7592461B2 (en) 2005-12-21 2009-09-22 Bristol-Myers Squibb Company Indane modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
US8202902B2 (en) 2006-05-05 2012-06-19 The Regents Of The University Of Michigan Bivalent SMAC mimetics and the uses thereof
EA017279B1 (en) 2006-05-05 2012-11-30 Дзе Риджентс Оф Дзе Юниверсити Оф Мичиган BIVALENT Smac MIMETICS AND THE USES THEREOF
US7795291B2 (en) 2006-07-07 2010-09-14 Bristol-Myers Squibb Company Substituted acid derivatives useful as anti-atherosclerotic, anti-dyslipidemic, anti-diabetic and anti-obesity agents and method
MX2009000646A (en) 2006-07-20 2009-01-29 Novartis Ag Amino-piperidine derivatives as cetp inhibitors.
US7968577B2 (en) 2006-11-01 2011-06-28 Bristol-Myers Squibb Company Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
EP2099767A1 (en) 2006-11-01 2009-09-16 Brystol-Myers Squibb Company Modulators of glucocorticoid receptor, ap-1, and/or nf- b activity and use thereof
EP2089389A2 (en) 2006-11-01 2009-08-19 Bristol-Myers Squibb Company Heterocyclic compounds as modulators of glucocorticoid receptor, ap-1, and/or nf-kappa-b activity
TW200838501A (en) * 2007-02-02 2008-10-01 Theravance Inc Dual-acting antihypertensive agents
TWI448284B (en) 2007-04-24 2014-08-11 Theravance Inc Dual-acting antihypertensive agents
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
EP2527360B1 (en) 2007-06-04 2015-10-28 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
TWI406850B (en) 2007-06-05 2013-09-01 Theravance Inc Dual-acting benzoimidazole antihypertensive agents
US7834041B2 (en) * 2007-09-07 2010-11-16 Theravance, Inc. Dual-acting antihypertensive agents
DK2207775T3 (en) 2007-11-05 2012-06-18 Novartis Ag 4-Benzylamino-1-carboxyacylpiperidine derivatives as CETP inhibitors useful in the treatment of diseases such as hyperlipidemia or arteriosclerosis
ATE528289T1 (en) 2007-12-03 2011-10-15 Novartis Ag 1,2-DISUBSTITUTED 4-BENZYLAMINOPYRROLIDINE DERIVATIVES AS CETP INHIBITORS SUITABLE FOR THE TREATMENT OF DISEASES SUCH AS HYPERLIPIDEMIA OR ARTERIOSCLEROSIS
US20110015158A1 (en) 2007-12-11 2011-01-20 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitors using metal binding moieties in combination with targeting moieties
JP2011506459A (en) 2007-12-11 2011-03-03 セラヴァンス, インコーポレーテッド Dual acting benzimidazole derivatives and their use as antihypertensive agents
JP2011518884A (en) 2008-04-29 2011-06-30 セラヴァンス, インコーポレーテッド Dual active antihypertensive
ES2627848T3 (en) 2008-06-04 2017-07-31 Synergy Pharmaceuticals Inc. Guanylate cyclase agonists useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
CN102149710A (en) 2008-06-24 2011-08-10 百时美施贵宝公司 Cyclopentathiophene modulators of the glucocorticoid receptor, AP-1, and/or NF-Kappa B activity and use thereof
WO2010009319A2 (en) 2008-07-16 2010-01-21 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
WO2010011821A2 (en) 2008-07-24 2010-01-28 Theravance, Inc. Dual-acting antihypertensive agents
SG175925A1 (en) 2009-05-15 2011-12-29 Novartis Ag Aryl pyridine as aldosterone synthase inhibitors
ES2430088T3 (en) 2009-05-15 2013-11-18 Novartis Ag Benzoxazolone derivatives as aldosterone synthase inhibitors
US20100317593A1 (en) * 2009-06-12 2010-12-16 Astrazeneca Ab 2,3-dihydro-1h-indene compounds
US7956054B2 (en) 2009-07-07 2011-06-07 Theravance, Inc. Dual-acting pyrazole antihypertensive agents
JP2012533626A (en) 2009-07-22 2012-12-27 セラヴァンス, インコーポレーテッド Dual action oxazole antihypertensive
JP5654608B2 (en) 2009-11-17 2015-01-14 ノバルティス アーゲー Aryl-pyridine derivatives as aldosterone synthase inhibitors
ES2472446T3 (en) 2009-11-30 2014-07-01 Novartis Ag Imidazole derivatives as aldosterone synthase inhibitors
EP2526095A1 (en) 2010-01-19 2012-11-28 Theravance, Inc. Dual-acting thiophene, pyrrole, thiazole and furan antihypertensive agents
WO2011116115A1 (en) 2010-03-16 2011-09-22 Novartis Ag Aliskiren composition comprising a medium chain fatty acid, their process of manufacturing
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
US8993631B2 (en) 2010-11-16 2015-03-31 Novartis Ag Method of treating contrast-induced nephropathy
RU2605557C2 (en) 2010-12-15 2016-12-20 ТЕРЕВАНС БАЙОФАРМА Ар энд Ди АйПи,ЭлЭлСи Neprilysin inhibitors
CN105061314A (en) 2010-12-15 2015-11-18 施万生物制药研发Ip有限责任公司 Neprilysin inhibitors
MX342212B (en) 2011-02-17 2016-09-20 Theravance Inc Substituted aminobutyric derivatives as neprilysin inhibitors.
JP5959066B2 (en) 2011-02-17 2016-08-02 セラヴァンス バイオファーマ アール&ディー アイピー, エルエルシー Substituted aminobutyric acid derivatives as neprilysin inhibitors
EP2714648B1 (en) 2011-05-31 2017-08-16 Theravance Biopharma R&D IP, LLC Neprilysin inhibitors
WO2012166387A1 (en) 2011-05-31 2012-12-06 Theravance, Inc. Neprilysin inhibitors
EP2714660B1 (en) 2011-05-31 2018-09-26 Theravance Biopharma R&D IP, LLC Neprilysin inhibitors
TWI560172B (en) 2011-11-02 2016-12-01 Theravance Biopharma R&D Ip Llc Neprilysin inhibitors
EP2855464B1 (en) 2012-05-31 2016-10-26 Theravance Biopharma R&D IP, LLC Nitric oxide donor neprilysin inhibitors
EP2858650B1 (en) 2012-06-08 2018-11-14 Theravance Biopharma R&D IP, LLC Neprilysin inhibitors
NZ702749A (en) 2012-06-08 2017-01-27 Theravance Biopharma R&D Ip Llc Neprilysin inhibitors
ES2615275T3 (en) 2012-08-08 2017-06-06 Theravance Biopharma R&D Ip, Llc Neprilysin inhibitors
JP6382831B2 (en) 2012-11-30 2018-08-29 サンフォード−バーンハム メディカル リサーチ インスティテュート Antagonists of apoptosis inhibitory protein (IAP)
LT2964616T (en) 2013-03-05 2017-07-25 Theravance Biopharma R&D Ip, Llc Neprilysin inhibitors
JP2016514671A (en) 2013-03-15 2016-05-23 シナジー ファーマシューティカルズ インコーポレイテッド Guanylate cyclase agonists and uses thereof
JP2016514670A (en) 2013-03-15 2016-05-23 シナジー ファーマシューティカルズ インコーポレイテッド Guanylate cyclase receptor agonists in combination with other drugs
BR112015030326A2 (en) 2013-06-05 2017-08-29 Synergy Pharmaceuticals Inc ULTRAPURE GUANYLATE CYCLASE C AGONISTS, METHOD OF MANUFACTURING AND USING THEM
WO2015027021A1 (en) 2013-08-22 2015-02-26 Bristol-Myers Squibb Company Imide and acylurea derivatives as modulators of the glucocorticoid receptor
CA2934936A1 (en) 2014-01-30 2015-08-06 Theravance Biopharma R&D Ip, Llc Neprilysin inhibitors
RU2016135057A (en) 2014-01-30 2018-03-12 ТЕРЕВАНС БАЙОФАРМА Ар энд Ди АйПи, ЭлЭлСи DERIVATIVES OF 5-BIPHENYL-4-HETEROARYL CARBONILAMINOPENTANIC ACID AS NEPRILISINE INHIBITORS
EP3101123B1 (en) 2014-01-31 2019-12-11 API Corporation Pipecolinic acid position-4 hydroxylase and method for producing 4-hydroxyamino acid using same
CA2950911C (en) 2014-06-04 2023-10-10 Sanford-Burnham Medical Research Institute Use of inhibitor of apoptosis protein (iap) antagonists in hiv therapy
US9212206B1 (en) 2014-11-24 2015-12-15 William H Simmons 4-Fluoro-Thio-containing inhibitors of APP2, compositions thereof and method of use
SG11201706308RA (en) 2015-02-11 2017-09-28 Theravance Biopharma R&D Ip Llc (2s,4r)-5-(5'-chloro-2'-fluorobiphenyl-4-yl)-4-(ethoxyoxalylamino)-2-hydroxymethyl-2-methylpentanoic acid as neprilysin inhibitor
PT3259255T (en) 2015-02-19 2021-01-26 Theravance Biopharma R&D Ip Llc (2r,4r)-5-(5'-chloro-2'-fluorobiphenyl-4-yl)-2-hydroxy-4-[(5-methyloxazole-2-carbonyl)amino]pentanoic acid
AU2017229466C1 (en) 2016-03-08 2021-02-11 Theravance Biopharma R&D Ip, Llc Crystalline(2S,4R)-5-(5'-chloro-2'-fluoro-[1,1'-biphenyl]-4-YL)-2-(ethoxymethyl)-4-(3-hydroxyisoxazole-5-carboxamido)-2-methylpentanoic acid and uses thereof

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT20991B (en) 1903-12-22 1905-08-10 Duplex Radiator Company Radiators for gas and petroleum stoves.
AT198791B (en) 1950-12-20 1958-07-25 Westinghouse Air Brake Co Control valve for air brakes on rail vehicles
DE2210633C2 (en) * 1972-03-06 1983-09-22 Bayer Ag, 5090 Leverkusen Condensed pyridine derivatives, processes for their preparation and pharmaceuticals containing these compounds
BG17877A1 (en) * 1972-09-26 1974-03-05
FR2265355B1 (en) * 1974-03-28 1977-11-04 Blum Jean
US4105776A (en) * 1976-06-21 1978-08-08 E. R. Squibb & Sons, Inc. Proline derivatives and related compounds
US4339600A (en) * 1976-05-10 1982-07-13 E. R. Squibb & Sons, Inc. Compounds for alleviating angiotensin related hypertension
CA1067079A (en) * 1976-07-22 1979-11-27 Yamanouchi Pharmaceutical Co. Nitrogen-containing heterobicyclic compounds
US4225495A (en) * 1978-12-07 1980-09-30 E. R. Squibb & Sons, Inc. Pyrrolo or pyrido [2,1-c][1,4] thiazines or thiazepines
US4192945A (en) * 1978-12-07 1980-03-11 E. R. Squibb & Sons, Inc. Process for preparing proline and homoproline derivatives
IL58849A (en) * 1978-12-11 1983-03-31 Merck & Co Inc Carboxyalkyl dipeptides and derivatives thereof,their preparation and pharmaceutical compositions containing them
IL61972A0 (en) * 1980-01-30 1981-02-27 Beecham Group Ltd Azabicyclic compounds,their preparation and pharmaceutical compositions containing them
US4337201A (en) * 1980-12-04 1982-06-29 E. R. Squibb & Sons, Inc. Phosphinylalkanoyl substituted prolines
US4415496A (en) * 1981-03-23 1983-11-15 Merck & Co., Inc. Bicyclic lactams
US4432971A (en) * 1981-08-03 1984-02-21 E. R. Squibb & Sons, Inc. Phosphonamidate compounds
US4432972A (en) * 1981-08-03 1984-02-21 E. R. Squibb & Sons, Inc. Phosphonamidate compounds
US4873235A (en) * 1982-06-01 1989-10-10 Merck & Co., Inc. Benzofused lactams as antihypertensives
FR2540495B1 (en) * 1983-02-07 1986-02-14 Roussel Uclaf NOVEL DERIVATIVES OF O-MERCAPTOPROPANAMIDE AND ITS HOMOLOGUES, THEIR PREPARATION METHOD, THEIR APPLICATION AS MEDICAMENTS, THE COMPOSITIONS CONTAINING THEM AND THE NEW INTERMEDIATES OBTAINED
US4711884A (en) * 1983-02-28 1987-12-08 E. R. Squibb & Sons, Inc. Thiazine and thiazepine containing compounds
US4460579A (en) * 1983-02-28 1984-07-17 E. R. Squibb & Sons, Inc. Thiazine and thiazepine containing compounds
US4617301A (en) * 1983-06-22 1986-10-14 Merck & Co., Inc. Sulfoxide and sulfone derivatives of bicyclic lactams as antihypertensives
US4722810A (en) * 1984-08-16 1988-02-02 E. R. Squibb & Sons, Inc. Enkephalinase inhibitors
US4584294A (en) * 1984-11-07 1986-04-22 Merck & Co., Inc. Fused tricyclic lactams as angiotensin converting enzyme inhibitors and as antihypertensive agents
US4749688A (en) * 1986-06-20 1988-06-07 Schering Corporation Use of neutral metalloendopeptidase inhibitors in the treatment of hypertension
EP0254032A3 (en) * 1986-06-20 1990-09-05 Schering Corporation Neutral metalloendopeptidase inhibitors in the treatment of hypertension
US4801609B1 (en) * 1987-03-27 1993-11-09 Mercapto-acylamino acid antihypertensives
CA1334092C (en) 1986-07-11 1995-01-24 David John Carini Angiotensin ii receptor blocking imidazoles
CA1337400C (en) * 1987-06-08 1995-10-24 Norma G. Delaney Inhibitors of neutral endopeptidase
CA1338238C (en) 1988-01-07 1996-04-09 David John Carini Angiotensin ii receptor blocking imidazoles and combinations thereof with diuretics and nsaids
US4879309A (en) * 1988-09-27 1989-11-07 Schering Corporation Mercapto-acylamino acids as antihypertensives
US5075302A (en) * 1990-03-09 1991-12-24 Schering Corporation Mercaptoacyl aminolactam endopeptidase inhibitors
FR2664269B1 (en) * 1990-07-05 1992-10-02 Roussel Uclaf NOVEL N-SUBSTITUTED DERIVATIVES OF ALPHA-MERCAPTO ALKYLAMINES, THEIR PREPARATION PROCESS, THEIR APPLICATION AS MEDICAMENTS AND THE COMPOSITIONS CONTAINING THEM.
CA2053340C (en) * 1990-10-18 2002-04-02 Timothy P. Burkholder Mercaptoacetylamide derivatives useful as inhibitors of enkephalinase and ace
US5232920A (en) * 1990-12-21 1993-08-03 Schering Corporation N-(mercaptoalkyl)amides
FR2679564A1 (en) * 1991-07-23 1993-01-29 Inst Nat Sante Rech Med NOVEL ACYLMERCAPTOALCANOLDIPEPTIDES, THEIR PREPARATION AND THE COMPOSITIONS CONTAINING THEM.
EP0534363B1 (en) * 1991-09-27 1997-07-09 Merrell Pharmaceuticals Inc. Novel 2-substituted indane-2-mercaptoacetylamide derivatives useful as inhibitors of enkephalinase and ace
CA2078759C (en) * 1991-09-27 2003-09-16 Alan M. Warshawsky Novel carboxyalkyl derivatives useful as inhibitors of enkephalinase and ace
AU657793B2 (en) * 1991-09-27 1995-03-23 Merrell Pharmaceuticals Inc. Novel 2-substituted indane-2-carboxyalkyl derivatives useful as inhibitors of enkephalinase and ACE
ES2117123T3 (en) * 1992-02-14 1998-08-01 Merrell Pharma Inc DERIVATIVES OF AMINOCETILMERCAPTOACETILAMIDA USED AS INHIBITORS OF ENCEPHALINASE AND ANGIOTENSIN CONVERSION ENZYME.
US5552397A (en) * 1992-05-18 1996-09-03 E. R. Squibb & Sons, Inc. Substituted azepinone dual inhibitors of angiotensin converting enzyme and neutral exdopeptidase
US5627191A (en) 1992-07-10 1997-05-06 The Boots Company Plc Therapeutic agents
EP0656001B1 (en) * 1992-08-24 1999-09-15 Merrell Pharmaceuticals Inc. Novel 2-substituted indane-2-mercaptoacetylamide tricyclic derivatives useful as inhibitors of enkephalinase
US5208236A (en) * 1992-09-23 1993-05-04 Schering Corporation N-(acylaminomethyl)glutaryl amino acids and use
US5504080A (en) * 1992-10-28 1996-04-02 Bristol-Myers Squibb Co. Benzo-fused lactams
CA2146238C (en) * 1992-10-30 2001-03-13 Gary A. Flynn Novel mercaptoacetylamide bicyclic lactam derivatives useful as inhibitors of enkephalinase and ace
GB9302331D0 (en) * 1993-02-05 1993-03-24 Smithkline Beecham Plc Process
US5508272A (en) * 1993-06-15 1996-04-16 Bristol-Myers Squibb Company Compounds containing a fused bicycle ring and processes therefor
US5362727A (en) * 1993-07-26 1994-11-08 Bristol-Myers Squibb Substituted azepino[2,1-a]isoquinoline compounds
US5525723A (en) * 1993-11-18 1996-06-11 Bristol-Myers Squibb Co. Compounds containing a fused multiple ring lactam

Also Published As

Publication number Publication date
GEP19981301B (en) 1998-05-14
RO112870B1 (en) 1998-01-30
JP3569550B2 (en) 2004-09-22
US5756832A (en) 1998-05-26
IL109924A0 (en) 1994-10-07
CZ140294A3 (en) 1996-08-14
EP0629627A3 (en) 1995-05-17
US5672599A (en) 1997-09-30
FI20000815A (en) 2000-04-06
DE69433752T2 (en) 2005-04-21
FI111950B (en) 2003-10-15
HU9401776D0 (en) 1994-09-28
FI942793A (en) 1994-12-16
TW329423B (en) 1998-04-11
RU2125056C1 (en) 1999-01-20
CN1099392A (en) 1995-03-01
NZ260736A (en) 1997-01-29
KR100395604B1 (en) 2004-05-10
SK72594A3 (en) 1995-05-10
LV10622B (en) 1995-10-20
ES2219644T3 (en) 2004-12-01
SK282529B6 (en) 2002-10-08
LTIP1954A (en) 1995-02-27
ATE266032T1 (en) 2004-05-15
EE03178B1 (en) 1999-04-15
DE69433752D1 (en) 2004-06-09
FI111947B (en) 2003-10-15
DK0629627T3 (en) 2004-07-26
RU94021350A (en) 1996-04-20
AU6466794A (en) 1994-12-22
PT629627E (en) 2004-09-30
EP0629627A2 (en) 1994-12-21
ZA944163B (en) 1995-02-09
NO942208D0 (en) 1994-06-13
PH30830A (en) 1997-10-17
PL178469B1 (en) 2000-05-31
BR1100970A (en) 1999-12-07
HK1001814A1 (en) 1998-07-10
BG98854A (en) 1995-05-31
US5670699A (en) 1997-09-23
AU672899B2 (en) 1996-10-17
KR950000711A (en) 1995-01-03
LV10622A (en) 1995-04-20
EG20537A (en) 1999-07-31
FI20000814A (en) 2000-04-06
CN1046525C (en) 1999-11-17
PL303832A1 (en) 1995-01-09
US5508272A (en) 1996-04-16
NO942208L (en) 1994-12-16
LT3626B (en) 1995-12-27
CZ289488B6 (en) 2002-02-13
US5627278A (en) 1997-05-06
IL120051A0 (en) 1997-04-15
EP0629627B1 (en) 2004-05-06
FI106464B (en) 2001-02-15
UY23787A1 (en) 1994-12-06
FI942793A0 (en) 1994-06-13
NO306405B1 (en) 1999-11-01
IL109924A (en) 1998-09-24
JPH0748259A (en) 1995-02-21
HUT70842A (en) 1995-11-28
BG62139B1 (en) 1999-03-31
UA39924C2 (en) 2001-07-16
MY123673A (en) 2006-05-31
CY2492B1 (en) 2005-09-02
CA2124375A1 (en) 1994-12-16
HU216791B (en) 1999-08-30
SG46510A1 (en) 1998-02-20

Similar Documents

Publication Publication Date Title
CA2124375C (en) Compounds containing a fused bicyclic ring and processes therefor
US5444152A (en) Endothelin antagonistic peptide derivatives
US5889053A (en) Farnesyl transferase inhibitors, preparation thereof and pharmaceuticals compositions containing said inhibitors
AU683658B2 (en) Substituted azepino (2,1-a) isoquinoline compounds
CA1246056A (en) Anti-hypertensive agents
US5731306A (en) Mercaptoacetylamido 1,3,4,5-tetrahydro-benzo c!azepin-3-one disulfide derivatives useful as inhibitors of enkephalinase and ace
CA2134149A1 (en) Compounds containing a fused multiple ring lactam
US5109000A (en) Thiol carboxylic acid derivatives and their use as collagenase inhibitor
CA2178355A1 (en) Diazepine containing dual action inhibitors
US5616775A (en) Process for preparing homocystein analogs useful as intermediates for compounds containing a fused bicyclic ring
US4882326A (en) Piperidine compounds and pharmaceutical uses thereof
US4690936A (en) Anti-hypertensive agents
FR2595704A1 (en) DERIVATIVES OF THE PROLINE
HU188177B (en) Process for producing new proline derivatives
HU225916B1 (en) Thiazolo[3,2-a]azepine derivatives, process for the preparation thereof and pharmaceutical compositions containing them
WO1995021857A1 (en) Novel 2-substituted indane-2-mercaptoacetylamide disulfide derivatives useful as inhibitors of enkephalinase and ace

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed
MKLA Lapsed

Effective date: 20100526